Application of abelmoschus manihot flower extract in preparation of medicine for treating diseases related to liver fibrosis

The proportion of flavonoids of hollyhock is adjusted by extracting coupled resin methods, which solves the problems of complexity and side effects of existing extracts, and achieves significant effects and safety of high-purity extracts in the treatment of various diseases.

CN119055689APending Publication Date: 2024-12-03SUZHONG PHARMACEUTICAL GROUP CO LTD +2
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410705684.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-06-01
Filing Date
2024-05-31
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The composition complexity and low extraction and metastasis rate of existing hollyhock extracts lead to unstable treatment effects and greater side effects, making it difficult to effectively use in a variety of diseases such as diabetic nephropathy, eye diseases and skin ulcers.

Method used

High-purity hollyhock flavonoid extract was prepared by extracting and coupling resin method, and the proportion of flavonoid components was adjusted to be cotton 8-O-β-D-glucuronidin, hypericin, isoquercetin, and bayberry The mass ratio to quercetin improves its effectiveness in treating multiple diseases and reduces side effects.

Benefits of technology

The flavonoid extract of hollyhock has achieved significant effects on the treatment of diabetic nephropathy, eye diseases, skin ulcers and inflammation, while reducing the side effects of the drug, providing a safer and more effective treatment plan.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
  • Figure SMS_4
    Figure SMS_4
Patent Text Reader

Abstract

The invention relates to an application of an abelmoschus manihot total flavone extract in preparation of a medicine with an effect of inhibiting hepatic stellate cell proliferation, belongs to the field of pharmacy, and has an obvious effect of preventing and treating liver fibrosis related tumors and relatively good safety.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the pharmaceutical field, and in particular relates to application of a hibiscus flower total flavonoids drug. Background Art

[0002] Medicinal Hibiscus flower is the dried corolla of Abelmoschus manihot (L.) Medic, a plant of the Malvaceae family. It tastes sweet and cold, and enters the kidney and bladder meridians. It has the effects of clearing dampness and heat, reducing swelling and detoxifying, and is used for carbuncle swelling, toxicity, and burns caused by water or fire. This medicine was first recorded in "Jiayou Materia Medica", which records: Hibiscus flower is used to treat all kinds of malignant sores and pus that have not healed for a long time, and it can be applied as a powder. "Compendium of Materia Medica" says: Hibiscus flower, its flower smell is sweet, cold, slippery, and non-toxic. It can treat all kinds of malignant sores and pus that have not healed for a long time, and it can be cured by applying it as a powder, and it is an important medicine for sores.

[0003] Flavonoids are one of the main components of hibiscus flower, and also one of its pharmacologically active ingredients. Hibiscus capsules have been on the market for many years, and their main active ingredient is hibiscus flower extract. Studies have confirmed that the flavonoids in hibiscus flower extract not only have a significant therapeutic effect on sores, but also have a significant protective effect on ischemic damage to the heart, brain, tissues, etc. In addition, many literature reports show that hibiscus flower total flavonoids may have good effects in anti-inflammatory, antipyretic and analgesic, protecting heart and brain ischemic damage, lowering blood sugar, and antiviral. For example, patent CN201210082553.7 discloses a total flavonoid extract of hibiscus flower, containing flavonoids with a weight ratio of (11-16) to (2.5-6) ​​to (4-6.5) of quercetin-3′-glucoside, quercetin-3′-glucoside, and isoquercetin, which can be used to prepare nephritis. Patent CN200610097615.6 discloses a total flavonoid extract of hibiscus australis flower, which has a total flavonoid content of 50-90% by weight. The flavonoid components contained in the extract are: 1.0-5.0% quercetin-3-acacia glycoside, 8-24.0% hyperoside, 7.0-20.0% isoquercetin, 5.0-15.0% quercetin-3′-glucoside, 3.0-10.0% gossypol-3′-glucoside, 0.5-5.0% myricetin, 0.5-5.0% gossypol, 2.0-8.0% quercetin, and several other flavonoid components. The total flavonoid extract of hibiscus australis flower can be used to prepare drugs for treating nephritis, the flavonoid components are clear in qualitative and quantitative terms, and the therapeutic effect is reliable.

[0004] Although bioflavonoids have various therapeutic effects, there are many types of flavonoids, which can currently be divided into 7 different subtypes, and different flavonoid composition will lead to different therapeutic effects. For example, although the literature reports that bioflavonoids can effectively prevent or treat diabetic retinopathy, compounds with five hydroxyl groups, such as quercetin, have a negative effect on ocular blood flow, and when flavonoids are dehydrogenated to flavanones, significant improvement in ocular blood flow is obtained. In addition, compounds that increase blood flow also lead to a significant increase in the recovery of retinal function after ischemic injury. How to develop such compounds to effectively treat eye diseases such as macular degeneration, visual fatigue and cataracts, and even improve the effect on diabetic retinopathy, is an important research task.

[0005] Choroidal neovascularization (CNV) is seen in many fundus diseases, such as age-related macular degeneration (AMD), central exudative chorioretinitis, and macular degeneration caused by high myopia. Among them, CNV secondary to AMD is the most common and has become one of the main causes of irreversible visual impairment in the elderly. Insufficient blood flow is also a factor affecting visual fatigue. Increasing eye blood flow or acting on eye smooth muscles can help to restore visual fatigue.

[0006] The reabsorption of glucose in the proximal renal tubule is mediated by the sodium-glucose cotransporter (SGLT) 1 and SGLT2 transporters, of which about 90% of glucose reabsorption is mediated by SGLT2 and the remaining 10% is mediated by SGLT1. SGLT2 inhibitors inhibit the reabsorption of glucose in the renal tubules by selectively binding to the SGLT2 receptor, which can lower the renal glucose threshold, increase urinary glucose excretion, and achieve a significant blood sugar lowering effect. In recent years, clinical studies have found that SGLT2 inhibitors have a renal protective effect on chronic kidney disease (CKD) caused by non-diabetes. SGLT2 inhibitors can reduce the expression of collagen and fibronectin by reducing TGFβ-1, PAI1, STAT 1, MMP 7 and inhibiting the AGEs-RAGE axis, thereby reducing the accumulation of extracellular matrix and alleviating the progression of renal fibrosis in DN. In addition to regulating tubuloglomerular feedback, reducing proteinuria progression, and anti-inflammatory and anti-fibrotic effects, SGLT2 inhibitors can also reduce uric acid (SUA) in diabetic patients. For example, compared with the control group, SGLT2 inhibitors (empagliflozin, canagliflozin, dapagliflozin, togliflozin, lupagliflozin, empagliflozin) significantly reduced serum uric acid levels. SGLT2 inhibitors can be beneficial for the prevention and treatment of heart failure by reducing plasma volume, reducing preload and postload, improving myocardial energy metabolism, and improving myocardial remodeling.

[0007] Epidermal growth factor receptor antagonists (EGFRIs) are the most widely used anti-tumor drugs in clinical practice in recent years. They are favored by doctors and patients for their outstanding clinical efficacy. However, their adverse reactions are diverse, and rash (mainly acne / acne-like rash) is the most common one. Acne / acne-like rash not only affects the patient's quality of life, but also may cause the treatment to be unable to proceed normally, seriously affecting the treatment effect of tumors. Acne / acne-like rash limits the application of EGFRIs to a certain extent. Western medicine often uses antibiotics, topical hormones and other methods for treatment, but the effect is not very obvious.

[0008] Skin wounds are a common clinical symptom. Conventional skin wound treatments include skin grafting and artificial substitute coverage. Skin ulcers are common and frequently occurring clinical diseases. They refer to local skin tissue defects caused by various reasons. Wounds are exposed and prone to infection. Chronic skin ulcers, in particular, cannot heal for a long time or are prone to recurrence. Treatment is difficult, seriously affecting the quality of life of patients and bringing a certain social burden. More safe, effective, and economical treatment methods and drug research and development are urgently needed in clinical practice.

[0009] Epidemiological surveys show that the incidence of diabetes in my country is increasing year by year. This trend is closely related to changes in lifestyle and the aging of society. In addition, 15% of diabetic patients will eventually develop long-term skin ulcers. How to promote the rapid healing of diabetic ulcer wounds, reduce the disability rate, and protect limb function is an important topic and hot topic in today's medical research. An animal model of chronic difficult-to-heal wounds under diabetic conditions can be established by artificially creating sterile wounds on the backs of experimental diabetic rats, so as to carry out research on drugs that promote wound healing.

[0010] Inflammatory bowel disease is a special chronic intestinal inflammatory disease, including ulcerative colitis and Crohn's disease. Clinical patients will show repeated abdominal pain, diarrhea, mucus and blood in the stool. Most patients have repeated attacks and are not cured. On the one hand, it seriously affects the quality of life of patients. On the other hand, it can increase the risk of colorectal cancer. The longer the course of the disease, the higher the degree of inflammation and the greater the possibility of cancer. Among them, UC can increase the risk of cancer by about 2.4 times; the canceration rates of patients with a course of 10, 20 and 30 years are 2%, 8% and 18%, respectively. At the same time, IBD-related colorectal cancer (CRC) is characterized by young age, disseminated and multifocal lesions. Its pathology and pathogenesis are different from sporadic CRC; "inflammatory bowel disease-dysplasia-colorectal cancer" is an important pathway for the occurrence of CRC. Colorectal cancer is the most common digestive tract malignancy, with an incidence rate second only to gastric cancer and esophageal cancer. At present, the incidence of colorectal cancer in my country is on the rise, with the domestic incidence rate rising at about 4.8%, far exceeding the international level of 2%. Therefore, the treatment of inflammatory bowel disease and the prevention and treatment of colorectal cancer have received widespread attention from scholars at home and abroad. Chinese patent CN201310645683.1 discloses the use of hibiscus flowers and their extracts in the preparation of drugs for the prevention and treatment of inflammatory bowel disease. The experimental results show that the hibiscus flowers and hibiscus flower extracts provided by the invention can significantly inhibit TNBS-induced chronic colitis in mice with inflammatory bowel disease, and can significantly reduce the mortality rate of model mice caused by long-term administration of TNBS, and can significantly reduce the colon weight / length ratio; the results of pathological examination show that it can significantly reduce the intestinal inflammation induced by TNBS, limit the severity of the lesions, reduce crypt damage, and significantly reduce TNBS-induced inflammatory bowel disease, and is expected to be developed into a new drug for the prevention and treatment of inflammatory bowel disease.

[0011] Liver fibrosis is a common pathological process in most liver diseases, endangering the life and health of all mankind. Every year, more than 1 million people die from liver disease worldwide, and about 1-2% of the world's population is shrouded in the shadow of liver fibrosis. Liver diseases include non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), viral hepatitis (chronic hepatitis B virus (HBV), hepatitis C virus (HCV) infection, etc.), drug-induced liver disease, primary / secondary cholangitis, autoimmune hepatitis and primary / secondary liver cancer, etc. The pathological process of liver fibrosis is common in these liver diseases. The pathogenic factors that induce these liver diseases include hepatitis viruses, congenital liver dysfunction, autoimmune disorders, chronic inflammation, cholestasis, long-term exposure to alcohol, high-fat diet, parasitic diseases (such as schistosomiasis), metabolic disorders (such as Wilson's disease) and long-term use of hepatotoxic drugs.

[0012] Hepatic stellate cells (HSCs) are the main source of myofibroblasts. In normal liver, HSCs proliferate very slowly and maintain their dynamic balance by regulating the synthesis and degradation of the extracellular matrix. When the liver is continuously stimulated by external pathogenic factors, a series of complex mechanisms are activated, which ultimately causes HSCs to transform from a quiescent type to an activated type, and secrete various profibrotic factors such as TGF-β and PDGF, producing a large amount of disorderly accumulated extracellular matrix (ECM), which promotes the occurrence and development of fibrosis. Therefore, HSCs are a potential target for anti-liver fibrosis treatment. Currently, many anti-liver fibrosis drugs under development achieve their therapeutic goals by inhibiting the proliferation and fibrogenic ability of HSCs and promoting the apoptosis of HSCs.

[0013] By inhibiting the reproduction of hepatic stellate cells, it can significantly reduce liver fat accumulation, alleviate liver collagen deposition, and have a good effect on fatty liver.

[0014] TGF β signaling can promote the invasion and spread of fibroblasts, endothelial cells, and pericytes in the tumor microenvironment and reduce the sensitivity of anticancer drugs. In addition, TGF β signaling reshapes the extracellular matrix by affecting the structure of cancer cells and inhibiting the activity of protective immune cells, thereby interfering with the physiological functions of various immune cells such as T cells and natural killer cells, and weakening the inhibition of cancer cell metastasis by immune cells. At the same time, TGF β inhibitors can treat diseases such as fibrosis, inflammation, and congenital defects, so the research on TGF β inhibitors has a wide range of application value.

[0015] The extraction methods of hibiscus flower reported in the literature include ethanol reflux extraction, ultrasonic extraction, and room temperature immersion extraction, but the composition of hibiscus flower extracts is complex, the content of effective ingredients varies greatly, the extraction transfer rate is low, the extraction energy consumption is high, and the amount of solvent used is large. Therefore, it is necessary to explore a hibiscus flower therapeutic drug and its extraction process that can be used to treat kidney disease, especially diabetic nephropathy, and can also treat multiple diseases such as eye diseases.

[0016] The applicant counted the adverse reactions of Huangkui Capsules and found that in a recent year, a total of 194 cases of adverse reactions to Huangkui Capsules were received. According to the statistics of adverse drug reactions, nausea, itching, rash, vomiting, diarrhea, upper abdominal distension and discomfort, etc., occurred more than 10 times, all of which are known adverse reactions. Recently, new ADR manifestations have appeared, such as dizziness, headache, and decreased appetite. In addition, among the serious adverse reactions received, one case involved liver cell damage, which may be a signal that Huangkui Capsules damage liver cells. Therefore, it is clinically significant to develop a new hibiscus flower flavonoid extract to reduce side effects and be used to treat diseases such as liver fibrosis and anti-tumor drugs. Summary of the invention

[0017] In view of the above-mentioned deficiencies, the present invention provides an effective part, extract, composition, preparation process, application, and pharmaceutical preparation and application thereof of hibiscus flower flavonoids.

[0018] The present invention realizes the preparation of a high-purity hibiscus flower flavonoid effective part, extract, composition, and pharmaceutical preparation by extraction coupling resin method, and it is found that the effective part has better renal disease treatment activity, such as diabetic nephropathy, contrast agent renal injury or lupus erythematosus nephritis, and it also has the effect of treating eye diseases, and it also has the effect of anti-fibrosis, the effect of preventing and treating ulcerative diseases, the effect of preventing and treating inflammation, the effect of preventing and treating skin diseases, promoting wound healing, and anti-tumor effects. At the same time, the hibiscus flower flavonoid medicine and preparation of the present invention have lower side effects, and provide a better therapeutic medicine for patients.

[0019] In order to solve the above technical problems, the technical solution adopted by the present invention is as follows:

[0020] In the first main aspect, the present invention provides a high-purity effective part, extract and composition of flavonoids from hibiscus flowers.

[0021] In a first aspect, the present invention provides an effective flavonoid fraction of hibiscus tiliaceus flower, comprising flavonoid components in the following mass ratio: the mass ratio of gossypol-8-O-β-D-glucuronide: hyperoside: isoquercetin: myricetin: quercetin-3'-O-glucoside is: 10: 3.0-20: 4.0-18: 1.9-6.0: 6.0-20.

[0022] Specifically, the mass ratio of gossypol-8-O-β-D-glucuronide: hyperoside: isoquercetin: myricetin: quercetin-3'-O-glucoside is: 10: 4.0-17: 4.50-16: 1.9-5.5: 7.0-16; preferably: 10: 6.0-15: 5.0-13: 2.0-5.0: 8.0-14; further, the composition contains quercetin, wherein the mass ratio of gossypol-8-O-β-D-glucuronide: quercetin is 10: 1.0-10.0, preferably 10: 1.0-6. 0, preferably 10:1.5-5.0; further, containing rutin, wherein linalool-8-O-β-D-glucuronide:rutin is 10:0.05-0.6, preferably 10:0.1-0.4, and further preferably 10:0.1-0.3; further, containing quercetin-3-O-acacia glycoside, wherein linalool-8-O-β-D-glucuronide:quercetin-3-O-acacia glycoside is 10:0.1-2.5, 10:0.1-0.9, and preferably 10:0.15-0.5.

[0023] In a second aspect, the present invention provides an effective part of flavonoids from hibiscus flower, comprising flavonoid components in the following mass ratio: the mass ratio of isoquercetin: quercetin: quercetin-3′-O-glucoside: myricetin: gossypol-8-O-β-D-glucuronide: hyperoside is: 0.8-1.2: 0.05-1.6: 0.2-4.6: 0.05-1.2: 0.2-3.5: 0.25-3.6.

[0024] Specifically, the flavonoid effective part of hibiscus flower includes flavonoid components in the following mass ratio: the mass ratio of isoquercetin: quercetin: quercetin-3′-O-glucoside: myricetin: gossypol-8-O-β-D-glucuronide: hyperoside is: 0.8-1.2: 0.1-1.2: 0.4-3.1: 0.10-0.9: 0.4-3.1: 0.5-3.0; further 0.8-1.2: 0.16-1.0: 0.6-2.4: 0.14-0.7 5∶0.6-2.5∶0.6-2.4; further 0.8-1.2∶0.2-0.8∶0.8-2.1∶0.18-0.6∶0.8-2.0∶0.7-2.0; further 0.8-1.2∶0.2-0.7∶0.8-1.6∶0.2-0.5∶0.8-1.8∶0.8-1.4; further 0.8-1.2∶0.2-0.6∶1.0-1.2∶0.2-0.4∶0.9-1.7∶1.0-1.3.

[0025] Specifically, the effective flavonoid part of hibiscus flower includes flavonoid components in the following mass ratio: the mass ratio of isoquercetin:quercetin:quercetin-3′-O-glucoside: myricetin: gossypol-8-O-β-D-glucuronide: hyperoside is: 0.8-1.2: 0.09-1.6: 0.2-2.0: 0.05-1.2: 0.5-3.0: 0.25-3.6.

[0026] Specifically, the effective flavonoid part of hibiscus flower includes flavonoid components in the following mass ratio: the mass ratio of isoquercetin:quercetin:quercetin-3′-O-glucoside: myricetin: gossypol-8-O-β-D-glucuronide: hyperoside is: 0.8-1.2: 0.12-0.7: 0.8-1.6: 0.2-0.5: 0.85-1.7: 1.0-1.4.

[0027] More specifically, the mass ratio of the isoquercetin is 1.2 or 1.0.

[0028] More specifically, the hibiscus flower flavonoid effective part further contains rutin, and the mass ratio of isoquercetin to rutin is 1:0.001-0.08, preferably 1:0.005-0.06, preferably 1:0.006-0.05, preferably 1:0.007-0.04, preferably 1:0.009-0.04, or preferably 1:0.008-0.03, preferably 1:0.009-0.03; further, it contains quercetin-3-O-sophoroside, and the mass ratio of isoquercetin to quercetin-3-O-sophoroside is 10:0.1-2.5, 10:0.1-0.9, preferably 10:0.15-0.5.

[0029] More specifically, the total content of quercetin, quercetin-3′-O-glucoside, myricetin, gossypol-8-O-β-D-glucuronide, isoquercetin and hyperoside contained in the flavonoid effective part of Hibiscus truncatum flower is 55% or more, preferably 60% or more, preferably 65-85%, preferably 69-82%; further, the content of quercetin-3′-O-glucoside is 12.1-25%, and further, the content of quercetin- The content of 3′-O-glucoside is 12.6-23% or 13-20%, 13-20%, or 14-25%; or further, the content of quercetin is higher than 0.7%, further higher than 1.0%, further 1.0%-10%, further 1.5%-5%; or further, the content of quercetin-8-O-β-D-glucuronide is 8.5-30%, further 12%-23%.

[0030] More specifically, the effective fraction contains quercetin, quercetin-3′-O-glucoside, myricetin, gossypol-8-O-β-D-glucuronide, isoquercetin, rutin and hyperoside in a total content of more than 55%, preferably more than 60%, preferably 65-85% or 66-84%, preferably 69-82%, or 69-90%; further, the content of quercetin-3′-O-glucoside is 12.1-25%, and further the content of quercetin-3′-O-glucoside is 12.6-23% or 13-20%.

[0031] In a third aspect, the present invention provides a plant extract containing flavonoid components, including the following components by mass content: 10-25% hyperoside, 8-19% isoquercetin, 5-30% gossypol-8-O-β-D-glucuronide, and 12.1-25% quercetin-3′-O-glucoside; further, 12-23% hyperoside, 10-17% isoquercetin, 8.5-25% gossypol-8-O-β-D-glucuronide, and 12.6-23% quercetin-3′-O-glucoside; further, 13-22% hyperoside, 11-17% isoquercetin, 12-21% gossypol-8-O-β-D-glucuronide, and 13-20% quercetin-3′-O-glucoside.

[0032] Specifically, the extract also contains 2-10% quercetin, preferably 2.5-9% quercetin, preferably 3-8.5% quercetin, and further 1.5%-5%; further, it contains 2-11% myricetin, preferably 3-7% myricetin, preferably 3-5% myricetin, and further, it contains 0.08-2.5% quercetin-3-O-sophora glycoside, preferably 0.1-1.5%, further 0.1-0.9%, and further 0.1-0.5%; further, the plant is the flower of hibiscus okra, which can be the whole flower or the corolla, and is preferably a hibiscus flower.

[0033] In a fourth aspect, the present invention provides a hibiscus flower extract containing flavonoid components, including the following components by mass content: 8-26% hyperoside, 12.0-19.8% isoquercetin, 8.5-30% gossypol-8-O-β-D-glucuronide, 3.0-4.9% or 5.1-6.0% myricetin, 14-25% quercetin-3′-O-glucoside, and 1.6-4.9% quercetin; further, 11-22% hyperoside, 12.0-17% isoquercetin, 12-23% gossypol-8-O-β-D-glucuronide, 1.6-4.9% or 5.1-9.0% myricetin, 13-22% quercetin-3′-O-glucoside, and 1.4-8% or 1.4-7.8% quercetin.

[0034] Specifically, the extract also contains 0.01-1.0% by mass of rutin, further 0.05-0.8%, further 0.09-0.8%, further 0.1-0.6%; further, it contains 0.08-2.5% of quercetin-3-O-sophora glycoside, preferably 0.1-1.5%, further 0.1-0.9%, and further 0.1-0.5%.

[0035] Specifically, the mass content of flavonoid components in the hibiscus flower extract is above 55%, preferably above 60%, preferably 65-85% or 66-84%, preferably 69-82% or 69-90%.

[0036] In a fifth aspect, the present invention provides a composition comprising the following mass ratios of flavonoid components: the mass ratio of isoquercetin: quercetin: quercetin-3′-O-glucoside: myricetin: gossypol-8-O-β-D-glucuronide: hyperoside is 1: 0.05-1.6: 0.2-4.6: 0.05-1.2: 0.2-3.5: 0.25-3.6; further 1: 0.1-1.2: 0.4-3.1: 0.10-0.9 ∶0.4-3.1∶0.5-3.0; further 1∶0.16-1.0∶0.6-2.4∶0.14-0.75∶0.6-2.5∶0.6-2.4; further 1∶0.2-0.8∶0.8-2.1∶0.18-0.6∶0.8-2.0∶0.7-2.0; further 1∶0.2-0.7∶0.8-1.6∶0.2-0.5∶0.8-1.8∶0.8-1.4; further 1: 0.2-0.6: 1.0-1.2: 0.2-0.4: 0.9-1.7: 1.0-1.3 or 1.2: 0.05-1.6: 0.2-4.6: 0.05-1.2: 0.2-3.5: 0.25-3.6; further 1: 0.1-1.2: 0.4-3.1: 0.10-0.9: 0.4-3.1: 0.5-3.0; further 1: 0.16-1.0: 0.6-2.4: 0. 14-0.75∶0.6-2.5∶0.6-2.4; further 1∶0.2-0.8∶0.8-2.1∶0.18-0.6∶0.8-2.0∶0.7-2.0; further 1∶0.2-0.7∶0.8-1.6∶0.2-0.5∶0.8-1.8∶0.8-1.4; further 1∶0.2-0.6∶1.0-1.2∶0.2-0.4∶0.9-1.7∶1.0-1.3.

[0037] Specifically, the composition also includes rutin, and the mass ratio of isoquercetin to rutin is 1:0.001-0.08, preferably 1:0.005-0.06, preferably 1:0.006-0.05, preferably 1:0.007-0.04, preferably 1:0.008-0.03, and preferably 1:0.009-0.03; further, the content of quercetin-3′-O-glucoside in the flavonoid components is 12.1-25%, further, the content of quercetin-3′-O-glucoside is 12.6-23% or 13-20%, further, it contains 0.08-2.5% of quercetin-3-O-sophora glycoside, preferably 0.1-1.5%, further 0.1-0.9%, and further 0.1-0.5%.

[0038] More specifically, the composition contains quercetin, quercetin-3′-O-glucoside, myricetin, gossypol-8-O-β-D-glucuronide, isoquercetin, rutin and hyperoside in a total content of more than 55%, preferably more than 60%, preferably 65-85%, and preferably 69-82%.

[0039] In a sixth aspect, the present invention provides a pharmaceutical composition, comprising the above-mentioned effective fraction, the above-mentioned hibiscus extract or the above-mentioned composition, and the pharmaceutical composition also includes a pharmaceutically acceptable carrier.

[0040] Specifically, the pharmaceutically acceptable carrier includes a solvent, an emulsifier, a disintegrant, a filler, a solubilizer, an antioxidant, a pH regulator, an osmotic pressure regulator, an antibacterial agent, a diluent, a wetting agent, a binder and / or a film-forming agent, and the lubricant does not contain magnesium stearate.

[0041] Specifically, the dosage forms of the pharmaceutical composition include injections, tablets, suppositories, ointments, gels, pills, tablets, granules, capsules or mixtures, suspensions, and dispersible tablets.

[0042] In a seventh aspect, the present invention provides a pharmaceutical composition comprising the following components in parts by weight: 3.0-20.0 of hyperoside, 4.0-18.0 of isoquercetin, 1.9-6.0 of myricetin, 6.0-20 of quercetin-3′-O-glucoside, 8.0-12.0 of gossypol-8-O-β-D-glucuronide; further, the pharmaceutical composition comprises the following components in parts by weight: 4.0-17.0 of hyperoside, 4.5-16.0 of isoquercetin, 1.9-5.5 of myricetin, 7.0-16.0 of quercetin-3′-O-glucoside, 8.0-12.0 of gossypol-8-O-β-D-glucuronide;

[0043] Further, the pharmaceutical composition contains the following components in parts by weight: 6.0-15.0 of hyperoside, 5.0-13.0 of isoquercetin, 2.0-5.0 of myricetin, 8.0-14.0 of quercetin-3′-O-glucoside, 8.0-12.0 of linalool-8-O-β-D-glucuronide; further, the pharmaceutical composition contains the following components in parts by weight: 8.0-15.0 of hyperoside, 6.0-12.5 of isoquercetin, 2.0-5.0 of myricetin, 8.0-14.0 of quercetin-3′-O-glucoside, 8.0-12.0 of linalool-8-O-β-D-glucuronide. 0-4.0, quercetin-3′-O-glucoside 9.0-13.0, and gossypol-8-O-β-D-glucuronide 8.0-12.0; and further, the pharmaceutical composition contains the following components in parts by weight: hyperoside 10-15.0, isoquercetin 7.0-12.0, myricetin 2.0-3.0, quercetin-3′-O-glucoside 9.0-12.0, and gossypol-8-O-β-D-glucuronide 8.0-12.0.

[0044] The pharmaceutical composition further contains quercetin, wherein the weight ratio of quercetin-8-O-β-D-glucuronide to quercetin is 9-11:1.0-10.0, preferably 10:1.0-6.0, more preferably 10:1.5-5.0, and further preferably 10:1.0-10.0.

[0045] The pharmaceutical composition further contains quercetin-3-O-acacia glycoside, wherein the weight ratio of quercetin-8-O-β-D-glucuronide to quercetin-3-O-acacia glycoside is 9-11:0.05-2.5, 10:0.1-0.9, preferably 10:0.15-0.5, and more preferably 10:0.05-2.5.

[0046] The pharmaceutical composition, the content of the component as a pharmaceutical active ingredient is above 60%, further above 65%, further above 75%, preferably the weight portion of the cottonseed linalool-8-O-β-D-glucuronide is 9-11 parts, preferably 10 parts.

[0047] The pharmaceutical composition further contains a pharmaceutically acceptable carrier.

[0048] In an eighth aspect, the present invention provides a hibiscus flower extract, which comprises flavonoid components in the following mass ratio: the mass ratio of gossypol-8-O-β-D-glucuronide: hyperoside: isoquercetin: myricetin: quercetin-3′-O-glucoside is 10:3.0-20:4.0-18:1.9-6.0:6.0-20.

[0049] Specifically, the mass ratio of gossypol-8-O-β-D-glucuronide: hyperoside: isoquercetin: myricetin: quercetin-3′-O-glucoside is 10: 4.0-17: 4.50-16: 1.9-5.5: 7.0-16; preferably 10: 6.0-15.6: 5.0-13: 2.0-5.0: 8.0-14, or 10: 6.0-15: 5.0-13: 2.0-5.0: 8.0-14; further, the composition contains quercetin, wherein the mass ratio of gossypol-8-O-β-D-glucuronide to quercetin is 10: 1.0-10.0, preferably 10: 1. 0-6.0, preferably 10:1-5.6, preferably 10:1.5-5.0; further, containing rutin, wherein the mass ratio of gossypol-8-O-β-D-glucuronide to rutin is 10:0.05-0.6, preferably 10:0.1-0.5, preferably 10:0.1-0.45, or 10:0.1-0.3; further, containing quercetin-3-O-acacia glycoside, wherein the mass ratio of gossypol-8-O-β-D-glucuronide to quercetin-3-O-acacia glycoside is 10:0.1-2.5, preferably 10:0.1-0.9, preferably 10:0.15-0.5.

[0050] In the ninth aspect, the present invention also provides a hibiscus flower extract, which includes flavonoid components in the following mass ratio: the mass ratio of gossypol-8-O-β-D-glucuronide: hyperoside: isoquercetin: myricetin: quercetin-3′-O-glucoside: quercetin is 10:6-15:5-13:1.0-2.9:4.0-9.5:0.6-6.0, or 10:6-15:5-13:1.0-1.8:4.0-5.9:0.6-0.99.

[0051] Further, it contains rutin, wherein the mass ratio of gossypol-8-O-β-D-glucuronide to rutin is 10:0.05-0.6, preferably 10:0.1-0.4, preferably 10:0.1-0.3; further, it contains quercetin-3-O-acacia glycoside, wherein the mass ratio of gossypol-8-O-β-D-glucuronide to quercetin-3-O-acacia glycoside is 10:0.1-2.5, preferably 10:0.1-0.9, preferably 10:0.15-0.5.

[0052] In the tenth aspect, the present invention provides a hibiscus flower extract, which includes flavonoid components in the following mass ratio: gossypol-8-O-β-D-glucuronide: hyperoside: isoquercetin: myricetin: quercetin-3′-O-glucoside: quercetin in a mass ratio of 10:6-15:5-13:1.0-2.9:4.0-9.5:0.6-6.0, or 10:6-15:5-13:1.0-1.8:4.0-5.9:0.6-0.99.

[0053] Further, it contains rutin, wherein the mass ratio of gossypol-8-O-β-D-glucuronide to rutin is 10:0.05-0.6, preferably 10:0.1-0.4, preferably 10:0.1-0.3; further, it contains quercetin-3-O-acacia glycoside, wherein the mass ratio of gossypol-8-O-β-D-glucuronide to quercetin-3-O-acacia glycoside is 10:0.1-2.5, preferably 10:0.1-0.9, preferably 10:0.15-0.5.

[0054] In the eleventh aspect, the present invention provides an application of a flavonoid effective part in the preparation of a drug for treating and / or preventing ulcerative diseases, wherein the flavonoid effective part comprises flavonoid components in the following mass ratio: the mass ratio of isoquercetin:quercetin:quercetin-3′-O-glucoside: myricetin: gossypol-8-O-β-D-glucuronide: hyperoside is: 0.8-1.2: 0.05-1.6: 0.2-4.6: 0.05-1.2: 0.2-3.5: 0.25-3.6.

[0055] Specifically, the flavonoid effective part of hibiscus flower includes flavonoid components in the following mass ratio: the mass ratio of isoquercetin: quercetin: quercetin-3′-O-glucoside: myricetin: gossypol-8-O-β-D-glucuronide: hyperoside is: 0.8-1.2: 0.1-1.2: 0.4-3.1: 0.10-0.9: 0.4-3.1: 0.5-3.0; further 0.8-1.2: ∶0.16-1.0∶0.6-2.4∶0.14-0.75∶0.6-2.5∶0.6-2.4; further 0.8-1.2∶0.2-0.8∶0.8-2.1∶0.18-0.6∶0.8-2.0∶0.7-2.0; further 0.8-1.2∶0.2-0.7∶0.8-1.6∶0.2-0.5∶0.8-1.8∶0.8-1.4.

[0056] Specifically, the effective flavonoid part of hibiscus flower includes flavonoid components in the following mass ratio: the mass ratio of isoquercetin:quercetin:quercetin-3′-O-glucoside: myricetin: gossypol-8-O-β-D-glucuronide: hyperoside is: 0.8-1.2: 0.2-0.6: 1.0-1.2: 0.2-0.4: 0.9-1.7: 1.0-1.3.

[0057] Specifically, the effective flavonoid part of hibiscus flower includes flavonoid components in the following mass ratio: the mass ratio of isoquercetin:quercetin:quercetin-3′-O-glucoside: myricetin: gossypol-8-O-β-D-glucuronide: hyperoside is: 0.8-1.2: 0.09-1.6: 0.2-2.0: 0.05-1.2: 0.5-3.0: 0.25-3.6.

[0058] Specifically, the effective flavonoid part of hibiscus flower includes flavonoid components in the following mass ratio: the mass ratio of isoquercetin:quercetin:quercetin-3′-O-glucoside: myricetin: gossypol-8-O-β-D-glucuronide: hyperoside is: 0.8-1.2: 0.12-0.7: 0.8-1.6: 0.2-0.5: 0.85-1.7: 1.0-1.4.

[0059] More specifically, the mass ratio of the isoquercetin is 1.2 or 1.0.

[0060] More specifically, the hibiscus flower flavonoid effective part further contains rutin, and the mass ratio of isoquercetin to rutin is 1:0.001-0.08, preferably 1:0.005-0.06, preferably 1:0.006-0.05, preferably 1:0.007-0.04, preferably 1:0.008-0.04, or preferably 1:0.009-0.04; further, it contains quercetin-3-O-sophoraside, and the mass ratio of isoquercetin to quercetin-3-O-sophoraside is 10:0.01-0.25, 10:0.01-0.09, preferably 1:0.015-0.065, preferably 10:0.015-0.05.

[0061] Wherein, the ulcerative disease is any one of ulcerative enteritis, ulcerative gastritis, ulcerative pharyngitis and ulcerative stomatitis.

[0062] In the eighth to eleventh aspects, the total content of quercetin, quercetin-3′-O-glucoside, myricetin, gossypol-8-O-β-D-glucuronide, isoquercetin and hyperoside contained in the hibiscus flower flavonoid extract or effective part is 55% or more, preferably 60% or more, preferably 65-85%, preferably 69-82%; further, the content of quercetin-3′-O-glucoside is 12.1-25%, preferably 12.6-25%, preferably 13.9-26.8%. 13-25%, preferably 14-25%, or, 12.6-23%, or 13-20%; further, the content of quercetin is more than 0.7%, preferably more than 1.0%, preferably 1.0-12%, preferably 1.5-12%, or 1.0%-10%, or 1.5%-5%; further, the content of quercetin-8-O-β-D-glucuronide is 8.5-34%, preferably 12-34%, or 8.5-30%, or 12%-23%.

[0063] In the eighth to eleventh aspects above, the extract or effective part contains quercetin, quercetin-3'-O-glucoside, myricetin, gossypol-8-O-β-D-glucuronide, isoquercetin, rutin and hyperoside in a total content of 55% or more, preferably 60% or more, preferably 65-85% or 66-84%, preferably 69-82% or 69-90%; further, the content of quercetin-3'-O-glucoside is 12.1-25%, preferably 12.6-23%, preferably 13-20%.

[0064] In a twelfth aspect, the present invention provides a Hibiscus truncatum flower extract containing flavonoid components, wherein the extract comprises the following components by mass content: 8-30% hyperoside, 10-24% isoquercetin, 8.5-34% gossypol-8-O-β-D-glucuronide, 3.0-4.9% or 5.1-7.0% myricetin, 14-25% quercetin-3′-O-glucoside, 1.6-12% quercetin; or 8-26% hyperoside, 12.0-19.8% isoquercetin, 8-O-β-D-glucuronide, 3.0-4.9% or 5.1-7.0% myricetin, 14-25% quercetin-3′-O-glucoside, 1.6-12% quercetin; β-D-glucuronide 8.5-30%, myricetin 3.0-4.9% or 5.1-6.0%, quercetin-3′-O-glucoside 14-25%, quercetin 1.6-4.9%; or hyperoside 11-22%, isoquercetin 12.0-17%, gossypol-8-O-β-D-glucuronide 12-23%, myricetin 1.6-4.9% or 5.1-9.0%, quercetin-3′-O-glucoside 13-22%, quercetin 1.4-8% or 1.4-7.8%.

[0065] Specifically, the extract also contains 0.01-1.0% rutin by mass, further 0.05-0.95%, further 0.09-0.95%, further 0.1-0.95%, or 0.05-0.8%, further 0.09-0.8%, further 0.1-0.6%; further, it contains 0.08-2.5% quercetin-3-O-sophora glycoside, preferably 0.1-1.5%, further 0.1-0.9%, further 0.1-0.8%, further 0.1-0.5%.

[0066] Specifically, the mass content of flavonoid components in the hibiscus flower extract is above 55%, preferably above 60%, preferably 65-90%, and preferably 69-82%.

[0067] Wherein, the ulcerative disease is any one of ulcerative enteritis, ulcerative gastritis, ulcerative pharyngitis and ulcerative stomatitis.

[0068] In a thirteenth aspect, the present invention provides a composition, comprising the following mass ratios of flavonoid components: the mass ratio of isoquercetin: quercetin: quercetin-3′-O-glucoside: myricetin: gossypol-8-O-β-D-glucuronide: hyperoside is 1: 0.05-1.6: 0.2-4.6: 0.05-1.2: 0.2-3.5: 0.25-3.6; further 1: 0.1-1.2: 0.4-3.1: 0.10-0.9 ∶0.4-3.1∶0.5-3.0; further 1∶0.16-1.0∶0.6-2.4∶0.14-0.75∶0.6-2.5∶0.6-2.4; further 1∶0.2-0.8∶0.8-2.1∶0.18-0.6∶0.8-2.0∶0.7-2.0; further 1∶0.2-0.7∶0.8-1.6∶0.2-0.5∶0.8-1.8∶0.8-1.4; further 1: 0.2-0.6: 1.0-1.2: 0.2-0.4: 0.9-1.7: 1.0-1.3 or 1.2: 0.05-1.6: 0.2-4.6: 0.05-1.2: 0.2-3.5: 0.25-3.6; further 1: 0.1-1.2: 0.4-3.1: 0.10-0.9: 0.4-3.1: 0.5-3.0; further 1: 0.16-1.0: 0.6-2.4: 0. 14-0.75∶0.6-2.5∶0.6-2.4; further 1∶0.2-0.8∶0.8-2.1∶0.18-0.6∶0.8-2.0∶0.7-2.0; further 1∶0.2-0.7∶0.8-1.6∶0.2-0.5∶0.8-1.8∶0.8-1.4; further 1∶0.2-0.6∶1.0-1.2∶0.2-0.4∶0.9-1.7∶1.0-1.3.

[0069] Specifically, the composition also includes rutin, and the mass ratio of isoquercetin to rutin is 1:0.001-0.08, preferably 1:0.005-0.06, preferably 1:0.006-0.05, preferably 1:0.007-0.04, preferably 1:0.008-0.03, and preferably 1:0.009-0.03; further, the content of quercetin-3'-O-glucoside in the flavonoid components is 12.1-25%, and further, the content of quercetin-3'-O-glucoside is 12.6-23% or 13-20%, and further, it contains 0.08-2.5% of quercetin-3-O-sophora glycoside, preferably 0.1-1.5%, further 0.1-0.9%, and further 0.1-0.5%.

[0070] More specifically, the composition contains quercetin, quercetin-3'-O-glucoside, myricetin, gossypol-8-O-β-D-glucuronide, isoquercetin, rutin and hyperoside in a total content of more than 55%, preferably more than 60%, preferably 65-85%, preferably 69-82%.

[0071] In a fourteenth aspect, the present invention provides a pharmaceutical composition, comprising the above-mentioned effective fraction, the above-mentioned hibiscus extract or the above-mentioned composition, and the pharmaceutical composition also includes a pharmaceutically acceptable carrier.

[0072] Specifically, the pharmaceutically acceptable carrier includes a solvent, an emulsifier, a disintegrant, a filler, a solubilizer, an antioxidant, a pH regulator, an osmotic pressure regulator, an antibacterial agent, a diluent, a wetting agent, a binder and / or a film-forming agent, and the lubricant does not contain magnesium stearate.

[0073] Specifically, the dosage forms of the pharmaceutical composition include injections, tablets, suppositories, ointments, gels, pills, tablets, granules, capsules or mixtures, suspensions, and dispersible tablets.

[0074] In a second main aspect, the present invention provides methods for preparing the flavonoid effective parts, extracts, and compositions in each of the technical solutions of the first main aspect.

[0075] In a first aspect, the present invention provides a method for preparing the above-mentioned effective part or the above-mentioned hibiscus flower extract, the method comprising the following steps: (1) extracting hibiscus flower or the medicinal part of hibiscus flower with ethanol to obtain an extract; (2) concentrating the extract and then extracting it to obtain an extract; (3) removing the solvent from the extract and eluting it with a macroporous resin to obtain the hibiscus flower flavonoid effective part or extract; the preferred extraction method is percolation.

[0076] Specifically, the amount of ethanol used in step (1) is 10-25 times that of hibiscus flower or medicinal part of hibiscus, and the ethanol is a 60-95% ethanol solution; the extractant used for the extraction in step (2) is n-butanol, petroleum ether or ethyl acetate, the extraction method is continuous countercurrent extraction, the material-liquid ratio of the extraction is 0.8-4:1, and the extraction level of the extraction is 1-5; the macroporous resin model in step (3) is D101, HPD100 or AB-8.

[0077] Specifically, step (2) further comprises subjecting the extract to activated carbon adsorption, alcohol precipitation or acid precipitation treatment before extraction.

[0078] Specifically, the elution process of the macroporous resin described in step (3) is as follows: the diameter-to-height ratio of the macroporous resin is 1:4-1:9, the loading solution concentration is 0.10-0.30 g crude drug / mL, the loading solution volume is 4-12 BV, the sample is loaded at a flow rate of 1-4 BV / h, 4-8 or 0.5-8 BV of pure water and 1-5 BV of 3-15% ethanol are used for impurity removal at a flow rate of 0.5-4 BV / h, and 2-8 BV of 50-80% ethanol are used for elution at a flow rate of 1-5 BV / h.

[0079] In a second aspect, the present invention provides a method for preparing the above-mentioned effective part or the above-mentioned hibiscus flower extract, wherein the method comprises the following steps: The preparation method comprises the following steps: (1) extracting hibiscus flower or the medicinal part of hibiscus flower with ethanol to obtain an extract; (2) adding a clarifier to the extract, treating it in a water bath, and filtering out the supernatant; (3) eluting the supernatant with a polyamide resin to obtain the hibiscus flower flavonoid effective part or extract; the preferred extraction method is percolation.

[0080] Specifically, the amount of ethanol in step (1) is 10-25 times that of hibiscus flower or medicinal part of hibiscus, and the ethanol is a 60-95% ethanol solution; the water bath temperature in step (2) is 50-70°C, and the water bath time is 30-90min; the resin diameter-to-height ratio in step (3) is 1:4-1:9, the loading solution concentration is 0.10-0.60g crude drug / mL, the loading solution volume is 4-12BV, and elution is performed with 4-8BV pure water and 4-8BV 60-95% ethanol.

[0081] In a third aspect, the present invention provides a method for preparing the above-mentioned effective part or the above-mentioned hibiscus extract, and the preparation method comprises the following steps: (1) extracting hibiscus flowers or the medicinal part of hibiscus with ethanol to obtain an extract; (2) adjusting the pH value of the extract to 2.0-3.0, refrigerating, filtering out the precipitate, and dissolving it in water; (3) extracting the dissolved solution to obtain an extract; (4) removing the solvent from the extract and eluting it with a polyamide resin to obtain the hibiscus flower flavonoid effective part or extract; the preferred extraction method is reflux.

[0082] Specifically, the amount of ethanol in step (1) is 10-25 times that of hibiscus flower or medicinal part of hibiscus, and the ethanol is a 60-95% ethanol solution; the pH regulator in step (2) is hydrochloric acid, sulfuric acid, acetic acid, phosphoric acid, citric acid, tartaric acid or maleic acid; the extractant used for extraction in step (3) is n-butanol, petroleum ether or ethyl acetate, the extraction method is continuous countercurrent extraction, the material-liquid ratio of the extraction is 0.8-4:1, and the extraction level of the extraction is 1-5; the resin diameter-to-height ratio in step (4) is 1:4-1:9, the sample solution concentration is 0.10-0.60g crude drug / mL, the sample solution volume is 4-12BV, and elution is performed with 4-8BV pure water and 4-8BV 60-95% ethanol.

[0083] In the third main aspect, the present invention provides the application of the effective parts, extracts and compositions in each technical solution of the first and second main aspects.

[0084] The application is an application in preparing kidney disease drugs, or an application in preparing eye disease drugs, or an application in preparing drugs for lupus nephritis, or kidney damage caused by contrast agents, or pulmonary fibrosis, or heart failure, or drugs for lowering uric acid, or SGLT2 inhibitors, or an application in preparing anti-fibrosis drugs, or an application in preparing drugs for treating and / or preventing ulcerative diseases, or an application in preparing products for preventing and treating inflammatory bowel disease, or an application in preparing drugs for treating and / or preventing skin diseases, or an application in preparing drugs for promoting wound healing.

[0085] The application is in the preparation of a drug that inhibits the proliferation of hepatic stellate cells, in the preparation of a drug for preventing or treating anti-tumor, and in the preparation of a drug for treating diseases related to liver fibrosis; the anti-liver fibrosis is anti-TGF-β-induced liver fibrosis. It is used to alleviate one or more of the following symptoms: cirrhosis, liver fibrosis, liver damage, and intrahepatic lipid deposition. The application is in the preparation of a drug for treating fatty liver; the fatty liver is selected from alcoholic fatty liver.

[0086] Preferably, the renal disease is chronic kidney disease, chronic nephritis, diabetic nephropathy, or diabetic nephropathy or nephritis with renal fibrosis, lupus nephritis, or renal injury caused by contrast agent; preferably, the renal disease is diabetic nephropathy or nephritis with renal fibrosis; preferably, the eye disease is preferably macular degeneration, visual fatigue or cataract, diabetic retinopathy, age-related macular degeneration, central exudative chorioretinitis, maculopathy caused by high myopia; preferably, the fibrosis can be selected from pulmonary fibrosis, and further Specific pulmonary fibrosis; preferably, the ulcerative disease is any one of ulcerative enteritis, ulcerative gastritis, ulcerative pharyngitis and ulcerative stomatitis; preferably, the inflammatory bowel disease is ulcerative colitis and Crohn's disease; preferably, the skin disease is any one of rash and acne; preferably, the wounds include but are not limited to burn wounds, residual small wounds, donor site wounds, chronic ulcer wounds and fresh and refractory skin wounds; preferably, the chronic ulcer wounds include but are not limited to diabetic, vascular, and radiation ulcers.

[0087] The pharmaceutical composition of the present invention, when combined in a specific ratio, has a good effect in treating diabetic nephropathy, has little side effects, and also has an effect in treating pulmonary fibrosis.

[0088] In a fourth main aspect, the present invention provides a pharmaceutical preparation comprising the effective parts, extracts, compositions, and preparation methods and uses thereof as described in the various technical solutions of the first and second main aspects above.

[0089] The effective parts and extracts contained in the pharmaceutical preparation invention are called extracts, and the effective parts and extracts prepared by extracting hibiscus flowers are called hibiscus flower extracts.

[0090] In a first aspect, the present invention provides a pharmaceutical preparation comprising a hibiscus flower extract and a pharmaceutically acceptable excipient, wherein the hibiscus flower extract,

[0091] The flavonoid components contain the following mass ratio: the mass ratio of gossypol-8-O-β-D-glucuronide: hyperoside: isoquercetin: myricetin: quercetin-3′-O-glucoside: quercetin is 10: 2.0-25: 3.0-20: 1.0-7.0: 4.0-23: 0.6-12.0;

[0092] Alternatively, the flavonoid component contains the following mass ratio: isoquercetin:quercetin:quercetin-3′-O-glucoside:myricetin:gossypol-8-O-β-D-glucuronide:hyperoside is 0.8-1.2:0.05-1.6:0.2-4.6:0.05-1.2:0.2-3.5:0.25-3.6;

[0093] Alternatively, the flavonoid components contain the following mass contents: hyperoside 8-26%, isoquercetin 12.0-19.8%, gossypol-8-O-β-D-glucuronide 5-30%, myricetin 1.6-11%, quercetin-3′-O-glucoside 12.1-25%, quercetin 1.4-10%; further, hyperoside 8-26%, isoquercetin 12.0-19.8%, gossypol-8-O-β-D-glucuronide 8.5-30%, myricetin 3.0-4.9% or 5.1-6.0%, quercetin-3′-O-glucoside 14-25%, quercetin 1.6-4.9%; here refers to the proportion of flavonoids such as hyperoside in the Hibiscus tiliaceus flower extract;

[0094] The preparation is a non-aqueous liquid preparation;

[0095] The mass content of the pharmaceutically acceptable excipients in the preparation is 0.5%-99.5%.

[0096] In some embodiments, the Hibiscus tiliaceus flower extract contains the following mass ratios of flavonoid components:

[0097] The mass ratio of gossypol-8-O-β-D-glucuronide: hyperoside: isoquercetin: myricetin: quercetin-3′-O-glucoside: quercetin is 10: 3.0-20: 4.0-18: 1.9-6.0: 6.0-20: 1.0-10.0, or 10: 6-15: 5-13: 1.0-2.9: 4.0-9.5: 0.6-6.0, or 10: 6-15: 5-13: 1.0-1.8: 4.0-5.9: 0.6-0.99;

[0098] Further, the mass ratio of gossypol-8-O-β-D-glucuronide: hyperoside: isoquercetin: myricetin: quercetin-3′-O-glucoside is 10: 4.0-17: 4.50-16: 1.9-5.5: 7.0-16;

[0099] Further, the mass ratio of gossypol-8-O-β-D-glucuronide: hyperoside: isoquercetin: myricetin: quercetin-3′-O-glucoside is 10:6.0-15:5.0-13:2.0-5.0:8.0-14;

[0100] Further, the mass ratio of quercetin-8-O-β-D-glucuronide to quercetin is 10:1.0-6.0, preferably 10:1.2-6, and more preferably 10:1.5-5.0;

[0101] Furthermore, it contains rutin, and the mass ratio of the cotton lin-8-O-β-D-glucuronide to rutin is 10:0.05-0.6, preferably 10:0.1-0.4, and more preferably 10:0.1-0.3;

[0102] Furthermore, it contains quercetin-3-O-acacia glycoside, wherein the ratio of quercetin-8-O-β-D-glucuronide to quercetin-3-O-acacia glycoside is 10:0.1-2.5, preferably 10:0.1-0.9, and more preferably 10:0.15-0.5;

[0103] Further, the mass ratio of gossypol-8-O-β-D-glucuronide: hyperoside: isoquercetin: myricetin: quercetin-3′-O-glucoside: quercetin is 10: 6-16: 5-13: 1.0-4.5: 4.0-12: 0.6-6.0, or 10: 15.1-16: 5-13: 3.0-4.5: 9.6-12: 0.6-6.0;

[0104] Furthermore, it contains rutin, and the mass ratio of the cotton lin-8-O-β-D-glucuronide to rutin is 10:0.05-0.6, preferably 10:0.1-0.4, and more preferably 10:0.1-0.3;

[0105] Furthermore, it contains quercetin-3-O-acacia glycoside, and the mass ratio of quercetin-8-O-β-D-glucuronide to quercetin-3-O-acacia glycoside is 10:0.1-2.5, preferably 10:0.1-0.9, and more preferably 10:0.15-0.5.

[0106] In some embodiments, the Hibiscus tiliaceus flower extract contains the following mass ratios of flavonoid components:

[0107] Isoquercetin: quercetin: quercetin-3′-O-glucoside: myricetin: cottonwood-8-O-β-D-glucuronide: hyperoside is 0.8-1.2: 0.05-1.6: 0.2-4.6: 0.05-1.2: 0.2-3.5: 0.25-3.6; further 0.8-1.2: 0.1-1.2: 0.4-3.1: 0.10-0.9: 0.4-3.1: 0.5-3.0; further 0.8-1.2: 0.16-1.0: 0.6-2.4: 0.14-0.75: 0.6-2.5: 0.6-2.4; further 0.8-1.2: 0.2-0.8: 0.8-2.1 ∶0.18-0.6∶0.8-2.0∶0.7-2.0; further 0.8-1.2∶0.2-0.7∶0.8-1.6∶0.2-0.5∶0.8-1.8∶0.8-1.4; further 0.8-1.2∶0.2-0.6∶1.0-1.2∶0.2-0.4∶0.9-1.7∶1.0-1.3; or 0.8-1.2∶0.09-1.6∶0.2-2.0∶0.05-1.2∶0.5-3.0∶0.25-3.6; or 0.8-1.2∶0.12-0.7∶0.8-1.6∶0.2-0.5∶0.85-1.7∶1.0-1.4;

[0108] Furthermore, the mass ratio of the isoquercetin is 1.2 or 1.0;

[0109] Further, the ratio of isoquercetin:quercetin:quercetin-3′-O-glucoside:myricetin:cotton-8-O-β-D-glucuronide:hyperoside is 1:0.05-1.6:0.2-4.6:0.05-1.2:0.2-3.5:0.25-3.6; further 1:0.1-1.2:0.4-3.1:0.10-0.9:0.4-3.1:0.5-3.0; further 1:0.1 6-1.0∶0.6-2.4∶0.14-0.75∶0.6-2.5∶0.6-2.4; further 1∶0.2-0.8∶0.8-2.1∶0.18-0.6∶0.8-2.0∶0.7-2.0; further 1∶0.2-0.7∶0.8-1.6∶0.2-0.5∶0.8-1.8∶0.8-1.4; further 1∶0.2-0.6∶1.0-1.2∶0.2 -0.4∶0.9-1.7∶1.0-1.3; or 1.2∶0.05-1.6∶0.2-4.6∶0.05-1.2∶0.2-3.5∶0.25-3.6; further 1.2∶0.1-1.2∶0.4-3.1∶0.10-0.9∶0.4-3.1∶0.5-3.0; further 1.2∶0.16-1.0∶0.6-2.4∶0.14-0.75∶0.6 -2.5∶0.6-2.4; further 1.2∶0.2-0.8∶0.8-2.1∶0.18-0.6∶0.8-2.0∶0.7-2.0; further 1.2∶0.2-0.7∶0.8-1.6∶0.2-0.5∶0.8-1.8∶0.8-1.4; further 1.2∶0.2-0.6∶1.0-1.2∶0.2-0.4∶0.9-1.7∶1.0-1.3;

[0110] Furthermore, it contains rutin, and the mass ratio of isoquercetin to rutin is 1:0.001-0.08, preferably 1:0.005-0.06, more preferably 1:0.006-0.05, more preferably 1:0.007-0.04, still more preferably 1:0.008-0.03, and most preferably 1:0.009-0.03;

[0111] Furthermore, it contains quercetin-3-O-acacia glycoside, and the mass ratio of isoquercetin to quercetin-3-O-acacia glycoside is 10:0.1-2.5, preferably 10:0.1-0.9, and more preferably 10:0.15-0.5.

[0112] In some embodiments, the Hibiscus tiliaceus flower extract contains the following flavonoid components by mass: hyperoside 10-25%, isoquercetin 8-19%, gossypol-8-O-β-D-glucuronide 5-30%, quercetin-3′-O-glucoside 12.1-25%;

[0113] Further, the quercetin-3′-O-glucoside content is 12.6-23% or 13-20%;

[0114] Further, hyperoside 12-23%, isoquercetin 10-17%, gossypol-8-O-β-D-glucuronide 8.5-25%, quercetin-3'-O-glucoside 12.6-23%;

[0115] Further, hyperoside 13-22%, isoquercetin 11-17%, gossypol-8-O-β-D-glucuronide 12-21%, quercetin-3′-O-glucoside 13-20%;

[0116] Furthermore, it also contains 2-10% quercetin, preferably 2.5-9% quercetin, further preferably 3-8.5% quercetin, and further preferably 1.5%-5% quercetin;

[0117] Furthermore, it contains 2-11% myricetin, preferably 3-7% myricetin, and further preferably 3-5% myricetin.

[0118] Further, it contains 0.08-2.5% of quercetin-3-O-acacia glycoside, preferably 0.1-1.5% of quercetin-3-O-acacia glycoside, further preferably 0.1-0.9% of quercetin-3-O-acacia glycoside, and further preferably 0.1-0.5% of quercetin-3-O-acacia glycoside;

[0119] Further, hyperoside 11-22%, isoquercetin 12.0-17%, gossypol-8-O-β-D-glucuronide 12-23%, myricetin 1.6-4.9% or 5.1-9.0%, quercetin-3′-O-glucoside 13-22%, quercetin 1.4-8% or 1.4-7.8%;

[0120] Furthermore, it contains 0.01-1.0% rutin, preferably 0.05-0.8% rutin, further preferably 0.09-0.8% rutin, and further preferably 0.1-0.6% rutin.

[0121] In some embodiments, the mass content of flavonoids in the Hibiscus hibiscus flower extract is 55% or more, preferably 60% or more, more preferably 65-85% or 66-84%, and even more preferably 69-82% or 69-90%;

[0122] Furthermore, the total content of quercetin, quercetin-3′-O-glucoside, myricetin, gossypol-8-O-β-D-glucuronide, isoquercetin and hyperoside is 55% or more, preferably 60% or more, more preferably 65-85%, and even more preferably 69-82%;

[0123] Further, the quercetin-3′-O-glucoside content is 12.1-25%, preferably the quercetin-3′-O-glucoside content is 12.6-23%, 13-20%, 13-20%, or 14-25%;

[0124] Or further, the content of quercetin is higher than 0.7%, preferably higher than 1.0%, further preferably 1.0%-10%, further preferably 1.5%-5%;

[0125] Or further, the content of cotton lin-8-O-β-D-glucuronide is 8.5-30%, preferably 12%-23%.

[0126] In some embodiments, the hibiscus flower extract is prepared by the following steps: (1) extracting hibiscus flowers or medicinal parts of hibiscus with ethanol to obtain an extract; (2) concentrating the extract and then extracting it to obtain an extract; (3) removing the solvent from the extract and eluting it with a macroporous resin to obtain the hibiscus flower extract; preferably, the extraction method is percolation;

[0127] Alternatively, the method can be prepared by the following method: (1) extracting hibiscus flower or its medicinal part with ethanol to obtain an extract; (22) adding a clarifying agent to the extract, treating it in a water bath, and filtering out the supernatant; (33) eluting the supernatant with a polyamide resin to obtain a hibiscus flower extract; the preferred extraction method is percolation.

[0128] In some embodiments, in step (1), the amount of ethanol is 10-25 times that of hibiscus flower or medicinal part of hibiscus, and the ethanol is a 60-95% ethanol solution; in step (2), the extractant used for extraction is n-butanol, petroleum ether or ethyl acetate, the extraction method is continuous countercurrent extraction, the solid-liquid ratio of the extraction is 0.8-4:1, and the extraction level of the extraction is 1-5; in step (3), the macroporous resin model is D101, HPD100 or AB-8; in step (22), the water bath temperature is 50-70°C, and the water bath time is 30-90min; in step (33), the resin diameter-to-height ratio is 1:4-9, the loading solution concentration is 0.10-0.60g crude drug / mL, the loading solution volume is 4-12BV, and elution is performed with 4-8BV pure water and 4-8BV 60-95% ethanol.

[0129] In some embodiments, step (2) includes subjecting the extract to activated carbon adsorption, alcohol precipitation or acid precipitation before extraction.

[0130] In some embodiments, the elution process of the macroporous resin is as follows: the diameter-to-height ratio of the macroporous resin is 1:4-9, the loading solution concentration is 0.10-0.30 g crude drug / mL, the loading solution volume is 4-12BV, the sample is loaded at a flow rate of 1-4BV / h, 4-8BV pure water and 1-5BV 3-15% ethanol are used for impurity removal at a flow rate of 0.5-4BV / h, and 2-8BV 50-80% ethanol is used for elution at a flow rate of 1-5BV / h.

[0131] In some embodiments, the hibiscus flower extract is prepared by the following method: adding ethanol to hibiscus flowers, heating to reflux, filtering, reducing the pressure of the filtrate to recover ethanol, concentrating, adjusting the pH to 5-7, standing, removing the upper oil layer, vacuum drying, and crushing to obtain; further, the amount of ethanol used is 10-20 times that of hibiscus flowers, reflux for 0.5-2 hours, and the pH is 6.0.

[0132] In an embodiment, the preparation of the hibiscus flower extract comprises the following steps: (1) extracting hibiscus flowers with ethanol to obtain an extract; (2) removing ethanol from the hibiscus flower extract, diluting with water, adsorbing with activated carbon, and continuously countercurrent extracting with n-butanol to obtain an extract; (3) removing the solvent from the extract, eluting with D101 macroporous resin, removing impurities with pure water and ethanol in turn, and eluting to obtain an eluate, and removing the solvent from the eluate under reduced pressure to obtain the hibiscus flower extract. Preferably, the ethanol is a 50-70% ethanol solution, and its dosage is 5-25 times that of hibiscus flower, preferably 10-20 times, and more preferably 15 times; the solid-liquid ratio of the extraction is 0.5-2.5:1, preferably 1.0-2.0:1, and more preferably 1.5:1; the number of extraction levels is 1-3, and more preferably 2; the diameter-to-height ratio of the macroporous resin is 1:5-7, preferably 1:5.5-6.5, and more preferably 1:6; the loading solution concentration is 0.05-0.25g crude drug / mL, preferably 0.1-0.2g crude drug / mL, and more preferably 0.15g crude drug / mL.

[0133] In some embodiments, the preparation of the hibiscus flower extract comprises the following steps: 1) crushing the hibiscus flower into coarse powder, extracting with 15 times 60% ethanol by percolation to obtain a hibiscus flower extract; 2) removing ethanol from the hibiscus flower extract, diluting with water, adsorbing with activated carbon, and continuously countercurrent extracting with n-butanol, the material-liquid ratio of the extraction (i.e., extractant: extracting solution) is 1.5:1, the extraction injection speed is 40mL / min, the extraction machine speed is 40Hz, the extraction level is 2, and the extract is decompressed and the solvent is recovered at 40°C; 3) treating with D101 macroporous resin, the treatment process of the macroporous resin is: the macroporous resin diameter-to-height ratio is 1:6, the loading solution (aqueous solution) concentration is 0.15g crude drug / mL, the loading solution volume is 7BV, loading at a flow rate of 2BV / h, removing impurities with 6BV pure water and 3BV 5% ethanol at a flow rate of 2BV / h, and removing impurities with 4BV 60% ethanol is eluted at a flow rate of 2BV / h to obtain an eluate, and then the eluate is decompressed at 50°C to recover ethanol to obtain a hibiscus flower flavonoid extract. Preferably, the prepared hibiscus flower extract has a total flavonoid component mass content of 40-90%, preferably 50-80%, and more preferably 60-70%.

[0134] In some embodiments, the hibiscus flower extract is prepared by the following method: 80% ethanol is added to hibiscus flowers for extraction, the extract is filtered and concentrated, and the filtrate is concentrated into a concentrated solution with a relative density of 1.13 to 1.16 at 60°C to obtain a concentrated solution; water is added to the concentrated solution to precipitate, filtered and concentrated to a corresponding volume, and the eluted solution is passed through a macroporous adsorption resin column with an alcohol-water gradient, and the eluate is concentrated, dried, and crushed to obtain the hibiscus flower extract.

[0135] In some embodiments, the hibiscus flower extract is prepared by the following method: add 80% ethanol to hibiscus flower, extract once, extract for 2 hours, combine the extracts, filter, concentrate the filtrate into a concentrate with a relative density of 1.13 to 1.16 at 60°C, add appropriate amount of water to precipitate for 24 hours, filter, concentrate to the corresponding volume, pass through a macroporous adsorption resin column, use alcohol-water gradient elution, water elution for 3 column volumes, 10% and 30% ethanol elution for 3 column volumes each, 70% ethanol elution for 1 column volume. After the eluate is concentrated, dried, and crushed, the hibiscus flower extract is obtained.

[0136] In some embodiments, the preparation of the hibiscus flower extract comprises the following steps: adding 70-80% ethanol to the hibiscus flower, extracting 1-2 times, each time for 1-4 hours, combining the extracts, filtering, concentrating the filtrate into a concentrate with a relative density of 1.13-1.16 at 60°C, adding an appropriate amount of water to precipitate for 24 hours, filtering, concentrating to a corresponding volume, passing through a macroporous adsorption resin column, using an alcohol-water gradient elution, eluting with water for 3 column volumes, eluting with 10% and 30% ethanol for 3 column volumes each, and eluting with 70% ethanol for 1 column volume. After the eluate is concentrated, dried, and crushed, a total flavonoid extract is obtained, and its total flavonoid content is 5-95%.

[0137] In a second aspect, the present invention also provides a pharmaceutical preparation of hibiscus flower extract, containing pharmaceutically acceptable excipients, and the preparation is a non-aqueous liquid preparation; the content of the pharmaceutically acceptable excipients in the preparation is 0.5%-99.5%; the extract is prepared by the following steps: (1) extracting hibiscus flower or hibiscus medicinal part with ethanol to obtain an extract; (2) concentrating the extract and then extracting it to obtain an extract; (3) removing the solvent from the extract and eluting it with a macroporous resin to obtain the hibiscus flower extract; the preferred extraction method is percolation;

[0138] Alternatively, the method can be prepared by the following method: (1) extracting hibiscus flower or its medicinal part with ethanol to obtain an extract; (22) adding a clarifying agent to the extract, treating it in a water bath, and filtering out the supernatant; (33) eluting the supernatant with a polyamide resin to obtain a hibiscus flower extract; the preferred extraction method is percolation.

[0139] In some embodiments, in step (1), the amount of ethanol is 10-25 times that of hibiscus flower or medicinal part of hibiscus, and the ethanol is a 60-95% ethanol solution; in step (2), the extractant used for extraction is n-butanol, petroleum ether or ethyl acetate, the extraction method is continuous countercurrent extraction, the solid-liquid ratio of the extraction is 0.8-4:1, and the extraction level of the extraction is 1-5; in step (3), the macroporous resin model is D101, HPD100 or AB-8; in step (22), the water bath temperature is 50-70°C, and the water bath time is 30-90min; in step (33), the resin diameter-to-height ratio is 1:4-9, the loading solution concentration is 0.10-0.60g crude drug / mL, the loading solution volume is 4-12BV, and elution is performed with 4-8BV pure water and 4-8BV 60-95% ethanol.

[0140] In some embodiments, step (2) includes subjecting the extract to activated carbon adsorption, alcohol precipitation or acid precipitation before extraction.

[0141] In some embodiments, the elution process of the macroporous resin is as follows: the diameter-to-height ratio of the macroporous resin is 1:4-9, the loading solution concentration is 0.10-0.30 g crude drug / mL, the loading solution volume is 4-12BV, the sample is loaded at a flow rate of 1-4BV / h, 4-8BV pure water and 1-5BV 3-15% ethanol are used for impurity removal at a flow rate of 0.5-4BV / h, and 2-8BV 50-80% ethanol is used for elution at a flow rate of 1-5BV / h.

[0142] In a third aspect, the preparation method of the hibiscus flower extract in the pharmaceutical preparation described in the first aspect comprises the following steps: (101) extracting hibiscus flowers or medicinal parts of hibiscus with ethanol to obtain an extract; (102) adjusting the pH value of the extract to 2.0-3.0, refrigerating, filtering out the precipitate, and dissolving it in water; (103) extracting the dissolved solution to obtain an extract; (104) removing the solvent from the extract and eluting with a polyamide resin to obtain an effective part or extract of flavonoids from hibiscus flowers; the preferred extraction method is reflux.

[0143] In some embodiments, the amount of ethanol in step (101) is 10-25 times that of hibiscus flower or medicinal part of hibiscus, and the ethanol is a 60-95% ethanol solution; the pH adjuster in step (102) is hydrochloric acid, sulfuric acid, acetic acid, phosphoric acid, citric acid, tartaric acid or maleic acid; the extractant used for extraction in step (103) is n-butanol, petroleum ether or ethyl acetate, the extraction method is continuous countercurrent extraction, the material-liquid ratio of the extraction is 0.8-4:1, and the extraction level of the extraction is 1-5; the resin diameter-to-height ratio in step (104) is 1:4-9, the sample solution concentration is 0.10-0.60g crude drug / mL, the sample solution volume is 4-12BV, and elution is performed with 4-8BV pure water and 4-8BV 60-95% ethanol.

[0144] In the first to third aspects above, the non-aqueous liquid preparation is a solid preparation or a semi-solid preparation; further selected from suppositories, ointments, gels, pills, tablets, granules, capsules or mixtures.

[0145] In the first to third aspects, the pharmaceutically acceptable excipients include any one or any combination of two or any combination of three or more of solvents, emulsifiers, disintegrants, fillers, solubilizers, antioxidants, pH regulators, osmotic pressure regulators, antibacterial agents, diluents, wetting agents, adhesives or film-forming agents; further, the excipients are selected from lactose, polyethylene glycol, cross-linked polyvinyl pyrrolidone, magnesium lauryl sulfate, hydroxypropyl cellulose, talc, calcium sulfate, microcrystalline cellulose, low-substituted hydroxypropyl methylcellulose, cross-linked sodium carboxymethyl cellulose, magnesium stearate Any one or any combination of two or any combination of three or more of the above; further, the filler and disintegrant are 1%-80% of the weight of the preparation, further 3%-78%, further 5%-75%, further 10%-70%, 15%-75%, 15%-65%, 20%-70%, 20%-60%, 25%-65%, 25%-55%, 30%-60%, 30%-50%, 35%-55%, further 1%-30%, 25%-55%, 50%-80% of the weight of the preparation.

[0146] In the above-mentioned first to third aspects, the mass content of the pharmaceutically acceptable excipients in the preparation is 2%-95%; further 5%-95%; further 10%-90%; further 15%-85%; further 20%-80%, 25%-75%, 30%-70%, 40%-60%, 50%-80%, 15%-90%; further 20%-85%, 4%-50%.

[0147] In a fourth aspect, the present invention further provides the use of the above-mentioned pharmaceutical preparation in the preparation of kidney disease drugs, or in the preparation of eye disease drugs, or in the preparation of lupus nephritis, or kidney damage caused by contrast agents, or pulmonary fibrosis, or heart failure, or in the preparation of uric acid-lowering drugs, or in the preparation of anti-fibrosis drugs, or in the preparation of drugs for treating and / or preventing ulcerative diseases, or in the preparation of products for preventing and treating inflammatory bowel disease, or in the preparation of drugs for treating and / or preventing skin diseases, or in the preparation of drugs for promoting wound healing; preferably, the kidney disease is diabetic nephropathy, or diabetic nephropathy or nephritis accompanied by renal fibrosis, lupus nephritis, or kidney damage caused by contrast agents; preferably, the kidney disease is diabetic nephropathy or nephritis accompanied by renal fibrosis; preferably, the eye Preferably, the local disease is macular degeneration, visual fatigue or cataract, diabetic retinopathy, age-related macular degeneration, central exudative chorioretinitis, and macular degeneration caused by high myopia; preferably, the fibrosis can be selected from pulmonary fibrosis, and further is specific pulmonary fibrosis; preferably, the ulcerative disease is any one of ulcerative enteritis, ulcerative gastritis, ulcerative pharyngitis and ulcerative stomatitis; preferably, the inflammatory bowel disease is ulcerative colitis and Crohn's disease; preferably, the skin disease is any one of rash and acne; preferably, the wound includes but is not limited to burn wounds, residual small wounds, donor site wounds, chronic ulcer wounds and fresh and refractory skin wounds; preferably, the chronic ulcer wounds include but are not limited to diabetic, vascular, and radiation ulcers.

[0148] The hibiscus flower flavonoid effective part of the present invention, in addition to detecting the seven components of hyperoside, rutin, isoquercetin, hibifolin, myricetin, quercetin-3′-O-glucoside, and quercetin, also performs peak area conversion of quercetin-3-O-acacia glycoside content in the solid sample prepared by the embodiment of the present invention in the detection process, and the content conversion calculation method is=peak area of ​​hyperoside reference substance / concentration of hyperoside reference substance*correction factor*peak area of ​​quercetin-3-O-acacia glycoside*fixed volume / sample weight (after water reduction), and the content is not higher than 2.0%, further not higher than 0.9%, preferably 0.1%-0.7%. The total content of the detected multiple flavonoid components is above 70%, further above 75%, and further 80%-90%.

[0149] Unless otherwise specified, the % ethanol mentioned in the present invention is by volume percentage.

[0150] Beneficial effects:

[0151] (1) The effective part or extract of flavonoids from hibiscus flowers and the preparation thereof described in the present invention have the effect of treating various nephritis, such as diabetic nephropathy, contrast-induced renal injury or lupus erythematosus nephritis, and also have the effect of treating eye diseases, especially various diseases related to inhibiting blood flow and inhibiting ocular blood vessels, such as age-related macular degeneration, central exudative chorioretinitis and macular lesions caused by high myopia, etc. In particular, the effective part or extract of flavonoids from hibiscus flowers described in the present invention also has the effect of treating pulmonary fibrosis.

[0152] (2) The preparation method of the present invention has simple process, short production cycle, mild treatment conditions, low energy consumption and good separation effect of the seven flavonoid components of hibiscus flower. The raw materials and reagents used are widely available, low in cost, and easy to realize industrial large-scale production.

[0153] (3) The effective part or extract or composition of flavonoids from hibiscus flowers and the preparation thereof described in the present invention have relatively low side effects, thus providing a better treatment method for patients.

[0154] (4) The effective part or extract of flavonoids from hibiscus flowers and the preparation thereof provided by the present invention have good preventive and therapeutic effects on skin diseases, such as dermatitis and acne.

[0155] (5) The effective part or extract or composition of flavonoids from hibiscus flowers provided by the present invention and the preparation thereof can effectively treat skin diseases at a lower dosage.

[0156] (6) The effective part or extract of hibiscus flower flavonoids and the preparation provided by the present invention have the effect of promoting wound healing, and have obvious effects of promoting wound healing and treating diabetic ulcers and have good safety.

[0157] (7) The effective part or extract or composition of flavonoids from hibiscus flowers provided by the present invention and the preparation thereof can effectively treat oral ulcers at a lower dosage.

[0158] (8) The present invention provides an enteric-coated preparation containing hibiscus flower extract, which has the characteristics of good stability and fast product dissolution rate. It is almost not released in the stomach, but can be quickly released in the intestinal environment, which can reduce the irritation of the drug to the stomach, improve the bioavailability of the drug, and allow the drug to be more completely absorbed in the intestine. At the same time, it has a significant therapeutic effect on ulcerative colitis, providing a new preparation for the clinical treatment of ulcerative colitis. BRIEF DESCRIPTION OF THE DRAWINGS

[0159] Figure 1 This is the dissolution process of 5-ASA and ZHT.

[0160] Figure 2Effects of ZHT on DSS-induced colon atrophy; (A) Colon appearance pictures of mice in each group, (B) Statistical graph of colon length of mice in each group, data are expressed as mean ± standard error. N = 8. **, P < 0.01, vs. Control; # , P < 0.05, vs. DSS, analyzed using one-way ANOVA and Dunnett's multiple comparison test.

[0161] Figure 3 The effect of ZHT on DSS-induced colonic tissue pathological changes; (A) H&E staining pictures of colonic tissue of mice in each group, 5x objective magnification, Scale bar = 500μm; 20x objective magnification, Scale bar = 100μm, (B) Statistical chart of colonic tissue inflammation scores of mice in each group. Data are expressed as mean ± standard error. N = 7. **, P < 0.01, vs. Control; ## , P < 0.01, vs. DSS, analyzed using one-way ANOVA and Dunnett's multiple comparison test.

[0162] Figure 4 These are the pathological pictures of each group in the oral ulcer efficacy experiment.

[0163] Figure 5 Flow chart for preparation, drug administration, and material collection of acne model.

[0164] Figure 6 Flowchart for construction and dosing of atopic dermatitis model.

[0165] Figure 7 The effects of ZHT and HKY on the appearance of DNFB-induced atopic dermatitis model.

[0166] Figure 8 The effects of ZHT and HKY on the skin pathological changes in the DNFB-induced atopic dermatitis model, where the representative images are HE staining of the skin tissue of mice in each group, the blue line indicates the thickness of the epidermis, and the scale bar = 100 μm.

[0167] Fig. 9 The following are representative images of the skin wound area of ​​rats in each group at different time points; (A) Representative images of the skin wound area of ​​rats in each group at different time points, (B) Skin wound healing curves of rats in each group. *P<0.05, **P<0.01 vs. Model.

[0168] Fig.10HE staining results of rat skin wound tissue and quantitative graph of epidermal thickness; (A) HE staining results of rat wound and edge tissue, (B) quantitative graph of epidermal thickness of rat skin wound in each group. **P<0.01, vs. Model; ##, P<0.01, vs. Control.

[0169] Fig.11 Masson staining results of rat skin wound tissue and quantitative collagen deposition; (A) Masson staining results of rat wound and edge tissue, (B) quantitative collagen deposition of rat skin wound in each group. N = 6, *P < 0.05, ** P<0.01 vs.Model; ##P<0.01, vs.Control.

[0170] Fig.12 The changes of CD31 and VEGF mRNA levels in rat skin wound tissue; (A) The changes of CD31 mRNA levels in rat skin wound tissue after 9 days of treatment, (B) The changes of VEGF mRNA levels in rat skin wound tissue after 9 days of treatment.

[0171] Fig.13 These are the results of CD31 immunofluorescence staining of rat skin wound tissue and the quantitative graph of fluorescence intensity; (A) CD31 immunofluorescence staining of rat skin tissue after 9 days of treatment, scale bar is 250μm; (B) Fluorescence intensity quantitative graph of CD31, N=6, #P<0.05vs.control.

[0172] Fig.14 The changes in VEGF protein levels in rat skin wound tissue; The changes in VEGF protein levels in rat skin wound tissue 9 days after modeling, N=6, **P<0.05vs model.

[0173] Fig.15 Serum ALT (A) and AST (B) levels in mice 7 days after bile duct ligation and oral administration. ##: P < 0.01, BDL group vs. sham operation group; **: P < 0.01, BDL + oral administration group vs. BDL group. Data are expressed as Mean ± SEM, n = 8.

[0174] Fig.16 Pathological evaluation of liver tissue after bile duct ligation and oral administration of mice 7 days later, Masson staining of liver tissue (A) and collagen area statistics (B). ##: P < 0.01, BDL group vs. sham operation group; *: P < 0.05, BDL + oral administration group vs. BDL group. Data are expressed as Mean ± SEM, n = 5.

[0175] Fig.17mRNA levels of α-Sma (A) and Collal (B) in liver tissue of mice 7 days after bile duct ligation and oral administration. ##: P<0.01, BDL group vs. sham operation group; *: P<0.05, BDL+oral administration group vs. BDL group. Data are expressed as Mean±SEM, n=6.

[0176] Fig.18 (A) Representative graph of α-SMA protein expression in liver tissue of mice 7 days after bile duct ligation and oral administration; (B) Statistical graph of protein band fluorescence values ​​in (A). ##: P<0.01, BDL group vs. sham operation group; **: P<0.01, BDL+oral administration group vs. BDL group. Data are expressed as Mean±SEM, n=8 DETAILED DESCRIPTION

[0177] The present invention will be further described in detail below in conjunction with specific examples. The following examples are not intended to limit the present invention, but are only intended to illustrate the present invention. The experimental methods used in the following examples are generally conventional, unless otherwise specified, and the materials, reagents, etc. used in the following examples are commercially available, unless otherwise specified.

[0178] The hibiscus flowers in the following embodiments are dried hibiscus corollas, and unless otherwise specified, are from the same batch of hibiscus flowers.

[0179] The contents of seven components of the flavonoid effective parts of Hibiscus tiliaceus prepared in each embodiment were determined. These seven components are: hyperoside, rutin, isoquercetin, quercetin-8-O-β-D-glucuronide, myricetin, quercetin-3′-O-glucoside, and quercetin. During the preparation of the effective part samples, the contents of the components of the solution before drying of the effective part were also tested, and the sample contents before and after drying had certain changes. The detection method uses the UPLC method reported in "One Test and Multiple Evaluation Method for Determination of Seven Components in Hibiscus tiliaceus Flowers" (Journal of Pharmaceutical Analysis, Issue 12, 2013, 2082-2087) to determine the contents of the components therein.

[0180] The material-liquid ratio of the extraction (ie, extractant: extracting liquid) refers to the volume ratio.

[0181] Unless otherwise specified, the Huangkui Capsules described in the following examples are all Huangkui Capsules produced and sold by Suzhong Pharmaceutical Group Co., Ltd.

[0182] Example 1 Preparation of the effective fraction of flavonoids from Hibiscus tiliaceus flowers

[0183] 100g of hibiscus flower was crushed into coarse powder, and 15 times of 60% ethanol was used for percolation extraction to obtain hibiscus flower extract; ethanol was removed from the hibiscus flower extract, diluted with water, adsorbed on activated carbon, and continuously countercurrently extracted with n-butanol, the material-liquid ratio of the extraction (i.e., extractant: extracting solution) was 1.5:1, the injection speed of the extraction was 40mL / min, the speed of the extraction machine was 40Hz, the extraction level of the extraction was 2, the extract was decompressed and the solvent was recovered at 40°C, and then treated with D101 macroporous resin, the treatment process of the macroporous resin was as follows: the diameter-to-height ratio of the macroporous resin was 1:6, the concentration of the loading solution (aqueous solution) was 0.15g crude drug / mL, the loading solution volume was 7BV, the sample was loaded at a flow rate of 2BV / h, 6BV pure water and 3BV 5% ethanol at a flow rate of 2BV / h for impurity removal, 4BV60% ethanol at a flow rate of 2BV / h for elution to obtain an eluate, and then the eluate was decompressed at 50°C to recover ethanol to obtain a hibiscus flower flavonoid extract, and the content was tested. According to the content determination results, the contents of the seven components were adjusted by addition method, so that the contents of each component were as shown in the following table, and 2.23g of total solids of the effective part of flavonoids in hibiscus flower were obtained, and the total of the seven components was 1769mg, accounting for 79.32% of the total solids.

[0184] Table 1 Content determination data of samples

[0185]

[0186]

[0187] Example 2 Preparation of the effective fraction of flavonoids from Hibiscus tiliaceus flowers

[0188] Example 2-1

[0189] 100g of hibiscus flower was crushed into coarse powder, and extracted by percolation with 18 times 70% ethanol to obtain hibiscus flower extract; ethanol was removed from the hibiscus flower extract, diluted with water, and continuously countercurrently extracted with ethyl acetate, the material-liquid ratio of the extraction (i.e., extractant: extract) was 2.5:1, the injection speed of the extraction was 80mL / min, the speed of the extraction machine was 40Hz, the extraction level of the extraction was 4, the extract was reduced pressure at 40°C to recover the solvent, and then treated with D101 macroporous resin, the treatment process of the macroporous resin was as follows: the macroporous resin diameter-to-height ratio was 1:5, the sample solution concentration was 0.15g crude drug / mL, the sample solution volume was 6BV, the sample was loaded at a flow rate of 2BV / h, 6BV pure water and 3BV 5% ethanol were used to remove impurities at a flow rate of 2BV / h, and 4BV 60% ethanol was eluted at a flow rate of 1.5 BV / h to obtain an eluate, and then the eluate was decompressed at 60°C to recover ethanol to obtain a hibiscus flower flavonoid extract, and the content was tested. According to the content determination results, the contents of the seven components were adjusted by addition method, so that the contents of each component were as shown in the following table, and the total solid content of the hibiscus flower flavonoid effective part was 2.99. The content of quercetin-3-O-acacia glycoside was 0.28%.

[0190] Table 2-1 Sample content determination data

[0191]

[0192] Example 2-A Preparation of the effective fraction of flavonoids from Hibiscus tiliaceus flowers

[0193] According to the method of Example 2-1 above, hibiscus flower was magnified 10 times, and two batches of hibiscus flower flavonoid effective parts were prepared to obtain samples with content determination data of samples in Table 2-2. The content of quercetin-3-O-acacia glycoside was 0.20-0.50%.

[0194] Table 2-2 Content determination data of samples

[0195]

[0196] Among them, 2-Al contains 0.24% quercetin-3-O-acacia glycoside content converted by peak area, and the proportion of each component is shown in Table 2-3 below.

[0197] Table 2-3 Content ratio data between each component of the sample

[0198]

[0199] Example 2-A3

[0200] Take hyperoside, isoquercetin, hibifolin, myricetin, quercetin-3′-O-glucoside, quercetin, and quercetin 3-O-acacia glycoside as raw materials, and mix them according to the ratio of Example 2-A1 (quercetin 3-O-acacia glycoside replaces rutin, and the ratio is adjusted to 0.02) as follows to prepare a total flavonoid composition.

[0201] Table 2-4

[0202]

[0203] Example 2-A4

[0204] Take hyperoside, isoquercetin, hibifolin, myricetin, quercetin-3′-O-glucoside, quercetin, and quercetin 3-O-acacia glycoside as raw materials, mix them according to the ratio of Example 2-A1 (quercetin 3-O-acacia glycoside replaces rutin, and the ratio is adjusted to 0.05) to prepare a total flavonoid composition.

[0205] Example 2-B

[0206] In order to obtain the effective part of hibiscus flower with uniform quality, the content relationship between the medicinal material and the extract was studied according to the content results of the components of the extracts of multiple batches of Example 2-1. Three batches of hibiscus flowers with different sources and large differences in components were mixed according to the software calculation method. 2000 g of the mixed hibiscus flowers were extracted by 18 times 70% ethanol percolation to obtain hibiscus flower extract. The ethanol was removed, diluted with water, and continuously countercurrent extracted with ethyl acetate. The material-liquid ratio of the extraction (i.e., the extractant: the extract) was 3:1. The extraction injection speed is 120mL / min, the extraction machine speed is 60Hz, the extraction level is 4, the extract is reduced pressure at 50°C to recover the solvent, then diluted with water, centrifuged, and the supernatant is treated with D101 macroporous resin. The treatment process of the macroporous resin is as follows: the macroporous resin diameter-to-height ratio is 1:6, the sample concentration is 0.15g crude drug / mL, the sample volume is 7BV, the sample is loaded at a flow rate of 2BV / h, 6BV pure water and 3BV 5% ethanol are used to remove impurities at a flow rate of 2BV / h, and 4BV 60% ethanol was eluted at a flow rate of 2BV / h to obtain an eluate, which was concentrated and dried under reduced pressure at 60°C to obtain a total solid content containing 0.22% rutin, 20.58% hyperoside, 17.81 isoquercetin, 16.07% hibifolin, 5.15% myricetin, 17.37% quercetin-3′-O-glucoside, 1.77% quercetin, and 0.43% quercetin-3-O-acacia glycoside peak area. The mass ratios of the components are shown in Table 2-5 below.

[0207] Table 2-5 Content ratio data between the components of the samples

[0208]

[0209] Example 3 Preparation of the effective fraction of flavonoids from Hibiscus tiliaceus flowers

[0210] Example 3-1

[0211] 100g of hibiscus flower was crushed into coarse powder, and extracted by percolation with 18 times 60% ethanol to obtain hibiscus flower extract; ethanol was removed from the hibiscus flower extract, diluted with water, and continuously countercurrently extracted with ethyl acetate, the material-liquid ratio of the extraction (i.e., extractant: extract) was 3:1, the injection speed of the extraction was 100mL / min, the speed of the extraction machine was 40Hz, the extraction level was 5, the extract was decompressed and the solvent was recovered at 40°C, and then treated with D101 macroporous resin, the treatment process of the macroporous resin was as follows: the diameter-to-height ratio of the macroporous resin was 1:8, the concentration of the sample solution was 0.15g crude drug / mL, the volume of the sample solution was 8BV, the sample was loaded at a flow rate of 2BV / h, 6BV of pure water and 3BV of 5% ethanol were used for impurity removal at a flow rate of 2BV / h, 4BV 60% ethanol was eluted at a flow rate of 3BV / h to obtain an eluate, and then the eluate was decompressed at 60°C to recover ethanol to obtain a hibiscus flower flavonoid extract, and the content was tested. According to the content determination results, the contents of the seven components were adjusted by addition method, so that the contents of each component were as shown in the following table, and 3.18g of total solid content of hibiscus flower flavonoid effective parts were obtained. The content of quercetin-3-O-acacia glycoside was 0.20-0.50%.

[0212] Table 3-1 Sample content determination data

[0213]

[0214] Example 3-2

[0215] According to the preparation method of Example 3-1, 500 g of Hibiscus hibiscus flower medicinal material was used for repeated experiments, and the content data of 2 batches were obtained as shown in Table 3-2 below. The content of quercetin-3-O-acacia glycoside was 0.30-0.80%. Where A represents "each component / total solids (%)", and B represents "each component / isoquercetin".

[0216] Table 3-2

[0217]

[0218]

[0219] Example 4 Preparation of the effective fraction of flavonoids from Hibiscus tiliaceus flowers

[0220] Example 4-1

[0221] 100g of hibiscus flower was extracted by percolation with 18 times 70% ethanol to obtain hibiscus flower extract; ethanol was removed from the hibiscus flower extract, diluted with water, and continuously countercurrently extracted with n-butanol, the material-liquid ratio of the extraction (i.e., extractant: extracting solution) was 3:1, the injection speed of the extraction was 120mL / min, the speed of the extraction machine was 60Hz, the extraction level was 5, the extract was decompressed and the solvent was recovered at 50°C, and then treated with D101 macroporous resin, the treatment process of the macroporous resin was as follows: the macroporous resin diameter-to-height ratio was 1:6, the sample solution concentration was 0.15g crude drug / mL, the sample solution volume was 7BV, the sample was loaded at a flow rate of 2BV / h, 6BV pure water and 3BV 5% ethanol were used for impurity removal at a flow rate of 2BV / h, 4BV 60% ethanol was used for elution at a flow rate of 2BV / h to obtain an eluate, and then the eluate was decompressed at 60°C to recover the ethanol to obtain a hibiscus flower extract. The content was tested, and the contents of the seven components were adjusted by addition method according to the determination results, so that the contents of each component were as shown in the following table, and 2.05g of total solids of the effective part of flavonoids in hibiscus flower were obtained.

[0222] Table 4-1 Sample content determination data

[0223]

[0224] Example 4-2

[0225] The flower of Hibiscus tiliaceus is extracted by percolation with 18 times of 70% ethanol, and the ethanol is removed from the extract to 0.5-1.0g crude drug / ml, and the amount of ZTC1+1-II clarifier added is 4% of B component and 2% of A component respectively. The water bath temperature is 60°C, the water bath insulation time is 60min, centrifugation, filtration, dilution, and treatment with polyamide resin (80-100 mesh). The resin treatment process is as follows: the resin diameter-to-height ratio is 1:7, the sample solution concentration is 0.15-0.5g crude drug / mL, the sample solution volume is 8BV, and the eluate is eluted with 5BV pure water and 5BV 80% ethanol to obtain an eluate, which is concentrated and dried under reduced pressure at 60°C. The content is tested, and the contents of 7 components are adjusted by addition method according to the content determination results, so that the contents of each component are shown in the following table, and the total solid content of the effective part of flavonoids of Hibiscus tiliaceus flower is obtained, and the content of quercetin-3-O-acacia glycoside is 0.39%.

[0226] Table 4-2

[0227]

[0228]

[0229] Example 5 Preparation of the effective fraction of flavonoids from Hibiscus tiliaceus flowers

[0230] Example 5-1

[0231] 100g of hibiscus flower was extracted by percolation with 15 times 70% ethanol to obtain hibiscus flower extract; ethanol was removed from the hibiscus flower extract, diluted with water, and continuously countercurrently extracted with n-butanol, the material-liquid ratio of the extraction (i.e., extractant: extracting solution) was 2.5:1, the injection speed of the extraction was 80mL / min, the speed of the extraction machine was 50Hz, the extraction level was 4, the extract was decompressed and the solvent was recovered at 50°C, and then treated with D101 macroporous resin, the treatment process of the macroporous resin was as follows: the diameter-to-height ratio of the macroporous resin was 1:6, the concentration of the sample solution was 0.2g crude drug / mL, the volume of the sample solution was 6BV, the sample was loaded at a flow rate of 2BV / h, 1BV of pure water and 4BV of 5% ethanol were used for impurity removal at a flow rate of 2BV / h, 3BV The eluate was eluted with 60% ethanol at a flow rate of 2BV / h, and the eluate was decompressed at 60°C to recover the ethanol to obtain a hibiscus flower extract. The content was tested, and the contents of seven components were adjusted by addition method according to the content determination results to obtain 2.86g of total solids of the effective part of flavonoids in hibiscus flower.

[0232] Example 5-2

[0233] The flower of Hibiscus hibiscus is extracted by reflux with 15 times 70% ethanol, the ethanol is removed from the extract to 0.5-1.0 g crude drug / ml, 10% hydrochloric acid solution is added to adjust the pH value to 2.0-3.0, refrigerated, filtered, washed, the precipitate is taken, water is added to dissolve, and continuous countercurrent extraction is performed with ethyl acetate, the material-liquid ratio of the extraction (i.e., the extractant: the extract) is 3:1, the extraction level is 4, the extract is reduced pressure at 50°C to recover the solvent, diluted with water, and treated with polyamide resin, the resin treatment process is: the resin diameter-height ratio is 1:6, the sample solution concentration is 0.15-0.5 g crude drug / mL, the sample solution volume is 6BV, 4BV pure water and 4BV 70% ethanol are used to elute to obtain the eluent, concentrated, and dried under reduced pressure at 60°C to obtain the quercetin-3-O-acacia glycoside content of 0.47%.

[0234] Table 5

[0235]

[0236] Example 6 Preparation of the effective fraction of flavonoids from Hibiscus tiliaceus flowers

[0237] 100g of hibiscus flower was extracted by percolation with 16 times of 60% ethanol to obtain hibiscus flower extract; ethanol was removed from the hibiscus flower extract, diluted with water, and continuously countercurrently extracted with ethyl acetate, the material-liquid ratio of the extraction (i.e., extractant: extract) was 2:1, the injection speed of the extraction was 100mL / min, the speed of the extraction machine was 40Hz, the extraction level was 4, the extract was reduced pressure at 50°C to recover the solvent, and then treated with D101 macroporous resin, the treatment process of the macroporous resin was as follows: the diameter-to-height ratio of the macroporous resin was 1:6, the concentration of the sample solution was 0.3g crude drug / mL, the volume of the sample solution was 3BV, the sample was loaded at a flow rate of 2BV / h, 3BV of pure water and 3BV of 5% ethanol were used for impurity removal at a flow rate of 2BV / h, 4BV 70% ethanol was used for elution at a flow rate of 2BV / h to obtain an eluate, and the content was tested. Seven specific ingredients were added to adjust the contents of the seven ingredients, so that the contents of each ingredient were as shown in the following table. The eluate was then decompressed and ethanol was recovered at 60°C to obtain a hibiscus flower extract, which was tested for content. The contents of the seven ingredients were adjusted by addition method according to the content determination results, and the added amount did not exceed 10% of the total weight, so that the contents of each ingredient were as shown in the following table, thereby obtaining 3.16 g of total solids of flavonoids effective parts of hibiscus flower.

[0238] Table 6 Content determination data of samples

[0239]

[0240] Example 7 Preparation of the Effective Fraction of Flavonoids from Hibiscus tiliaceus Flowers (Comparative Example)

[0241] Example 7-1

[0242] 500g of hibiscus flower was crushed into coarse powder, and extracted by percolation with 20 times 70% ethanol to obtain hibiscus flower extract; after reducing pressure to recover the solvent, it was treated with D101 macroporous resin, and the treatment process of the macroporous resin was as follows: the diameter-to-height ratio of the macroporous resin was 1:4, the concentration of the loading solution was 0.15g crude drug / mL, the volume of the loading solution was 6BV, the sample was loaded at a flow rate of 2BV / h, 7BV of pure water and 4BV of 5% ethanol were used at a flow rate of 2BV / h for impurity removal, 4BV of 60% ethanol was used at a flow rate of 1.5BV / h to obtain an eluent, and the eluent was reduced pressure at 60°C to recover ethanol to obtain 16.12g of hibiscus flower total solids, and the contents of each component thereof are shown in the following table.

[0243] Table 7-1 Sample content determination data

[0244]

[0245]

[0246] Example 7-2

[0247] 100g of hibiscus flower is crushed into coarse powder, and extracted by percolation with 18 times 70% ethanol to obtain hibiscus flower extract; after reducing pressure to recover the solvent, it is treated with D101 macroporous resin, and the treatment process of the macroporous resin is as follows: the diameter-to-height ratio of the macroporous resin is 1:5, the concentration of the loading liquid is 0.15g crude drug / mL, the volume of the loading liquid is 6BV, the sample is loaded at a flow rate of 2BV / h, 6BV of pure water and 3BV of 5% ethanol are used at a flow rate of 2BV / h for impurity removal, 4BV of 60% ethanol is used at a flow rate of 1.5BV / h to obtain an eluent, and the eluent is reduced pressure at 60°C to recover ethanol to obtain 3.56g of hibiscus flower total solids.

[0248] Table 7-2 Sample content determination data

[0249]

[0250] Example 8 Preparation of the Effective Fraction of Flavonoids from Hibiscus tiliaceus Flowers (Comparative Example)

[0251] 100g of hibiscus flower was crushed into coarse powder, and 70% ethanol was used for percolation extraction to obtain hibiscus flower extract; ethanol was removed from the hibiscus flower extract, diluted with water, and continuously countercurrently extracted with ethyl acetate, the material-liquid ratio of the extraction (i.e., extractant: extract) was 2.5:1, the injection speed of the extraction was 80mL / min, the speed of the extraction machine was 40Hz, the extraction level was 4, the extract was reduced pressure at 40°C to recover the solvent, and then treated with D101 macroporous resin, the treatment process of the macroporous resin was as follows: the diameter-to-height ratio of the macroporous resin was 1:5, the concentration of the sample solution was 0.15g crude drug / ml, the volume of the sample solution was 6BV, the sample was loaded at a flow rate of 2BV / h, 6BV of pure water and 3BV of 5% ethanol were used for impurity removal at a flow rate of 2BV / h, 4BV 60% ethanol was used for elution at a flow rate of 1.5 BV / h to obtain an eluate, and the content was tested. Then, rutin and hyperoside were added to the eluate to make the contents of each component as shown in the following table. Then, ethanol was recovered under reduced pressure at 60°C to obtain 4.28 g of total solids of hibiscus flowers.

[0252] Table 8 Content determination data of samples

[0253]

[0254]

[0255] Example 9

[0256] Example 9-1 Preparation of the effective fraction of flavonoids from Hibiscus tiliaceus flowers

[0257] 25 kg of hibiscus flower was crushed into coarse powder, and 18 times of 70% ethanol was used for percolation extraction to obtain hibiscus flower extract; ethanol was removed from the hibiscus flower extract, diluted with water, and continuously countercurrently extracted with ethyl acetate, the material-liquid ratio of the extraction (i.e., extractant: extract) was 2.5:1, the extraction level was 4, the extract was reduced pressure at 40°C to recover the solvent, and then treated with D101 macroporous resin, the treatment process of the macroporous resin was as follows: the macroporous resin diameter-to-height ratio was 1:5, the sample solution concentration was 0.15 g crude drug / mL, the sample solution volume was 3BV, the sample was loaded at a flow rate of 1.5BV / h, 6BV pure water and 3BV 10% ethanol was used for impurity removal at a flow rate of 2BV / h, and 4BV60% ethanol was used for elution at a flow rate of 1.5BV / h to obtain an eluate, and the eluate was decompressed at 60°C to recover ethanol to obtain the total solids of hibiscus flower. By adding 7 specific ingredients, the 7 ingredients were adjusted (the content of the added ingredients did not exceed 20% of the total weight) so that the content of each ingredient was as shown in the following table, and the total solids of the effective part of flavonoids of hibiscus flower were obtained. The content of quercetin-3-O-acacia glycoside was 0.20-0.50%.

[0258] Table 9-1 Sample content determination data

[0259]

[0260] Example 9-2 Preparation of the effective fraction of flavonoids from Hibiscus tiliaceus flowers

[0261] Reference Example 2-B, 30kg of hibiscus flower mixture was crushed into coarse powder, and extracted by percolation with 18 times 70% ethanol to obtain hibiscus flower extract; ethanol was removed from the hibiscus flower extract, diluted with water, and continuously countercurrent extracted with ethyl acetate, the material-liquid ratio of the extraction (i.e., extractant: extracting solution) was 2.5:1, the extraction injection speed was 80mL / min, the extraction machine speed was 40Hz, the extraction level was 4, the extract was reduced pressure at 40°C to recover the solvent, and then treated with D101 macroporous resin, the treatment process of the macroporous resin was: the macroporous resin diameter-to-height ratio was 1:5, the sample solution concentration was 0.15g crude drug / mL, the sample solution volume was 5BV, the sample was loaded at a flow rate of 1.5BV / h, 3BV pure water and 4BV5% ethanol were used to remove impurities at a flow rate of 2BV / h, and 5BV The eluate was eluted with 60% ethanol at a flow rate of 1.5 BV / h to obtain an eluate, and the eluate was decompressed at 65°C to recover the ethanol to obtain the total solids of hibiscus flowers, which were vacuum dried and crushed. The contents (%) of 7 flavonoid components were detected, and the results showed that the content of quercetin-3-O-acacia glycoside was 0.20-0.50%.

[0262] Table 9-2 Sample content determination data

[0263]

[0264]

[0265] Example 11 Preparation of eye drops containing the effective fraction of flavonoids from hibiscus flowers

[0266] Preparation process: The effective part prepared by any method of Examples 1-7 is added with injection water, stirred and dissolved, added to 100L, and the pH is adjusted to 7, filtered, filled, and sterilized to obtain eye drops. The pH adjuster used is sodium hydroxide and / or hydrochloric acid.

[0267] Example 12 Pharmacological Experiment on Diabetic Kidney Model

[0268] Example 12-1

[0269] Animal model: Streptozotocin (STZ) + high-fat diet diabetic kidney model, C57BL / 6 mice, 20±10g, SPF grade, male.

[0270] Administration: intragastric administration.

[0271] Experimental modeling: After 3 days of adaptive feeding, the experimental mice were fed with a high-fat and high-sugar diet (prepared in the laboratory, formula: lard: sucrose: egg yolk: basic feed = 18:20:3:59) for 8 consecutive weeks, and then began to be intraperitoneally injected with STZ sodium citrate solution at a dose of 100 mg / kg for 7 consecutive days. The blood glucose level of the mice was tested through the tail vein on the 8th day, and the standard for the diabetic model was a blood glucose level greater than 16.7 mmol / L. The modeling was successful when the blood glucose was greater than 13.8 mmol / L, urine protein, and renal function abnormalities occurred.

[0272] Experimental groups: normal group, model group, positive drug group (dapagliflozin tablets, 45.5 mg / kg), sample group prepared by the method of Example 2-1 (62.4 mg / kg), sample group prepared by the method of Example 6 (62.4 mg / kg), sample group prepared by the method of Example 8 (62.4 mg / kg), a total of 6 groups, 15 mice in each group, urine protein and urine creatinine were detected after 4 weeks of administration, and the daily food intake and mouse status were calculated. The test results are shown in Table 12-1 below.

[0273] Table 12-1

[0274] Group Urine protein / mg Urine protein / creatinine Diarrhea / Number Abdominal distension / number Normal group 19.37±13.28 0.24±0.08 0 0 Model Group <![CDATA[58.36±36.31 * ]]> <![CDATA[2.82±1.12 * ]]> 0 0 Positive drug group <![CDATA[17.51±12.34 # ]]> <![CDATA[1.04±1.09 # ]]> 0 0 Example 8 Sample Group 39.62±18.67 <![CDATA[1.81±0.37 # ]]> 3 2 Example 2-1 Sample Group <![CDATA[20.15±15.67 # ]]> <![CDATA[1.04±2.21 # ]]> 1 0 Example 6 Sample Group 29.74±17.78 <![CDATA[1.11±0.98 # ]]> 4 3

[0275] Note: *Compared with normal control group, P<0.05; #Compared with model control group, P<0.05.

[0276] Each group of the examples had a reducing effect on urine protein, and the sample group of Example 2-1 could significantly reduce urine protein and urine protein / urine creatinine (ACR). The observation results of mouse status showed that the number of mice with diarrhea and abdominal distension in the sample group of Example 2-1 was significantly less than that in other groups.

[0277] Example 12-2

[0278] Animal models: db / db mice, 16 weeks old, C57BL / 6 mice, 16 weeks old.

[0279] Administration: intragastric administration.

[0280] Experimental modeling: After 17 weeks of breeding, urine protein was detected in db / db mice. If urine protein and renal function abnormalities were found, the model was successful and used for subsequent experiments.

[0281] Experimental groups: C57BL / 6 mice were divided into a normal group, db / db mice were divided into a model group, a positive drug group (dapagliflozin tablets, 45.5 mg / kg), a sample group prepared by the method of Example 3-1 (62.4 mg / kg), a sample group prepared by the method of Example 9-1 (62.4 mg / kg), a sample group prepared by the method of Example 2-A3 (62.4 mg / kg), and a sample group of Example 7-1 (62.4 mg / kg), 15 mice in each group, urine protein and urine creatinine and daily food intake were detected after 4 weeks of administration, and the state of the mice was observed. The test results are shown in Table 12-2 below.

[0282] Table 12-2

[0283] Group Urine protein / mg Urine protein / creatinine Diarrhea / Number Abdominal distension / number Normal group 17.21±10.07 0.29±0.16 0 0 Model Group <![CDATA[61.97±32.17 * ]]> <![CDATA[2.68±1.03 * ]]> 0 0 Positive drug group <![CDATA[15.09±10.27 # ]]> <![CDATA[1.17±1.26 # ]]> 0 0 Example 3-1 Sample Group 17.28±14.54 <![CDATA[1.29±1.21 # ]]> 1 0 Example 9-1 Sample Group <![CDATA[16.91±13.32 # ]]> <![CDATA[1.17±1.91 # ]]> 2 0 Example 2-A3 Sample Group <![CDATA[19.38±14.67 # ]]> <![CDATA[1.31±1.28 # ]]> 1 1 Example 7-1 Sample Group 36.42±14.23 <![CDATA[1.45±1.29 # ]]> 5 3

[0284] Note: *Compared with normal control group, P<0.05; #Compared with model control group, P<0.05.

[0285] Each group of the examples had a reducing effect on urine protein, and each sample group could reduce urine protein and urine protein / urine creatinine (ACR). The observation results of mouse status showed that the mice with diarrhea and abdominal distension in the sample groups of Example 3-1 and Example 9-1, and the sample group of Example 2-A3 were significantly less than those in other groups.

[0286] Example 13 Effects of flavonoids on ocular blood flow and choroidal neovascularization

[0287] Experimental animals: rats, body weight 150-180g, SPF grade, half male and half female.

[0288] Administration: intragastric administration.

[0289] Experimental modeling: Healthy male Brown-Norway rats were selected and anesthetized by intramuscular injection of ketamine (50 mg / kg). The mydriasis was dilated with a mixture of 0.5% tropicamide and phenylephrine. Krypton yellow laser (Coyle, USA) (wavelength 568 nm, parameters: spot diameter 100 μm, exposure time 0.1 s, power 150-200 mW) was used. Under a 120D special front lens, 8 points were photocoagulated between the large retinal blood vessels around the optic disc at a distance of 2-4 disc diameters. The qualified photocoagulation points were those with small bubbles produced after the Bruch's membrane was broken. Those with retinal, choroidal or vitreous hemorrhage were excluded.

[0290] Drug grouping and dosage: normal group, model group, positive control drug group (1.35 mg / kg of vertebofen), sample group of Example 2-1 (69.9 mg / kg), sample group of Example 3-1 (87.36 mg / kg), sample group of Example 7-2 (87.36 mg / kg), sample group of Example 9-1 (87.36 mg / kg), sample group of Example 9-2 (87.36 mg / kg), 15 mice in each group, choroidal blood flow inhibition rate and choroidal angiogenesis area were detected after 4 weeks of administration. The test results are shown in Table 13 below.

[0291] Table 13

[0292] Group Choroidal blood flow inhibition rate <![CDATA[Choroidal neovascularization area / μm 2 > Normal group 0 0 Model Group <![CDATA[39.78±10.45 * ]]> <![CDATA[34.67±1.78 * ]]> Positive drug control group <![CDATA[87.98±11.23 # ]]> <![CDATA[19.80±1.23 # ]]> Example 2-1 Sample Group <![CDATA[80.67±13.78 # ]]> <![CDATA[23.24±133 # ]]> Example 3-1 Sample Group <![CDATA[83.76±14.68 # ]]> <![CDATA[22.89±134 # ]]> Example 7-2 Sample Group <![CDATA[61.98±16.21 # ]]> <![CDATA[28.78±1.45 # ]]> Example 9-1 Sample Group <![CDATA[84.19±15.92 # ]]> <![CDATA[24.57±139 # ]]> Example 9-2 Sample Group <![CDATA[85.27±1134 # ]]> <![CDATA[23.79±1.41 # ]]>

[0293] Note: *Compared with normal control group, P<0.01; #Compared with model control group, P<0.05.

[0294] Conclusion: The samples in each example have an inhibitory effect on the choroidal blood flow inhibition rate and the choroidal angiogenesis area. The sample groups of Example 2-1, Example 3-1, Example 9-1 and Example 9-2 can significantly reduce choroidal angiogenesis.

[0295] The sample experiments of Example 4-1, Example 4-2, Example 5-1, and Example 5-2 also have functions or effects that are basically consistent with those of Example 2-1, Example 3-1, Example 9-1, and Example 9-2 in the present embodiment.

[0296] Example 14 Effect of flavonoids on contrast-induced renal injury

[0297] Experimental animals: SD rats, body weight 200-250g, SPF grade, half male and half female.

[0298] Administration: intragastric administration

[0299] Experimental modeling: Healthy male SD rats were selected and firstly, furosemide (10 ml / kg) was intramuscularly injected, and then the prostaglandin synthesis inhibitor (indomethacin, 10 mg / kg, dissolved in dimethyl sulfoxide, 1.25% NAHCO) was injected into the tail vein every 15 minutes. 3 solution diluted) and nitric oxide synthase inhibitor (N-nitro-L-arginine methyl ester, L-NAME, 10 mg / kg, dissolved in 0.9% NaCl solution) and 76% diatrizoate (10 ml / kg).

[0300] The modeling success criteria are based on the diagnostic criteria for acute kidney injury recommended by the 2012 KDIGOAKI clinical guidelines (any of the following conditions can be diagnosed): ① serum creatinine increases by more than 26.5umol / L (0.3mg / dl) within 48 hours; ② serum creatinine increases by more than 50% of the baseline - confirmed or presumed to occur within 7 days; ③ urine volume decreases by <0.5ml / (kg*h) and lasts for more than 6 hours. Among them, serum creatinine increases by more than 50% of the baseline are often used as the diagnostic criteria for acute kidney injury in animal models, that is, the modeling success criteria.

[0301] Drug grouping and dosage: normal group, model group, positive control drug group (irbesartan 50 mg / kg / d), Example 2-1 sample group (69.9 mg / kg), Example 3-1 sample group (87.36 mg / kg), Example 7 sample group (87.36 mg / kg), Example 9-1 sample group (87.36 mg / kg), Example 9-2 sample group (87.36 mg / kg, solid prepared according to Example 9-2), 15 mice in each group, choroidal blood flow inhibition rate and choroidal angiogenesis area were detected after 4 weeks of administration. The test results are shown in Table 14 below.

[0302] Table 14

[0303] Group Serum creatinine Serum urea nitrogen Normal group 10.12±3.89 2.48±0.89 Model Group <![CDATA[35.21±4.32 * ]]> <![CDATA[9.89±0.56 * ]]> Positive drug control group <![CDATA[16.67±1.23 # ]]> <![CDATA[3.01±0.98 # ]]> Example 2-A1 Sample Group <![CDATA[15.56±4.39 # ]]> <![CDATA[2.98±0.34 # ]]> Example 3-1 Sample Group <![CDATA[17.67±2.78 # ]]> <![CDATA[3.12±0.67 # ]]> Example 4-2 Sample Group <![CDATA[18.80±4.67 # ]]> <![CDATA[4.02±0.91 # ]]> Example 8 Sample Group <![CDATA[25.23±9.89 # ]]> <![CDATA[4.21±1.21 # ]]> Example 6 Sample Group <![CDATA[27.43±8.79 # ]]> <![CDATA[5.23±0.78 # ]]>

[0304] Note: *Compared with the normal group, P<0.01; #Compared with the model group, P<0.05

[0305] in conclusion:

[0306] The serum creatinine and serum urea nitrogen of rats with contrast-induced renal injury in the model group were significantly higher than those of the drug-administered groups; the serum creatinine and serum urea nitrogen of the sample group of Example 9-1, the sample group of Example 2-A1, the sample of Example 3.1, the sample of Example 8 and the sample of Example 6 all decreased the serum creatinine and serum urea nitrogen to varying degrees.

[0307] Example 15 Effects of flavonoids on lupus erythematosus nephritis

[0308] 26 MRL / lpr male mice (lupus nephritis mice) were selected as the observation group, with a body weight of 18-22g, 13 weeks of age, purchased from Nanjing Junke Biotechnology Co., Ltd., and 24 male C57BL / 6 mice were selected as the normal group, with a body weight of 18-22g, 13 weeks of age, purchased from Wuhan Hualianke Biotechnology Co., Ltd.

[0309] Drug grouping and dosage: normal group, MRL / lpr mouse model group, positive control drug group (dexamethasone 1 mg / kg), Example 2-B sample group (69.9 mg / kg), Example 3-1 sample group (87.36 mg / kg), Example 7-1 sample group (87.36 mg / kg), Example 5-2 sample group (87.36 mg / kg), Example 8 sample group (87.36 mg / kg), 15 mice in each group, gavage administration for 4 weeks.

[0310] Experimental indicators: After the administration, urine was collected for 24 hours for the detection of urine protein. After the urine was collected, the eyeballs of all mice were removed to collect blood, and serum was obtained by centrifugation for antinuclear antibody detection. At the same time, the kidneys were removed, quickly frozen in liquid nitrogen, and transferred to a negative 80 refrigerator for storage for kidney immune detection. The test results are shown in Table 15 below.

[0311] Table 15

[0312]

[0313] Note: *Compared with the normal group, P<0.01; #Compared with the model group, P<0.05.

[0314] Conclusion: The urine protein, serum antinuclear antibody level, IgG and C3 deposition in renal tissue of lupus nephritis mice in the model group were significantly higher than those in the drug-treated groups; while the sample group of Example 5-2, the sample group of Example 2-B, the sample of Example 3-1, the sample of Example 8 and the sample of Example 7-1 were able to improve the urine protein, serum antinuclear antibody level, IgG and C3 deposition in renal tissue, and the samples of Example 2-B, Example 3-1 and Example 5-2 had better effects.

[0315] Example 16 Toxic effects of flavonoids

[0316] Experimental animals: rats, body weight 150-180g, SPF grade, half male and half female.

[0317] Administration: intragastric administration.

[0318] Drug grouping and dosage: normal group, Huangkui capsule group (extract 8g / kg), Example 2-A1 sample group (5g / kg), Example 9-2 sample group (8g / kg), 30 mice in each group, once a day for 12 consecutive weeks, the dosage is calculated based on the extract.

[0319] Experimental results: After administration, kidney weight, visceral body and visceral brain coefficients of the Huangkui Capsule group were increased compared with the normal group. Pathology showed that the Huangkui Capsule group had moderate renal tubular hypertrophy, while pathological examination of the Example 9-2 sample group and the Example 2-A1 group showed no renal tubular hypertrophy. The test results are shown in Table 16 below.

[0320] Table 16

[0321]

[0322]

[0323] Note: Compared with the normal group, *P<0.05.

[0324] It has been verified that Example 2-A3, Example 3-1, Example 4-1, Example 5-2, and Example 9-1 also have the same safety effects or effects as those of Example 2-A1 and Example 9-2 in this embodiment.

[0325] Example 17 Effects of effective fractions of total flavonoids on idiopathic pulmonary fibrosis

[0326] Preparation of experimental sample 1: Take hyperoside, isoquercetin, hibifolin, myricetin, quercetin-3′-O-glucoside, quercetin, and quercetin 3-O-acacia glycoside raw materials, weigh each active ingredient according to the feeding ratio in Table 17-1, mix them, and prepare a pharmaceutical composition.

[0327] Table 17-1

[0328]

[0329] Experimental animals: Kunming mice, half male and half female, weighing 18-22 grams, clean grade.

[0330] Animal grouping: The mice were randomly divided into a normal group, a model group, a control drug group (rosiglitazone 5 mg / kg), an Example 2-A3 sample group (70 mg / kg), an Example 9-2 sample group (70 mg / kg), a Huangkui capsule sample group (180 mg / kg as the extract), and an experimental sample group 1 (62.4 mg / kg), with 10 mice in each group.

[0331] Experimental modeling: After the experimental mice were adaptively fed for 3 days, they were anesthetized by intraperitoneal injection of 4% chloral hydrate (0.01 ml / g). They were placed in a supine fixed position, routinely disinfected, and a midline cervical incision was performed. The trachea was exposed by blunt separation. The model group, control drug group, and treatment group were slowly injected with bleomycin (5 mg / kg) through puncture in the gap between the tracheal cartilage rings. The normal control group was injected with an equal volume of saline. Immediately after the injection, the mice were rotated upright for 3-5 minutes to evenly distribute the drug solution in both lungs. Then the skin was sutured and the suture was disinfected. After awakening, the mice were sent to a clean observation room for feeding.

[0332] Dosage method: Dosage began on the second day of modeling. The drug-treated group was gavaged with the above dose once a day. The normal group and the model group were given the same volume of distilled water (10 ml / kg) in the same way for 28 consecutive days.

[0333] Pathological section staining of lung tissue: After the administration, the right lung was taken and fixed, embedded, sectioned, and HE stained according to conventional pathological methods. The degree of alveolitis and pulmonary fibrosis was divided into four grades.

[0334] The experimental results are shown in Table 17-2 below. The experimental results show that the degree of alveolitis and pulmonary fibrosis in the lung tissue of the model group mice was significantly aggravated, showing typical pulmonary fibrosis parenchymal lesions. After 28 days of administration, the lung coefficient of mice in each dosage group was significantly reduced, and the degree of alveolitis and pulmonary fibrosis in the lung tissue was significantly alleviated. The effective fraction of total flavonoids of the present invention can significantly reduce the degree of alveolitis and pulmonary fibrosis in mice with pulmonary fibrosis, has a protective effect on the lungs of mice with pulmonary fibrosis, and can slow down the damage caused by fibrosis to the lung tissue of the other party.

[0335] Table 17-2

[0336]

[0337]

[0338] Note: *Compared with the normal group, P<0.01; #Compared with the model group, P<0.05.

[0339] It has been verified that Example 1, Example 2-1, Example 2-A2, Example 3.2-1, and Example 5-2 also have the same action or effect as the above-mentioned fibrosis of Example 2-A3 and Example 9-2 in this embodiment.

[0340] Example 18 Study on the mechanism of action of SGLT2

[0341] Sodium-glucose contransporter2 (SLC5A2, also known as SGLT2) is a gene that encodes a sodium-glucose co-transporter and can reabsorb more than 90% of glucose filtered by the glomerulus. SLC5A2 is only expressed in the brush border of the epithelial cell membrane of the proximal tubules of the kidney and is considered a marker of the proximal tubules. Its main function is to recycle filtered sodium and glucose. In the renal tissue of patients with diabetes and diabetic nephropathy, inhibiting the expression of SLC5A2 protein can play a role in excreting sodium, excreting water and lowering blood sugar, thereby protecting the renal tissue of diabetes and diabetic patients.

[0342] Animal model: db / db mice, 18 weeks old.

[0343] Administration: intragastric administration.

[0344] Experimental grouping: When UACR>200mg / g, db / db mice were divided into three groups: diabetic nephropathy group (DKD), Huangkui capsule group (DKD+HK, 0.84g / kg / d) and total flavonoids group (DKD+HT, Example 2-A2 sample, 0.0755g / kg / d). Huangkui capsule group and total flavonoids group were administered for four weeks (28d). Enzyme-linked immunosorbent assay (ELISA) method was used to measure the trace albumin (UACR) in urine of db / db mice, Reverse Transcription Polymerase Chain Reaction (RT-PCR) method was used to detect the expression level of SLC5A2 mRNA, and ImmunoHistoChemistry (IHC) method was used to detect the expression level of SLC5A2 protein.

[0345] Experimental results:

[0346] Compared with the DKD group, the weight of the HK group (Huangkui capsule group) and the HT group (total flavonoids group) before grouping DKD (N=5), HK (N=5), HT (N=6), the weight of the first week of administration and the weight of the fourth week of administration DKD (N=5), HK (N=5), HT (N=6) had no significant difference. There was no significant difference in blood glucose in the first week of administration and the fourth week of administration DKD (N=5), HK (N=5), HT (N=6). There was no significant difference in UACR value in the first week of administration DKD (N=5), HK (N=5), HT (N=6). Compared with the DKD group in the fourth week of administration, the UACR value of the HT group was significantly reduced, *P<0.05, with a significant difference. There was no significant difference in the mean kidney value in the fourth week of administration DKD (N=5), HK (N=5), HT (N=6); Renal index DKD (N=5), HK (N=5), HT (N=6) in the fourth week of administration; *P<0.05, the renal index increased significantly, with significant difference. In the fourth week of administration, some glomeruli in the DKD group were lobed, the basement membrane was significantly thickened, the glomerular capillaries were significantly compressed, the mesangial cells in the mesangial area proliferated, and the mesangial matrix was significantly expanded; in the HK group, the thickening of the glomerular basement membrane was significantly improved, the glomerular capillaries were intact, and the proliferation of mesangial cells and mesangial matrix was significantly improved; in the HT group, the glomerular basement membrane was significantly thinned, the glomeruli did not proliferate, the glomerular capillary interstitium did not proliferate, and the proliferation of mesangial cells and mesangial matrix did not proliferate. The IHC-P quantification results in the fourth week of administration showed that compared with the DKD group (N=5), the SLC5A2 protein expression level in the Huangkui HK group (N=5) and the HT group (N=6) was significantly reduced. The RT-PCR results at the fourth week of administration verified the immunohistochemistry results and showed that compared with the DKD group (N=5), the SLC5A2 mRNA expression level in the Huangkui HK group (N=5) and the HT group (N=6) was significantly reduced. Compared with the DKD group (N=5), the ratio of the SLC5A2 IHC-P quantified expression to the number of glomeruli in the Huangkui HK group (N=5) and the HT group (N=6) was significantly reduced at the fourth week of administration, which was consistent with the IHC-P quantification results.

[0347] Therefore, Huangkui capsule and total flavonoids can effectively reduce microalbuminuria in db / db mice. Huangkui capsule and total flavonoids can inhibit the expression of SLC5A2 protein on the proximal tubule cell membrane, reduce the expression of SLC5A2 protein in the kidneys of DKD mice, and effectively inhibit the activity of SLC5A2 protein, thereby effectively reducing the reabsorption of glucose by the kidneys of DKD mice.

[0348] Example 19 Preparation of total flavonoids extract from hibiscus flowers

[0349] Referring to the preparation method of Example 3-1 above, 5000 g of Hibiscus hibiscus flower was used for repeated experiments, and the content (unit: %) of 2 batches was obtained as shown in the following table: The content of quercetin-3-O-acacia glycoside was 0.30-0.80%.

[0350] Table 19

[0351]

[0352] Example 20 Animal Experiment on Ulcerative Colitis

[0353] 1. Experimental Materials

[0354] 1.1 Experimental animals

[0355] SPF male C57BL / 6J mice, 6-8 weeks old, weighing 22-25 g, were provided by the Center for Comparative Medicine of Yangzhou University.

[0356] 1.2 Reagents and drugs

[0357] Table 20-1

[0358]

[0359]

[0360] 2. Experimental Methods

[0361] 2.1 Animal husbandry and management

[0362] The experimental mice were kept in an SPF-grade animal room throughout the experiment. The light-to-dark time ratio was 1:1, the room temperature was controlled at 23±2℃, the humidity was controlled at 55%, and the mice were able to eat and drink freely. The bedding was changed every three days to ensure that the mice were in a dry and clean environment.

[0363] 2.2 Drug preparation

[0364] All medicines are Figure 1 Steps for dissolution: ①: Prepare 0.5% CMC-Na one day before administration: slowly add 0.5g CMC-Na powder to 100mL 70℃ pure water, stir evenly, and let stand at room temperature overnight. The next day, ultrasonicate before preparing the drug solution until a homogeneous 0.5% CMC-Na solution is obtained. ②: Weigh 12.5mg, 37.5mg, 75mg ZHT and 100mg 5-ASA respectively, and add 0.1mL DMSO to prepare DMSO mother solution. ③: Add 0.1mL Tween-80 to each mother solution in ②. ④: Add 4.8mL 0.5% CMC-Na solution to each solution in ③. Prepare 2.5mg / mL, 7.5mg / mL and 15mg / mL ZHT suspension and 20mg / mL 5-ASA suspension respectively.

[0365] Preparation method of 3% DSS solution: weigh 3g DSS powder and fully dissolve it in 100mL pure water to obtain 3% DSS solution.

[0366] 2.3 Preparation of DSS-induced ulcerative colitis (UC) model in mice

[0367] After 5 days of adaptive feeding, the mice were randomly divided into 6 groups, each with two cages and 4 mice in each cage. They were blank control group (Control), sunflower total flavonoids extract control group (150 mg / kg / day ZHT), model group (DSS), model + 5-aminosalicylic acid group (DSS + 200 mg / kg / day 5-ASA), model + ZHT group (DSS + 75 mg / kg / day ZHT).

[0368] As shown in the following method, the mouse ulcerative colitis model was induced by freely drinking 3% DSS for 7 consecutive days. The 3% DSS solution (80 mL) was replaced every 2 days for each cage of mice (4 mice) to ensure the effectiveness of the DSS solution; the mice in the blank control group were free to drink pure water, which was replaced every 2 days for each cage of mice (4 mice).

[0369] Different doses of ZHT or positive therapeutic drug 5-ASA were given by gavage at 0.1mL / 10gb.w. every morning from 9:00 to 10:00, and the blank group and model group were given the same dose of blank vehicle solution (containing 2% DMSO, 2% Tween 80 and 0.5% CMC-Na) for 7 consecutive days. Disease activity index (DAI) was scored before administration every day; on the 8th day, the mice were euthanized and blood and colon tissue were collected.

[0370] 2.4 Stool consistency / fecal occult blood test and DAI score

[0371] The weight of mice was recorded before daily administration, and feces were collected for fecal occult blood test. The severity of the disease was scored by DAI based on three indicators: weight loss, fecal viscosity, and fecal occult blood. Each indicator corresponds to 0-4 points. The scoring criteria are shown in Table 20-2. Fecal occult blood test: Take a small amount of feces and smear it in the middle of the glass slide (the glass slide was pre-burned to reduce color error), add 3 drops of 10 / L acetic acid solution of aminophenol sulfate and 3 drops of 3% hydrogen peroxide solution, mix well, observe the results immediately, and score according to Table 20-3.

[0372] Table 20-2 DAI scoring rules

[0373]

[0374] Table 20-3 Fecal occult blood test score table

[0375]

[0376] 2.5 Specimen Collection

[0377] After the last administration, mice in each group were fasted for 24 hours and killed by cervical dislocation. The abdominal cavity of the mouse was cut open to expose the colon of the mouse. All the colon tissues of the mouse were measured and their lengths were recorded. They were placed in freshly prepared pre-cooled saline for intestinal content flushing. The 1 cm proximal rectal colon was cut and fixed in 4% paraformaldehyde overnight for paraffin section preparation and subsequent pathological examination. The remaining tissue was quickly frozen in liquid nitrogen in the middle section and stored at -80 ° C for subsequent experiments. The blood sample was left at room temperature for 2-3 hours, then centrifuged at 3500 rpm for 15 minutes, and the serum was taken and quickly stored at -80 ° C for subsequent testing.

[0378] 2.6 Determination of myeloperoxidase (MPO) content in colon tissue

[0379] MPO is a functional marker and activation marker of neutrophils. 2 O 2 and 3,3′-dimethoxybenzidine hydrochloride as substrates, MPO can catalyze the substrates to generate orange products, and the amount of the product generated is measured by colorimetry at 460nm, thereby calculating the MPO content.

[0380] The specific measurement steps are as follows:

[0381] 1) Sample pretreatment: Accurately weigh the tissue, add homogenate medium at a weight-to-volume ratio of 1:9, grind in a tissue grinder at a frequency of 60 Hz for 1 min, repeat 5 times until no precipitation is visible to the naked eye, and prepare a 10% tissue homogenate;

[0382] 2) Prepare the reaction system: Take 0.09 mL of 10% tissue homogenate or serum sample to be tested into two new 2 mL EP tubes (control tube and test tube), and add the corresponding reagents in the kit according to Table 20-4 for reaction;

[0383] 3) Determine absorbance: Take 150 μL of the reaction product in a 96-well plate and measure the absorbance at 460 nm using an enzyme reader;

[0384] 4) Calculate the MPO content according to the following formula:

[0385]

[0386] Where W is the sample volume; for tissue homogenate, W (g) = homogenate concentration × sampling volume (mL).

[0387] Table 20-4 MPO content determination operation table

[0388]

[0389] 2.7 H&E staining

[0390] The colon was fixed with 4% paraformaldehyde for 24 hours and then routinely embedded in paraffin. The embedded colon tissue was serially sectioned (10 μm) and then stained with H&E. The steps of H&E staining were as follows:

[0391] 1) Dewaxing: dewaxing in xylene I for 10 min, dewaxing in xylene II for 5 min;

[0392] 2) Ethanol soaking: soak in anhydrous ethanol twice, then soak in 95%, 90%, and 85% ethanol once, each time for 1 min, and finally wash with water for 2 min;

[0393] 3) Staining: Stain with hematoxylin for 5 min, then wash with tap water for 1 min;

[0394] 4) Differentiation: Differentiate with 1% hydrochloric acid alcohol for 20 seconds, then wash with tap water for 1 minute;

[0395] 5) Anti-blueing: Anti-blueing with 1% dilute ammonia for 30 seconds, then washing with tap water for 1 minute;

[0396] 6) Eosin staining: stain for 5 minutes, then wash with tap water for 30 seconds;

[0397] 7) Ethanol dehydration: Dehydration was performed with different contents of ethanol in the following order: 85% ethanol dehydration for 20 s, 90% ethanol dehydration for 30 s, 95% ethanol I dehydration for 1 min, 95% ethanol II dehydration for 1 min, anhydrous ethanol I dehydration for 2 min, and anhydrous ethanol II dehydration for 2 min;

[0398] 8) Transparency: xylene I treatment for 2 min, xylene II treatment for 2 min, xylene III treatment for 2 min;

[0399] 9) Finally, the slides were sealed with neutral gum and scanned with a digital pathology slide scanner (NanoZoomer 2.0RS);

[0400] 10) Pathological examination: The degree of colon damage was scored based on pathological indicators such as the degree of colon tissue lesions, inflammatory cell infiltration, and crypt cell damage. The specific scoring criteria are shown in Table 20-5.

[0401] Table 20-5 Inflammation Score Table

[0402]

[0403] 2.8 Real-time fluorescence quantitative PCR

[0404] Place the colon tissue in a grinding tube, add grinding beads and 400 μL Trizol reagent, and grind continuously for 1 min at a frequency of 60 Hz in a tissue grinder. Repeat 5 times until no precipitation is visible to the naked eye. Collect the supernatant, centrifuge at 12,000 rpm for 10 min, and transfer the supernatant to a new 1.5 mL enzyme-free tube. Extract with chloroform-isopropanol overnight and centrifuge, discard the supernatant, wash off the ions attached to the RNA with 75% ethanol, dry and dissolve in DEPC water, and take 2 μL for quantification with Nano-100 micro-spectrophotometer. A 260 / A 280 It should be between 1.8 and 2.0. Use enzyme-free water to adjust the RNA concentration to 1μg, add 3μL of 5×gDNA wiperMix and heat at 42℃ for 2min, remove genomic DNA, then add 5μL of 4×qRT Super MixII to achieve a 20μL system, perform reverse transcription reaction at 25℃-2min, 50℃-30min, and 85℃-5min in a PCR instrument, and store cDNA at -80℃ for later use.

[0405] According to 1μL cDNA + 10μL Green+0.8μL Primers+8.2μL ddH 2 O system for real-time fluorescence quantitative PCR reaction, using Comparative Ct (2 -ΔΔCt ) method to calculate the relative mRNA expression, and the expression level of each gene was corrected by the expression level of GAPDH. The primers used are shown in Table 20-6.

[0406] Table 20-6 Primer sequences used in PCR

[0407]

[0408] 2.8 Determination of TNF-α, IL-1β and IL-6 levels

[0409] According to the operating procedures of the ELISA kit, the contents of TNF-α, IL-1β and IL-6 in colon tissue were detected.

[0410] 2.9 Statistical analysis

[0411] GraphPad Prism (Ver 6.0) was used for statistical analysis. All data were expressed as mean ± standard error (Mean ± SEM). Two-way ANOVA was used to analyze weight changes and DAI score changes, and One-way ANOVA was used to analyze other data. Dunnett's multiple test was used to analyze the significance of the differences between the groups. When P < 0.05, the differences between the groups were statistically significant.

[0412] 3. Experimental results

[0413] 3.1 Effects of different doses of total flavonoids from Astragalus membranaceus on DAI scores of mice

[0414] The DAI score was calculated by adding the three index values ​​in Table 20-2 and taking the average value. As shown in Table 20-7, the DAI score of mice in the DSS model group increased significantly from the 3rd day, and the difference was statistically significant compared with the Control group (P<0.01). Three mice had diarrhea on the 6th day of the experiment, and 7 mice had diarrhea on the 7th day. The DAI score in the DSS+ZHT (75 mg / kg / day) group showed a relatively slow growth trend. On the 4th, 5th, 6th, and 7th days, the DAI score was statistically significant (P<0.01) compared with the DSS model group. No mice had diarrhea during the experiment. The positive treatment drug 5-ASA (200 mg / kg / day) relieved the symptoms of DSS-induced colitis and reduced the DAI score. Starting from the 4th day, the difference was significant compared with the DSS model group (P<0.01). No mice had diarrhea during the experiment. During the experiment, there was no significant difference between the normal group and the control group, and there was no effect on the weight of mice. On the 6th day, one mouse showed diarrhea symptoms.

[0415] Table 20-7 DAI scores of mice in each group

[0416]

[0417] Note: Data are expressed as mean ± standard error. N = 8. *, P < 0.05, **, P < 0.01, vs. Control; # , P < 0.05, ##, P < 0.01, vs. DSS, analyzed using two-way ANOVA and Dunnett's multiple comparison test.

[0418] 3.2 Effects of different doses of total flavonoids from Astragalus membranaceus on colon length in mice

[0419] like Figure 2As shown in Table 20-8, the colon length of the Control group was 7.34±0.08cm, and the colon of the mice in the DSS model group atrophied to 4.85±0.18cm, which was significantly different from the Control group (P<0.01); the colon length of the ZHT (150mg / kg / day) group (7.43±0.13cm) was close to that of the Control group. 75mg / kg / day ZHT significantly improved the colon atrophy induced by DSS, and the difference between the DSS+ZHT (75mg / kg / day) group and the DSS model group was statistically significant (P<0.05); the positive drug 5-ASA (200mg / kg / day) also improved the colon atrophy induced by DSS, and the difference was statistically significant compared with the Control group (P<0.05).

[0420] Table 20-8 Statistics of colon length of mice in each group

[0421]

[0422] Note: Data are expressed as mean ± standard error. N = 8. **, P < 0.01, vs. Control; #, P < 0.05, vs. DSS, analyzed using one-way ANOVA and Dunnett's multiple comparison test.

[0423] 3.3 Effects of different doses of total flavonoids from Astragalus membranaceus on the content of myeloperoxidase (MPO) in mouse colon tissue

[0424] The MPO content in the colon tissue of the Control group was 0.30±0.04U / g, and the MPO content in the colon tissue of the DSS model group mice increased to 1.04±0.10U / g, and the difference was statistically significant compared with the Control group (P<0.01); 75mg / kg / day ZHT had an inhibitory effect on the DSS-induced increase in MPO content in the colon, and the inhibition rate of 75mg / kg / day ZHT was 92.8±19.4%, and the difference was statistically significant (P<0.01); the positive therapeutic drug 5-ASA (200mg / kg / day) significantly inhibited the DSS-induced increase in MPO content in the colon, and the inhibition rate was 88.7±9.9% (P<0.01).

[0425] 3.4 Effects of different doses of total flavonoids from Astragalus membranaceus on pathological changes in mouse colon tissue

[0426] The experimental results show that ( Figure 3), the colon tissue structure of mice in the Control group and ZHT (150mg / kg / day) group was normal, with few inflammatory cell infiltrations, and the crypt cells and epidermal cells were intact. In the DSS model group, the inflammatory cells in the colon tissue of mice increased significantly, the crypt cells and epidermal cells were completely missing, and the lesion range was more than 80%. Compared with the Control group, the pathological score was significantly different (P < 0.01); the colon tissue of the DSS+ZHT (75mg / kg / day) group was significantly improved, and the pathological score of the DSS+ZHT (75mg / kg / day) group was significantly different from that of the DSS model group (P < 0.01). The positive therapeutic drug 5-ASA (200mg / kg / day) significantly improved the DSS-induced colon tissue pathological changes, and the pathological score was significantly different from that of the DSS model group (P < 0.01).

[0427] 3.5 Effects of total flavonoids from Astragalus membranaceus on DSS-induced IL-1β, IL-2, IL-4, IL-6, TNF-α and IFN-γ mRNA expression levels

[0428] The experimental results showed that the mRNA expression of IL-1β in the colon tissue of mice in the DSS model group increased to 7.36±0.79 times that of the Control group (P<0.01); the administration of 150mg / kg / day ZHT alone increased the mRNA expression of IL-1β in the colon tissue of mice to 2.21±0.24 times that of the Control group, but the difference was not significant compared with the Control group (P>0.05). 75mg / kg / day ZHT could inhibit the upregulation of IL-1β mRNA expression induced by DSS, with an inhibition rate of 81.9±5.0% (P<0.01); the positive therapeutic drug 5-ASA (200mg / kg / day) inhibited the mRNA expression of IL-1β induced by DSS, with an inhibition rate of 91.6±3.6% (P<0.01).

[0429] The experimental results showed that the mRNA expression of IL-2 in the colon tissue of mice in the DSS model group was significantly increased to 6.65±0.56 times that of the Control group (P<0.01); ZHT (150mg / kg / day) alone increased the mRNA expression of IL-2 in the colon tissue of mice to 1.74±0.15 times that of the Control group, but the difference was not statistically significant (P>0.05). 75mg / kg / day ZHT inhibited the increase of IL-2 mRNA expression induced by DSS by 78.7±4.5%, which was significantly different from the DSS model group (P<0.01); the positive therapeutic drug 5-ASA (200mg / kg / day) significantly inhibited the increase of IL-2 mRNA expression in the colon tissue induced by DSS, with an inhibition rate of 94.2±2.8% (P<0.01).

[0430] The experimental results showed that the mRNA expression of IL-4 in the colon tissue of mice in the DSS model group was significantly increased to 5.78±1.22 times that of the Control group (P<0.01); the mRNA expression of IL-4 in the colon tissue of mice in the group given 150mg / kg / day ZHT alone was 1.07±0.16 times that of the Control group, and there was no significant difference compared with the Control group (P>0.05). 75mg / kg / day ZHT inhibited the upregulation of IL-4 mRNA expression induced by DSS, with an inhibition rate of 78.65±7.18%, which was significantly different from the DSS model group (P<0.01); the positive therapeutic drug 5-ASA (200mg / kg / day) significantly inhibited the upregulation of IL-4 transcription induced by DSS, with an inhibition rate of 69.15±6.17% (P<0.01).

[0431] The experimental results showed that the mRNA expression of IL-6 in the colon tissue of mice in the DSS model group increased significantly to 13.53±2.34 times that of the Control group (P<0.01); there was no significant change in the mRNA expression of IL-6 in the colon tissue of mice in the ZHT (150mg / kg / day) group compared with the Control group. 75mg / kg / day ZHT inhibited 79.4±6.5% of the DSS-induced IL-6 transcriptional upregulation, which was significantly different from the DSS model group (P<0.01); the positive therapeutic drug 5-ASA (200mg / kg / day) inhibited the DSS-induced IL-6 transcriptional upregulation, with an inhibition rate of 91.5±6.2% (P<0.01).

[0432] The experimental results showed that the mRNA expression of TNF-α in the colon tissue of mice in the DSS model group was significantly increased to 7.82±1.68 times that of the Control group (P<0.01); 150mg / kg / day ZHT increased the mRNA expression of TNF-α in the colon tissue of mice to 3.29±1.09 times that of the Control group, but the difference was not statistically significant (P>0.05). 75mg / kg / day ZHT inhibited 88.5±7.1% of the DSS-induced TNF-α transcriptional upregulation, and the DSS+ZHT (75mg / kg / day) group was significantly different from the DSS model group (P<0.01). The positive treatment drug 5-ASA (200mg / kg / day) group inhibited the DSS-induced TNF-α transcriptional upregulation, with an inhibition rate of 87.4±7.2% (P<0.01).

[0433] The experimental results showed that the mRNA expression of IFN-γ in the colon tissue of mice in the DSS model group was significantly increased to 5.60±0.50 times that of the Control group (P<0.01); there was no significant change in the expression of IFN-γ mRNA in the colon tissue of mice in the ZHT (150mg / kg / day) group compared with the Control group. 75mg / kg / day ZHT inhibited 74.2±6.0% of the DSS-induced IFN-γ transcriptional upregulation, and the difference between the DSS+ZHT (75mg / kg / day) group and the DSS model group was extremely significant (P<0.01). The positive therapeutic drug 5-ASA (200mg / kg / day) inhibited the DSS-induced IFN-γ transcriptional upregulation, with an inhibition rate of 83.0±4.2% (P<0.01).

[0434] 4. Experimental conclusions and discussion

[0435] In this example, a DSS-induced mouse ulcerative colitis model was used, and 5-aminosalicylic acid was used as a positive control drug to investigate the therapeutic effect of 75 mg / kg / day of total flavonoids from ZHT in treating colitis. The results showed that the ZHT (75 mg / kg / day) group significantly protected the DSS-induced colitis symptoms of mice, such as weight loss, diarrhea, and bloody stools; significantly improved DSS-induced colon atrophy, crypt structure damage, and tissue inflammatory infiltration and other histopathological changes; and reduced DSS-induced increases in tissue MPO levels and the expression of inflammatory factors, showing a good therapeutic effect on colitis, which was comparable to the effect of the positive therapeutic drug 5-aminosalicylic acid.

[0436] In summary, ZHT has a certain therapeutic effect on colitis. At 75 mg / kg / day, its effect is comparable to that of the positive drug 5-ASA and its safety is relatively good.

[0437] It has been verified that the samples of Example 1, Example 2-A3, Example 3.2-2, Example 5-2, and Example 19-2 also have basically the same effects or effects on colitis as those of Example 19-1 in this example.

[0438] Example 21 Oral ulcer efficacy experiment

[0439] 1 Experimental Materials

[0440] 1.1 Animals: SPF male SD rats, 250-300 g, purchased from Shanghai Jiesijie Experimental Animal Co., Ltd.

[0441] 1.2 Drugs: Guilin Watermelon Frost, Guilin Sanjin Pharmaceutical Co., Ltd.; ethanol extract of hibiscus flower (dry powder, prepared by refluxing extraction of hibiscus flower with 95% ethanol for three times, concentrating and drying); water extract of hibiscus flower (thick paste, prepared by refluxing extraction of hibiscus flower water for three times, concentrating and drying), total flavonoids extract of hibiscus flower (prepared in Example 19, batch number 19-2).

[0442] 1.3 Reagents: Phenol (analytical grade), Nanjing Chemical Reagent Co., Ltd.; Chloral hydrate (analytical grade), Sinopharm Chemical Reagent Co., Ltd.

[0443] 2 Experimental methods

[0444] 2.1 Modeling: SPF male SD rats were randomly divided into groups, with 9-11 rats in each group. They were blank group (normal group), model group, hibiscus flower ethanol extract group, hibiscus flower water extract group, hibiscus flower total flavonoids extract group, and watermelon frost group. All rats were anesthetized by intraperitoneal injection of chloral hydrate (400 mg / kg), and a glass tube with an inner diameter of 4 mm at the lower end was taken, and a small cotton ball was placed at its lower end. For the model group and rats in each drug-treated group, 90% phenol solution was dripped into the glass tube until the small cotton ball was just soaked, and the lower end was placed flat on the buccal mucosa about 1 mm from the left and right corners of the mouth of the rat for 30 seconds. White lesions with a diameter of about 4-5 mm were observed in this area. The blank group was treated in the same way with double distilled water instead of phenol.

[0445] 2.2 Administration: Each drug was prepared into a suspension with double distilled water, and evenly applied to the oral mucosal wound after modeling, 4 times a day. The dosage of each drug was as follows: watermelon frost, 20 mg / wound / day; 10 mg / wound / day of hibiscus flower alcohol extract; 8.75 mg / wound / day of hibiscus flower water extract, 1.05 mg / wound / day of hibiscus flower total flavonoids extract. The drug was administered for 5 consecutive days, and the ulcer area and ulcer healing were observed before and after administration. On the 6th day, the ulcer surface was photographed after anesthesia with chloral hydrate (400 mg / kg). After the rats were killed by cervical vertebrae dislocation, the bilateral buccal membrane tissues of the rats were removed. 7-9 samples were randomly selected from each group and immersed in 4% formaldehyde (prepared with saline) for fixation, routine sampling, dehydration, and paraffin embedding. The sections were stained with HE and observed under an optical microscope. The remaining buccal membrane tissues were frozen in a -70℃ refrigerator for use to measure other inflammatory indicators.

[0446] 2.3 Data statistics: Data are expressed as mean ± SD. The significant difference between the model group and the normal group (blank control group) was tested by Student's-t test; the significant difference between the model group and the other drug-treated groups was analyzed by One-way ANOVA test, and the significant difference between the two groups was further tested by Newman-Keuls multiple comparison test.

[0447] 3 Results

[0448] 3.1 Visual observation and evaluation

[0449] The surface of the oral mucosa of the rats in the blank group was smooth, uniform in color, and without blood spots. After phenol stimulation, the local mucosa turned white quickly, edema was visible after 2 hours, inflammatory exudation, bleeding, and local ulceration were visible within 1-5 days, and the surface was covered with a yellow-white pseudomembrane and fell off. On the 6th day, except for the blank group, the wound surface of rats in all groups was sunken; the vascular dilation of the wound surface of rats in the 50% model group was more obvious, and yellow pus spots were visible in one rat. The results are shown in Table 21-1 (each rat has two wound surfaces in the mouth).

[0450] Table 21-1 Statistics on the degree of phenol buccal ulcer in rats

[0451]

[0452] 0: no ulcer, normal oral mucosa;

[0453] I: There is ulcer depression, no obvious bleeding or vascular dilation, no obvious swelling, and no obvious pseudomembrane;

[0454] II: There are ulcers and pits, with fewer blood spots;

[0455] III: There are ulcer depressions, obvious blood spots, and slight swelling.

[0456] 3.2 Pathological changes

[0457] The following items were examined under an optical microscope: (1) whether the mucosal epithelial cells showed degeneration, necrosis, erosion, ulceration, or inflammatory cell infiltration; and (2) whether the submucosal tissue showed congestion, edema, or inflammatory cell infiltration.

[0458] Scoring criteria for lesion severity: The lesions are scored from 0.5 to 4 points from mild to severe, and the scoring criteria are: mild or very mild lesions are scored as 0.5 points; mild lesions are scored as 1 point; moderate lesions are scored as 2 points; severe lesions are scored as 3 points; very severe lesions are scored as 4 points; no lesions are scored as 0 points. The length of the ulcer is measured with a "microscope side micrometer" under a 40x light microscope (eyepiece 4×, objective lens 10×). The length of the ulcer <5mm / 40X ​​is scored as 1 point, >5mm / 40X ​​or 5mm / 40X ​​is scored as 2 points. Add all the scores and calculate the average score of lesions for each group of animals. The higher the score, the more severe the disease.

[0459] The statistical results of pathological changes in each group are shown in Table 21-2, and the pathological images are shown in Figure 4 , Figure 4 In b, the short black arrow shows skin necrosis and shedding to form an ulcer (without epidermal coverage), the long black arrow shows inflammatory cells infiltrating the dermis, the green arrow shows vascular dilation and congestion, the green arrow shows fibroblasts, and the green star shows the thin layer of stratified epithelium on the skin surface with mild keratinization on the surface.

[0460] Table 21-2 Scoring results of pathological changes in oral mucosa of rats

[0461]

[0462] Note: ## P<0.01 vs blank group; *P<0.05, **P<0.01 vs model group.

[0463] Example 22 Pharmacodynamic evaluation of total flavonoids from Astragalus membranaceus in treating skin diseases

[0464] Example 22-1 Pharmacodynamic evaluation of total flavonoids from Astragalus membranaceus in the treatment of acne

[0465] 1. Experimental purpose:

[0466] To investigate the therapeutic effect of topical administration of total flavonoids from Hibiscus truncatum (ZHT) on acne induced by 100% oleic acid and Propionibacterium acnes (P. acnes), and to compare the efficacy with that of positive drugs benzoyl peroxide / clindamycin.

[0467] 2. Experimental Materials

[0468] 2.1. Experimental animals

[0469] SPF-grade SD rats, half male and half female, were housed in separate cages, 6-8 weeks old, weighing 140-150 g, and were provided by the Medical Experimental Animal Center of Nanjing Medical University (Experimental Animal Production License No.: SCXK(Su)2021-0011).

[0470] Reagents and medicines

[0471] Total flavonoids from Astragalus membranaceus (ZHT-1) were prepared according to the method of Example 19, also known as "Total flavonoids extract from Astragalus membranaceus", batch number 19-1. Total flavonoids from Astragalus membranaceus (ZHT-2) were prepared according to the method of Example 6.

[0472] 2.3. Preparation of experimental drugs

[0473] Preparation method of ZHT cream: 1% total flavonoids cream of Astragalus membranaceus is prepared according to the prescription in Table 22-1.

[0474] Table 22-1: ZHT cream preparation prescription.

[0475]

[0476]

[0477] Aqueous phase: Weigh the prescribed amount of ethanol, add ZHT, stir to dissolve, add Tween 80, sodium lauryl sulfate, glycerol, isopropyl myristate, methylparaben, azone, and purified water into the beaker in sequence, and stir until evenly dispersed.

[0478] Oil phase: Weigh the prescribed amount of glyceryl monostearate, palmitic acid and white vaseline into a beaker, and heat in a water bath at 80°C to dissolve until liquid.

[0479] Slowly add the water phase into the oil phase while stirring. After all the water phase is added, take it out from the water bath and stir at room temperature until it cools into a cream.

[0480] Preparation method of reinforced Clostridial medium (RCM): weigh 19.0 g of reinforced Clostridial medium powder into a 500 mL conical flask, add 500 mL of distilled water, heat and stir, divide into portions, and sterilize at 121°C for 15 minutes for use.

[0481] Culture method of P. acnes: Add 4 mL of RCM culture medium and 1 mL of P. acnes bacterial solution into a sterile test tube and mix well by blowing. Wrap the sterile container with sealing film and place it vertically into an anaerobic culture bag containing an anaerobic gas-producing bag. Culture it in a 37°C electric constant temperature incubator and subculture it every 2 days.

[0482] Preparation of P.acnes injection: Prepare immediately before use. Dilute the bacterial solution to a concentration of 6×107 CFU / mL, and the P. acnes injection solution was obtained (the McFarland turbidity of the bacterial solution was about 2McFarland, and after diluting 10 times with normal saline, 6×10 7 CFU / mL concentration of bacterial suspension, measure its OD 600nm Between 0.63 and 0.65.)

[0483] 2.3 Construction and treatment of rat acne model

[0484] Rat acne model establishment and drug efficacy evaluation methods Figure 5 As shown, 100% oleic acid combined with P. acnes was used to establish an acne model, and ZHT cream was applied on the 8th day for treatment, and 2.5% benzoyl peroxide / 1% clindamycin (BPO) hydrogel was used as a positive control.

[0485] Rats, half male and half female, 6 in each group, were housed in separate cages. After one week of adaptive feeding, 100% oleic acid combined with P.acnes were used to induce acne model in rats other than the blank group. The right auricle of rats was used as a carrier to construct the acne model, and the left ear was not treated. 100% oleic acid was applied once on the inside of the right ear of the rats at 9 am every day, 0.5 mL each time, and the blank group was applied with an equal amount of saline; oleic acid was applied every other day, and the prepared P.acnes injection was injected into the inside of the right ear of the rats 1 hour later, 50 μL each time; the blank group was injected with saline.

[0486] On the 8th day of modeling, the rats were regrouped to ensure that the severity of the model in each group of rats was basically the same, and were divided into a blank control group (Veh), a model group (Model), a model + benzoyl peroxide / clindamycin group (Model+BPO), a model + 1% ZHT-1 group (Model+1% ZHT-1), and a model + 1% ZHT-2 group (Model+1% ZHT-2). Each group had one cage for each female and one cage for each male rat, with three rats in each cage. Starting from the afternoon of the 8th day after grouping, 50 mg of the drug to be tested was applied to the ears every afternoon.

[0487] 2.4 Auricular swelling measurement and symptom scoring

[0488] The thickness of the rats' right auricle was measured with a vernier caliper before modeling on the morning of the 0th, 3rd, 6th, 9th, 12th, 15th, and 18th day. Three different measurement sites were selected for each rat, and the average value was taken to ensure the accuracy and objectivity of the measurement. A graph of the change of the rat's right auricle thickness over time was drawn.

[0489] The right auricle of the rats was photographed and scored for symptoms before modeling on the morning of the 1st, 3rd, 7th, 11th, 15th, and 17th day. The severity of the disease was scored based on four indicators: redness, swelling, desquamation, papules, and cysts. Each indicator corresponded to 0-4 points, and the scores of the four indicators were added together to get the total score. According to the scoring standard: 0 points, no symptoms; 1 point, mild; 2 points, moderate; 3 points, severe; 4 points, extremely severe.

[0490] 2.5 Specimen Collection

[0491] The rats were killed on the 19th day, and the right auricles of the rats were completely cut off. 1 / 4 of the ear tissue was fixed in 4% paraformaldehyde overnight for paraffin section preparation and pathological examination. The remaining ear tissue was quickly frozen in liquid nitrogen and stored at -80°C for subsequent ELISA and qPCR detection.

[0492] 2.6 H&E staining and pathological examination

[0493] The rat ear tissue was fixed with 4% paraformaldehyde for 24 hours, embedded in paraffin, and then sectioned. H&E staining was performed, and the pathological changes of the rat acne model were evaluated according to the histological criteria.

[0494] The specific scoring criteria are shown in Table 22-2.

[0495] Table 22-2 Acne pathological histological scoring standard

[0496]

[0497] 2.8 Determination of protein contents of IL-1β, IL-6, TNF-α and MCP-1 in rat ear tissue

[0498] According to the operating procedures recommended by the ELISA kit manufacturer, the contents of IL-1β, IL-6, TNF-α and MCP-1 in various ear tissues were detected.

[0499] 3. Experimental results

[0500] 3.1 Effects of ZHT on the appearance and thickness of the auricle in acne rats

[0501] During the entire experiment, the inner side of the right auricle of the rats in the Veh group remained smooth and flat, without symptoms such as redness, swelling, desquamation, papules, and cysts, and the thickness of the right auricle remained basically unchanged.

[0502] The right auricle of the rats in the Model group showed obvious symptoms of redness, swelling and desquamation on the 7th day of modeling, and the symptoms of redness, swelling and desquamation continued to worsen with the progress of modeling. In the later stage, the surface of the right auricle became uneven and accompanied by cysts. The thickness of the right auricle of the rats increased significantly after modeling. From the 6th day, it was significantly higher than that of the Veh group, and the difference was statistically significant (P<0.01) (Table 22-3). The skin lesion symptom score showed that the degree of skin lesions gradually worsened after modeling, and from the 3rd day, it was significantly different from that of the Veh group (P<0.01) (Table 22-4).

[0503] The application of BPO hydrogel improved the redness, swelling, desquamation and cysts caused by modeling. The surface of the right auricle of rats in the Model+BPO group was also smoother and flatter. After treatment with BPO hydrogel, the thickening of the ear caused by modeling was gradually delayed. On the 18th day, the thickness of the right auricle of rats in the Model+BPO group was significantly reduced compared with that in the Model group (P<0.01) (Table 22-3). The skin lesion symptom score showed that the application of BPO hydrogel had a certain therapeutic effect on the acne-like symptoms caused by modeling. Starting from the 11th day, there was a significant difference compared with the Model group (P<0.01) (Table 22-4).

[0504] After applying 1% ZHT-1 and 1% ZHT-2 creams, the thickening of the ears caused by modeling was significantly reduced on the 12th day, which was significantly different from the Model group (P<0.01) (Table 22-3); the application of 1% ZHT-2 improved the desquamation caused by modeling on the 15th day, and the skin lesion symptom score was significantly reduced compared with the Model group (P<0.01), but it could not further improve the redness and papules caused by modeling, so there was no significant difference in the skin lesion symptom score compared with the Model group at other time points (P>0.05). The application of 1.0% ZHT-1 alleviated the acne-like symptoms such as redness, desquamation and papules caused by modeling. On the 11th, 15th and 17th days, the symptom score of the Model+1.0% ZHT group was significantly lower than that of the Model group (P<0.01) (Table 22-4).

[0505] Table 22-3 Changes in thickness of right auricle of rats in each group (unit: mm)

[0506]

[0507] Data are expressed as mean ± standard error. N = 6. **, P < 0.01, vs. Veh; ## , P < 0.01, vs. Model, analyzed using two-way ANOVA and Dunnett's multiple comparison test.

[0508] Table 22-4 Symptom scores of right auricle skin lesions in each group of rats

[0509]

[0510] 3.2 Effects of ZHT on ear pathological morphology in acne rats

[0511] There was no obvious abnormality in the ear tissue of rats in the Veh group. The thickness of the epidermis was measured to be 12.56±2.39μm. The boundaries between the hair follicles, epidermis, and dermis were clearly visible, and inflammatory cell infiltration was occasionally seen in the dermis.

[0512] The thickness of the epidermis of the ear tissue of rats in the Model group was 171.73±17.18μm, which was significantly increased compared with that in the Veh group (P<0.01). The epidermis and stratum corneum were excessively thickened, and inflammatory cells were seen in the stratum corneum. The hair follicles were dilated, and the follicle openings and infundibulum were filled with keratinized substances. The keratin plugs were heavily blocked and enlarged into a kettle shape. The sebaceous glands were atrophied, and the dermis was edematous with a large amount of inflammatory infiltration. The pathological score was 3.83±0.17 points, which was significantly different from that in the Veh group (P<0.01).

[0513] The thickness of the epidermis of the ear tissue of rats in the Model+BPO group was 104.90±7.35μm, which was significantly lower than that in the Model group (P<0.01); the stratum corneum was slightly thickened, the keratinized material in the hair follicle orifice and the infundibulum was less, the sebaceous glands were normal in morphology, the dermis was not edematous, and the degree of inflammatory cell infiltration was alleviated compared with that in the Model group. The pathological score was 2.67±0.33 points, which was significantly lower than that in the Model group (P<0.01).

[0514] The epidermal thickness of rat ear tissue in the Model+1% ZHT-2 group and the Model+1.0% ZHT-1 group were 133.36±13.17μm and 128.08±8.83μm, respectively. 1.0% ZHT-1 could significantly reduce the epidermal thickening caused by modeling (P<0.05).

[0515] Applying 1% ZHT-2 and 1.0% ZHT-1 can improve the excessive thickening of the epidermis and stratum corneum, alleviate dermal edema and reduce inflammatory cell infiltration in a dose-dependent manner. The pathological scores of each group were 3.33±0.33 and 3.33±0.33, respectively.

[0516] 3.3 Effect of ZHT on the mRNA expression levels of Mcp-1, Il-1β, Il-6 and Tnf-α in ear tissues of acne rats

[0517] The mRNA expression of Mcp-1 in the ear tissue of rats in the Model group increased to 3.11±0.30 times that of the Veh group (P<0.01); compared with the Model group, the application of BPO hydrogel can significantly improve the modeling-induced up-regulation of Mcp-1 mRNA expression, with an improvement rate of 70.9±14.9% (P<0.01vs.Model); the application of 1% ZHT-1 cream can improve the modeling-induced up-regulation of Mcp-1 mRNA expression, with an improvement rate of 25.5±16.0%, but the difference was not statistically significant (P>0.05vs.Model); and the application of 1% ZHT-2 cream has an inhibitory effect on the modeling-induced up-regulation of Mcp-1 mRNA expression.

[0518] The mRNA expression of Il-1β in the ear tissue of rats in the Model group increased to 14.23±2.24 times that of the Veh group, and the difference was statistically significant (P<0.01); compared with the Model group, the application of BPO hydrogel could improve the modeling-induced up-regulation of Il-1β mRNA expression, with an improvement rate of 76.6±6.9% (P<0.05vs.Model); the application of 1% ZHT-2 and 1% ZHT-1 creams could improve the modeling-induced up-regulation of Il-1β mRNA expression, with improvement rates of 18.5±15.3% (P>0.05vs.Model) and 58.4±6.5% (P<0.01vs.Model), respectively.

[0519] The mRNA expression of Il-6 in the ear tissue of rats in the Model group was significantly increased to 4.62±0.50 times that of the Veh group, and the difference was statistically significant (P<0.01); the application of BPO hydrogel, 1% ZHT-2, and 1% ZHT-1 cream reduced the upregulation of Il-6 mRNA expression induced by modeling, and the improvement rates were 60.0±13.5% (P<0.05vs.Model), 46.2±5.4% (P<0.05vs.Model), and 61.1±20.3% (P<0.05vs.Model), respectively.

[0520] The mRNA expression of Tnf-α in the ear tissue of rats in the Model group was significantly increased to 3.98±0.52 times that of the Veh group (P<0.01); the application of BPO hydrogel could improve the modeling-induced up-regulation of Tnf-α mRNA expression, with an improvement rate of 71.2±10.0% (P<0.05vs.Model); the application of 1% ZHT-2 and 1% ZHT-1 creams could inhibit the modeling-induced up-regulation of Tnf-α mRNA expression, with improvement rates of 18.2±12.9% (P>0.05vs.Model) and 58.3±15.0% (P<0.05vs.Model), respectively.

[0521] 3.5 Effect of ZHT on the contents of IL-1β, IL-6, TNF-a and MCP-1 in ear tissue of rats with acne

[0522] The IL-1β protein content in the ear tissue of the Veh group was 175.2±29.5 pg / mL, and the IL-1β protein content in the ear tissue of the rats in the Model group was 270.1±18.9 pg / mL, which was 1.54±0.11 times that of the Veh group (P<0.05). After administration of BPO, 1% ZHT-2 and 1% ZHT-1, the IL-1β protein content in the ears of rats was 224.0±20.0 pg / mL, 194.4±20.5 pg / mL and 179.7±25.8 pg / mL, which improved the increase of IL-1β protein content induced by modeling by 48.5±21.1% (P>0.05 vs. Model), 79.8±21.6% (P<0.05) vs. Model and 95.2±27.2% (P<0.05 vs. Model), respectively.

[0523] The IL-6 protein content in the ear tissue of the Veh group was 93.7±20.4 pg / mL, and the IL-6 protein content in the ear tissue of rats in the Model group was 266.4±15.2 pg / mL, which was 2.84±0.16 times that of the Veh group, and the difference was extremely significant (P<0.01); after administration of BPO hydrogel, the IL-6 protein content in the rat ear tissue was 189.0±10.8 pg / mL, which inhibited the increase of IL-6 protein content in the ear tissue of rats induced by modeling by 44.8±6.3% (P<0.01 vs. Model). The protein contents of IL-6 in the ear tissue of rats after administration of 1% ZHT-2 and 1% ZHT-1 were 237.2±21.4 pg / mL and 235.2±25.6 pg / mL, respectively. Each group improved the increase of IL-6 protein content in the ear tissue of rats induced by modeling by 16.9±12.4% (P>0.05vs.Model) and 18.1±14.8% (P>0.05vs.Model), respectively.

[0524] The protein content of TNF-α in ear tissue of rats in Veh group was 103.7±23.7pg / mL, and that in ear tissue of rats in Model group was 423.2±37.0pg / mL, which was 4.08±0.58 times higher than that in Veh group, and the difference was extremely significant (P<0.01). The protein content of TNF-α in ear tissue of rats after administration of BPO, 1% ZHT-2 and 1% ZHT-1 was 286.2±46.1pg / mL, respectively. pg / mL, 224.9±49.1pg / mL, and 221.5±60.3pg / mL, respectively, compared with the Model group, which improved the increase of TNF-α protein content in rat ear tissue induced by modeling by 62.1±15.4% (P<0.01vs.Model), 42.9±14.4% (P<0.05vs.Model), and 63.1±18.9% (P<0.01vs.Model), respectively.

[0525] The samples of Example 4-1 and Example 19-2 have been verified to have the same effects or effects on acne as those of Example 19-1 and Example 6 in the present embodiment.

[0526] Example 22-2 Pharmacodynamic evaluation of total flavonoids from Astragalus membranaceus in the treatment of atopic dermatitis

[0527] 1. Research content and purpose:

[0528] The therapeutic effects of different doses of total flavonoids from Asparagus cochinchinensis (ZHT-1, such as Example 22-1) and Asparagus cochinchinensis HKY on DNFB-induced atopic dermatitis (AD) were investigated and compared with the positive drug mometasone (Mome) to determine the therapeutic effects of ZHT and HKY on AD.

[0529] 2. Experimental Materials

[0530] 2.1 Experimental animals

[0531] SPF Balb / c mice were purchased from the Comparative Medicine Center of Yangzhou University [Laboratory Animal Production License No.: SCXK (Su) 2017-0007], 7-8 weeks old, weighing 18-20 g. They were kept in an environment with a room temperature of 23±2°C, a humidity of 55%, and a light-to-dark time ratio of 1:1, and the mice were free to eat and drink.

[0532] 2.2 Drugs and main reagents

[0533]

[0534] 2.3 Experimental instruments

[0535]

[0536] 3. Experimental Methods

[0537] 3.1 Animal grouping and atopic dermatitis model construction

[0538] After 5 days of adaptive feeding, 80 clean-grade Balb / c mice were randomly divided into 10 groups, including blank control group (Sham), DNFB modeling group (DNFB), positive drug mometasone furoate group (Mome), 0.5% group of total flavonoids of sunflower (ZHT) cream, 0.5% group of sunflower HKY (HKY) cream, and 100 mg / kg SZHT oral administration group. Rosin wax wax was used for hair removal. Each mouse was smeared with 50 μL of 1.0% [W / V, solvent is acetone olive oil mixture (acetone: olive oil = 3:1)] 2,4-dinitrofluorobenzene (DNFB) on the back in the morning of the first day. On the morning of the 4th, 6th, 8th, and 10th days, 0.5% (W / V) DNFB was applied, 50 μL each time, and the control group was smeared with the same amount of solvent control (acetone: olive oil = 3:1). Animal experiments followed the Guidelines for the Care and Use of Laboratory Animals and were in accordance with animal ethics standards. Construction of atopic dermatitis model Figure 6 shown.

[0539] 3.2 Administration and dosage

[0540] Starting from the 5th day, 100 mg of different doses of ZHT cream and HKY cream were accurately weighed with an electronic analytical balance every afternoon and evenly applied to the back modeling area. The control group was given 100 mg of blank cream; the 100 mg / kg SZHT group was given by gavage. Figure 6 shown.

[0541] 3.2.1 Preparation of ZHT cream and HKY cream

[0542] The prescriptions of ZHT cream and HKY cream are shown in Table 22-3-1.

[0543] Table 22-3-1 Total flavonoids cream of Huang Kui and Huang Kui HKY prescription

[0544]

[0545]

[0546] Cream preparation process:

[0547] Aqueous phase: Weigh the prescribed amount of ethanol, add ZHT / HKY, stir to dissolve, add Tween 80, sodium lauryl sulfate, glycerol, isopropyl myristate, methylparaben, azone, and purified water into the beaker in sequence, and stir until evenly dispersed.

[0548] Oil phase: Weigh the prescribed amount of glyceryl monostearate, palmitic acid and white vaseline into a beaker, and heat in a water bath at 80°C to dissolve until liquid.

[0549] Slowly add the water phase into the oil phase while stirring. After all the water phase is added, take it out from the water bath and stir at room temperature until it cools into a cream.

[0550] 3.2.2 Preparation of SZHT suspension

[0551] Preparation of 0.5% CMC-Na: One day before administration, slowly add 0.5g CMC-Na powder to 100mL 70℃ pure water, stir evenly, and let stand at room temperature overnight. The next day, accurately weigh 50mg ZHT and add 0.1mL DMSO to prepare DMSO mother solution. Add 0.1mL Tween-80 and 9.8mL ultrasonically homogenized 0.5% CMC-Na solution to the ZHT mother solution to obtain a 5mg / mL ZHT suspension.

[0552] 3.3 Atopic dermatitis severity score (AD Score)

[0553] On the 4th, 7th, 9th and 11th days of modeling, the back skin of each mouse was photographed and recorded, and the severity of dermatitis appearance was evaluated by four indicators: ① erythema / hemorrhage ② dryness ③ exudation / scab ④ edema. Each indicator was scored from 0 to 3 points, and the scores of the four indicators were added together to obtain the total score. The AD Score scoring criteria are as follows: 0, no symptoms; 1, mild symptoms; 2, moderate symptoms; 3, severe symptoms.

[0554] 3.5 HE staining

[0555] Paraffin sections were routinely dewaxed to water, and the sections were placed in hematoxylin dye, stained for 5 minutes, and then rinsed with tap water. The sections were then placed in hydrochloric acid ethanol, differentiated for 30 seconds, soaked in tap water for 15 minutes, and then placed in eosin dye and stained for 2 minutes. Routine dehydration, transparency, and neutral resin sealing were used. Photos were taken using a digital pathology section scanner, and the thickness of the epidermis was counted.

[0556] 3.10 Statistical analysis

[0557] GraphPad Prism 6.0 software was used for statistical analysis and drawing of data, and all data were expressed as mean ± standard error (mean ± SEM). Two-way ANOVA was used to analyze dermatitis scores, and one-way ANOVA was used to analyze other data. Dunnett's multiple test was used to analyze the significance of differences between groups. When P < 0.05, the differences between groups were significant and statistically significant.

[0558] 4. Experimental Results

[0559] 4.1 Effects of ZHT and HKY on the appearance of DNFB-induced atopic dermatitis model

[0560] like Figure 7 As shown, during the whole experiment, the back skin of the blank control group (Sham) was always smooth and flat, without exudation, scabs, erythema and bleeding. After repeated stimulation of DNFB, from the 4th day, the DNFB group mice showed obvious symptoms such as scabs, erythema and edema, and their dermatitis score (AD Score) was significantly different from that of the Sham group (P<0.01, N=8), indicating that the AD model was successfully established; the positive drug mometasone furoate (Mome) can gradually improve the AD-like symptoms caused by DNFB, and there is a significant difference between the Mome group and the DNFB group in the dermatitis score on the 11th day (P<0.05, N=8); applying 0.5% ZHT can significantly alleviate AD-like symptoms, and the difference between the 0.5% ZHT group and the DNFB group in the dermatitis score on the 11th day is extremely significant (P<0.01, N=8); oral administration of 100 mg / kg SZHT did not show any effect on alleviating AD-like symptoms (P>0.05, N=8); 0.5% HKY could alleviate AD-like symptoms to a certain extent, but there was no significant difference in dermatitis scores between the 0.5% HKY group and the DNFB group (P>0.05, N=8).

[0561] 4.3 Effects of ZHT and HKY on skin pathological changes in DNFB-induced atopic dermatitis model.

[0562] The results of HE staining of skin tissue sections in each group are as follows Figure 8As shown in the figure, there was no significant change in the back skin tissue of the Sham group, the structure of each layer of the skin was intact, the boundary between the dermis and the epidermis was clear, there was no obvious inflammatory cell infiltration, and the epidermal thickness (shown by the blue line) was 37.18±8.93μm; the skin tissue of the DNFB group showed obvious hyperkeratosis and acanthosis, and the epidermal thickness was 134.28±22.46μm, which was significantly increased compared with the Sham group (P<0.01, N=6), which was consistent with the pathological characteristics of atopic dermatitis skin tissue; after applying Mome treatment, it was obviously observed that the degree of epidermal thickening was reduced, and the thickness of the epidermis was 46.0 9±14.29μm (P<0.01, N=6, compared with the DNFB group); the skin spinous hypertrophy in the 0.5% ZHT group was improved, and the epidermal thickness was 100.59±10.95μm. Compared with the DNFB group, 0.5% ZHT reduced the thickening by 34.7±5.0%, which was significantly different (P<0.05, N=6), which was consistent with the dermatitis score results; however, 0.5% HKY had no significant improvement on DNFB-induced AD-like pathological changes, and its epidermal thickness was not significantly different from that of the DNFB group (P>0.05, N=6).

[0563] Example 3.2-1, Example 4-2, and Example 9-2 also have the same functions or effects as the total flavonoids of Astragalus membranaceus in the present example.

[0564] Example 23 Pharmacodynamic evaluation of total flavonoids from Astragalus membranaceus in promoting wound healing

[0565] 1. Experimental Materials

[0566] 1.1 Experimental animals

[0567] SPF SD rats, 6-8 weeks old, 150-200g.

[0568] 1.2 Reagents and drugs

[0569] Table 23-1

[0570]

[0571]

[0572] 2. Experimental Methods

[0573] 2.1 Animal husbandry and management

[0574] SD rats (purchased from Nanjing Medical University, license number: SCXK (Su) 2021-0001) were kept in an SPF animal room throughout the whole process, with a light-to-dark time ratio of 1:1, room temperature controlled at 23 ± 2 °C, humidity controlled at 55%, and rats were free to eat and drink. The bedding was changed every three days during the high-sugar and high-fat diet feeding stage, and the bedding was changed once a day during the STZ injection stage to establish the diabetes model. After the full-thickness skin excision model was established, the bedding was changed every half a day to ensure that the rats were in a dry and clean environment. All animal experimental protocols were approved by the Experimental Animal Care and Use Committee of China Pharmaceutical University (License No.: SYXK (Su) 2018-0019).

[0575] 2.2 Administration and Dosage

[0576] An electronic analytical balance was used to weigh 100 mg of blank cream, 0.5%, 1%, and 2% total flavonoids cream from Astragalus membranaceus, and Deshijie hydrocolloid, respectively, and applied evenly on the surface of the ulcer wound twice a day. The groups and the drugs applied in each group are as follows:

[0577] Blank control group (Control): no treatment

[0578] Model group: applied a blank cream without total flavonoids from Astragalus membranaceus;

[0579] Positive group: Apply Dewex hydrocolloid;

[0580] Low-0.5% group: 0.5% total flavonoids from Astragalus membranaceus cream was applied;

[0581] Middle-1% group: Apply 1% total flavonoids ointment of Astragalus membranaceus;

[0582] High-2% group: Apply 2% total flavonoids cream from Astragalus membranaceus;

[0583] 2.3 Reagent preparation

[0584] STZ solution preparation: ① Preparation of citric acid buffer: Add 2.1g of citric acid to 100mL of distilled water to prepare solution A; add 2.94g of sodium citrate to 100mL of distilled water to prepare solution B. ② When using, mix A and B in proportion and adjust the pH to 4.2-4.5, which is the citric acid buffer for preparing STZ. ③ Before injection, dissolve STZ in citric acid buffer at a concentration of 1%. Protect from light and refrigerate at 4℃ for later use.

[0585] Preparation of 4% chloral hydrate: Weigh 4g chloral hydrate, add appropriate amount of physiological saline to dissolve, and dilute to 100mL. Protect from light and refrigerate at 4℃ for later use.

[0586] Preparation of different concentrations of total flavonoids from Astragalus membranaceus cream: 0.5%, 1% and 2% total flavonoids from Astragalus membranaceus cream were prepared according to the prescription in Table 22-1 of Example 22, and different concentrations were made up with water.

[0587] 2.4 Establishment of diabetic ulcer rat model

[0588] 2.4.1 STZ-induced diabetic rat model

[0589] After one week of adaptive feeding, 70 healthy male SD rats (SPF grade, 4-6 weeks old, weighing 150-200g) were randomly divided into cages, 5 rats per cage, and fed with high-sugar and high-fat feed as the diabetes model group. Ten normal rats were selected, 5 rats per cage, and fed with ordinary feed as the blank control group. Fasting blood glucose (FBG) and body weight were measured for 60 SD rats. After four weeks of feeding, streptozotocin (35mg / kg) was injected intraperitoneally according to body weight in the diabetes model group rats, and the blank control group was injected with an equal amount of citric acid buffer according to body weight. STZ solution and citric acid buffer were injected into the left lower abdomen of the rats according to fasting body weight, and the injection was completed within 10min. All rats were fasted for 6h before administration, and tail vein blood was collected 72h after injection to measure fasting blood glucose. The fasting blood glucose value was ≥16.7mmol / L and the body weight was not significantly reduced. The diabetes model was successfully constructed. Some rats with blood sugar levels between 5-8mmol / L were injected with STZ (35mg / kg) again; some rats with blood sugar levels between 8-10mmol / L were injected with STZ (25mg / kg) again; some rats with blood sugar levels between 10-16mmol / L were injected with STZ (20mg / kg). 72 hours after the injection, tail vein blood was collected to measure fasting blood sugar. If the fasting blood sugar value was ≥16.7mmol / L, the diabetes model was considered to be successfully established. If the fasting blood sugar value was <16.7mmol / L, STZ was injected again according to body weight until the fasting blood sugar value was ≥16.7mmol / L, which was considered to be a successful preparation of the diabetes model. It took 12 days to inject STZ to induce the diabetic animal model in SD rats in this experiment. After all the models were established, they were fed with a high-sugar and high-fat diet for one week to stabilize the model.

[0590] 2.4.2 Establishment of full-thickness skin excision wound model in diabetic rats

[0591] After the diabetic rats were stably molded, the rats were anesthetized by intraperitoneal injection of 4% chloral hydrate according to their body weight (2me / kg). After the rats were completely anesthetized, the backs of the rats were shaved with an electric shaver. After shaving, medical cotton swabs were dipped in iodine and applied to the backs of the rats for 4-5 times for disinfection. A sterile 8-mm Biopsy Punch was used to print a circular area with a diameter of 8 mm in the middle of the back of the rats. The skin in the middle of the circular area was clamped with sterile tweezers, and the skin was excised along the circular mark outlined by the Biopsy Punch with sterile iris scissors to create a circular full-thickness skin excision open wound with a diameter of 8 mm, deep to the muscles, avoiding arterial and venous blood vessels. Immediately afterwards, the wound was continuously applied with iodine for 4-5 times, and appropriate pressure was given to fully stop bleeding. Rats in the blank control group were only injected with an equal dose of chloral hydrate according to their body weight, and their backs were shaved, and no full-thickness skin excision open wound was established. The rats that died during modeling were eliminated, and the diabetic rats that were successfully modeled, awake and in good condition were randomly divided into the following groups according to the random number table method: model group (blank cream), positive drug group (Deshijie hydrocolloid), low-dose group (0.5% cream of total flavonoids of Asparagus cochinchinensis), medium-dose group (1% cream of total flavonoids of Asparagus cochinchinensis), and high-dose group (2% cream of total flavonoids of Asparagus cochinchinensis). After the full-thickness skin excision wound model was established, drug treatment was given immediately, and photos were taken and recorded on the 0th day (before drug application), 3rd day, 7th day, and 9th day after treatment, and the wound area was measured using ImageJ software.

[0592] 2.5 Overall evaluation of type 2 diabetic ulcer model

[0593] 1. Observe general symptoms, i.e., whether there are changes in polydipsia, polyphagia, polyuria, poor mental state, dull and yellow fur, hair loss, and a significant decrease in activity;

[0594] 2. Fasting blood glucose measured by tail vein blood sampling was 16.7-33.3mmol / L;

[0595] 3. Typical appearance of full-thickness skin defect: ulcer, redness and swelling. The ulcer area is used as an indicator for statistics. The calculation formula is as follows: wound area (%) = unhealed wound area / original wound area × 100%.

[0596] 2.6 HE staining

[0597] The skin tissue was attached to the filter paper, fixed vertically in 4% paraformaldehyde solution for 48 hours, and then embedded in paraffin wax. The embedded skin tissue was sliced ​​into full-thickness sections (5 μm) in a row, with 2 sections placed on each slide, and then HE staining was performed. The specific steps are as follows:

[0598] 1) Dewaxing: dewaxing in xylene I for 10 min, dewaxing in xylene II for 5 min;

[0599] 2) Ethanol soaking: soak in anhydrous ethanol twice, then soak in 95%, 90%, and 85% ethanol once, each time for 1 min, and finally wash with water for 2 min;

[0600] 3) Staining: Stain with hematoxylin for 5 min, then wash with tap water for 1 min;

[0601] 4) Differentiation: Differentiate with 1% hydrochloric acid alcohol for 20 seconds, then wash with tap water for 1 minute;

[0602] 5) Anti-blueing: Anti-blueing with 1% dilute ammonia for 30 seconds, then washing with tap water for 1 minute;

[0603] 6) Eosin staining: stain for 5 minutes, then wash with tap water for 30 seconds;

[0604] 7) Ethanol dehydration: Dehydration was performed with different contents of ethanol in the following order: 85% ethanol dehydration for 20 s, 90% ethanol dehydration for 30 s, 95% ethanol I dehydration for 1 min, 95% ethanol II dehydration for 1 min, anhydrous ethanol I dehydration for 2 min, and anhydrous ethanol II dehydration for 2 min;

[0605] 8) Transparency: xylene I treatment for 2 min, xylene II treatment for 2 min, xylene III treatment for 2 min;

[0606] 9) Finally, the slides were sealed with neutral gum and scanned with a digital pathology slide scanner (NanoZoomer 2.0 RS).

[0607] 2.7 Masson staining

[0608] The paraffin sections were dewaxed to water, stained with Weigert's hematoxylin solution for 10 minutes, differentiated with 1% hydrochloric acid ethanol for 1 minute, rinsed with distilled water for 25 minutes, stained with Ponceau acid fuchsin solution for 10 minutes, differentiated with 1% phosphomolybdic acid aqueous solution for 5 minutes, stained with 2% brilliant green dye solution for 5 minutes, and rinsed with 1% glacial acetic acid aqueous solution for 1 minute. Subsequently, they were dehydrated with 95% ethanol and anhydrous ethanol, transparentized in xylene, and sealed with neutral gum. The sections were scanned and imaged using a digital pathology slide scanner (NanoZoomer 2.0 RS).

[0609] 2.8 Immunofluorescence of vascular marker CD31

[0610] Take skin tissue, fix it with 4% paraformaldehyde overnight, embed it in paraffin, and make skin paraffin sections. Put the paraffin sections in a 60℃ oven, bake for 20 minutes, then soak in xylene I for 15 minutes, xylene II for 15 minutes, anhydrous ethanol I for 5 minutes, anhydrous ethanol II for 5 minutes, 95% alcohol for 5 minutes, 85% alcohol for 5 minutes, 75% alcohol for 5 minutes, and then rinse with distilled water and PBS for 5 minutes respectively. Place the sections in a staining jar filled with antigen retrieval buffer and perform antigen heat retrieval in a pressure cooker. Rinse the pressure cooker with running water, cool to room temperature, shake off the excess liquid, add 5% BSA, and block at room temperature for 1 hour. Then, shake off the blocking solution, add diluted primary antibody (1:400), and place the sections in a wet box for overnight incubation at 4℃. The next day, the primary antibody was removed, and the sections were rinsed with PBS for 3 times, 5 min each time, followed by the addition of diluted fluorescent secondary antibody (1:1000), incubated at room temperature in the dark for 1 h, the secondary antibody was removed, and the sections were rinsed with PBS for 3 times, 5 min each time. After drying the sections, anti-fluorescence quencher containing Hoechst was added, and the sections were observed and photographed under a fluorescence microscope.

[0611] 2.9 Real-time fluorescence quantitative PCR

[0612] Place the skin tissue in a grinding tube, add grinding beads and 800 μL Trizol reagent, and grind it in a tissue grinder at a frequency of 60 Hz for 1 min. Repeat 5 times until no precipitation is visible to the naked eye. Collect the supernatant, centrifuge at 12,000 rpm for 10 min, and transfer the supernatant to a new 1.5 mL enzyme-free tube. Extract with chloroform-isopropanol overnight and centrifuge, discard the supernatant, wash the ions attached to the RNA with 75% ethanol, dry it, add DEPC water to dissolve it, and draw 2 μL for quantification with Nano-100 micro-spectrophotometer. During the detection, A260 / A280 should be between 1.8-2.0. Use enzyme-free water to adjust the RNA concentration to 1 μg, add 3 μL of 5×gDNA wiperMix and heat at 42°C for 2 min to remove genomic DNA, then add 5 μL of 4×qRT Super MixII to achieve a 20 μL system, perform reverse transcription reaction at 25°C-2 min, 50°C-30 min, and 85°C-5 min in a PCR instrument, and store cDNA at -80°C for later use.

[0613] According to 1μL cDNA + 10μL Green+0.8μL Primers+8.2μL ddH 2 O system for real-time fluorescence quantitative PCR reaction, using 2 -ΔCt Methods mRNA expression was calculated, and the expression of each gene was corrected by the expression of GAPDH. The primers used are shown in Table 23-2.

[0614] Table 23-2 Primer sequences used in PCR

[0615]

[0616] 2.10 Determination of vascular endothelial growth factor (VEGF) content

[0617] According to the operating procedures of the ELISA kit, the content of VEGF in skin tissue was detected.

[0618] 2.11 Statistical analysis

[0619] GraphPad Prism (Ver 6.0) was used for statistical analysis. All data were expressed as mean ± standard error (Mean ± SEM). The wound appearance healing rate data were analyzed by Two-way ANOVA, and other data were analyzed by One-way ANOVA. Dunnett's multiple test was used to analyze the significance of the differences between the groups. When P < 0.05, the differences between the groups were statistically significant.

[0620] 3. Experimental results

[0621] 3.1 Effects of different concentrations of total flavonoids cream from Astragalus membranaceus on skin wound area in rats

[0622] In order to investigate the effect of different concentrations of total flavonoids cream from Astragalus membranaceus on promoting wound healing, a full-thickness skin wound model of diabetic rats was constructed, and the wound healing of each group of rats was observed. Photos were taken before application of medication on days 0, 3, 7, and 9, and the wound changes were recorded. The wound area was calculated and statistical analysis was performed.

[0623] Fig. 9 A is a representative diagram of the skin wound area of ​​rats in each group at different time points. Before drug administration (24h after injury), fibrin clots ("scabs") appeared at the skin wounds of each group, and there was a small amount of exudate, indicating that there was an inflammatory reaction at the wound at this time; on the third day after drug administration, the scabs of the wounds in each drug administration group began to harden and the scabs became dry. The dry scabs can play an antibacterial role, thereby protecting the wound to a certain extent, and provide a temporary extracellular matrix for the proliferation and migration of keratinocytes, promoting wound re-epithelialization; the wound area of ​​the model group was 99.48±8.76% of the original wound area. Compared with the drug administration group and the model group, the wound area of ​​the rats in the Deshijie hydrocolloid group began to shrink, and the wound area was 64.52±7.04% of the initial wound area. The wound areas of the 0.5%, 1%, and 2% total flavonoids ointment groups were 106.80±9.37%, 91.41±5.51%, and 98.38±8.74% of the initial wound area, respectively. Fig. 9B). On the 7th day after administration, the hard scabs in each group began to fall off. The wound area of ​​the model group was 47.62±10.68% of the initial wound area, and the wound areas of the 0.5%, 1%, and 2% total flavonoids ointment groups were 49.65±8.79%, 27.38±6.61%, and 36.54±5.72% of their initial wound areas. Among them, the 1% ointment group promoted wound healing most significantly, while the wound area of ​​the Deshijie hydrocolloid group was 17.86±4.68% of the initial wound area, and its effect on promoting wound healing was better than that of the 1% total flavonoids ointment group. On the ninth day after administration, the wound area of ​​the model group was 12.05±4.03% of the original wound area; the wound areas of the 0.5%, 1%, and 2% sunflower flavonoids cream groups were 15.98±5.63%, 10.04±5.64%, and 10.60±3.14% of the initial wound area, respectively; and the wound area of ​​the Deshijie hydrocolloid group was 8.03±4.70% of the initial wound area. Overall, the wound healing of the positive drug Deshijie hydrocolloid group was obvious, with significant differences compared with the model at 3 days and 7 days, and the 1% sunflower flavonoids cream group showed that the treatment was basically cured.

[0624] 3.2 Analysis of HE staining results

[0625] In order to further evaluate the effect of different concentrations of total flavonoids cream of Asparagus cochinchinensis on promoting diabetic wound healing, we performed HE staining on rat skin tissue 9 days after modeling to observe the changes in the tissue microscopic level. HE staining is one of the commonly used paraffin section staining methods. It uses hematoxylin, eosin and other dyes for staining, so it is also called hematoxylin-eosin staining. Hematoxylin stain is an alkaline dye that can dye the cell nucleus purple-blue, eosin dyes the components in the extracellular matrix and cytoplasm pink, and other structures show different shades and combinations of these colors. In addition, the overall color pattern of the stained tissue shows the overall layout and distribution of cells, and provides an overall overview of the structure of the tissue sample, which can be used to observe the number and distribution of fibroblasts, capillaries, inflammatory cells, etc. during wound healing.

[0626] like Fig.10As shown in A, the results of microscopic examination of tissue sections showed that the skin tissue of the normal group rats showed a complete keratinocyte layer, skin appendages, collagen fibers cross-linked and arranged in parallel bundles, and a small number of fibroblasts and inflammatory cells. In contrast, the skin tissue of the model group rats was loosely arranged, and keratinocytes began to proliferate, but had not yet migrated to the center of the wound. The overall skin structure was disordered, the new epidermis was thin, the new granulation tissue was less, and inflammatory cells and fibroblasts migrated to the wound, among which the number of inflammatory cells was relatively large, indicating that the model group rats were mainly in the first stage of wound healing: the inflammatory stage. The keratinocyte layer at the wound of the different concentrations of the total flavonoids cream group and the Deshijie hydrocolloid group had proliferated and migrated to the center of the wound. The collagen fibers in the granulation tissue under the keratinocyte layer were closely arranged, and more fibroblasts were seen growing. New capillaries were scattered and visible, the new epidermis was thick, and the inflammatory cells were relatively small, indicating that the skin wounds of the rats in each drug-treated group had entered the 2nd-3rd stage of wound healing: the proliferation and remodeling stage. Fig.10 B is a quantitative statistical graph of rat epidermal thickness. The blank control group had an epidermal thickness of 26.83±2.65μm, and the model group had an epidermal thickness that increased significantly to 87.72±1.95μm (P<0.01vs. control group). The Dejie hydrocolloid group had an epidermal thickness of 112.70±7.58μm, and the epidermal thicknesses of the 0.5% sunflower total flavonoids cream group, the 1% sunflower total flavonoids cream group, and the 2% sunflower total flavonoids cream group were 99.97±3.06μm, 121.00±2.35μm, and 121.10±5.64μm, respectively. The results showed that the epidermal thickness of rats in the 1% sunflower total flavonoids cream group, the 2% sunflower total flavonoids cream group, and the Dejie hydrocolloid group was significantly higher than that of the model group, indicating that the degree of re-epithelialization at the wound was higher than that of the model group, and that it could effectively promote the healing of full-thickness skin wounds in rats.

[0627] 3.3 Analysis of Masson staining results

[0628] Masson staining is a commonly used staining method in histology. It can dye collagen fibers blue and keratin and muscle fibers red. It is used to evaluate the formation of collagen fibers in the wound.

[0629] Fig.11 A shows the collagen deposition in each group after 9 days of treatment. The darker the color, the greater the amount of collagen deposition. It can be seen intuitively from the figure that the blue staining in the model group is lighter, and the blue staining in the Deshijie hydrocolloid group and different concentrations of sunflower total flavonoids cream groups has different degrees of deepening. Among them, the 1% sunflower total flavonoids cream group has a larger blue area, darker color, and more uniform distribution than other groups. Fig.11B is a quantitative statistical chart of collagen area percentage. The collagen area percentage of the blank control group was 36.02±2.95%, and the collagen area percentage of the model group decreased significantly to 14.74±1.64% (P<0.01 vs. control group). The collagen area percentage of the Dejie hydrocolloid group was 23.24±1.83%. The collagen area percentages of the 0.5% sunflower total flavonoids cream group, the 1% sunflower total flavonoids cream group, and the 2% sunflower total flavonoids cream group were 19.33±2.46%, 27.45±1.74%, and 22.76±2.48%, respectively. The results of difference analysis showed that there was a significant difference between the Dejie hydrocolloid group and the model group (P<0.05). Among the groups treated with different concentrations of sunflower total flavonoids cream, the 1% sunflower total flavonoids cream group had the highest collagen content, which was significantly different from the model group (P<0.01).

[0630] 3.4 Changes in CD31 and VEGF mRNA levels

[0631] Under normal conditions, blood vessels are stable and fully perfused, delivering sufficient nutrients and oxygen to tissues. Once tissue damage occurs, local ischemia and hypoxia occur, and a large number of angiogenic factors are produced at the wound site, thereby promoting the growth of microvessels. In order to determine the changes in the vascular marker CD31 and angiogenic factor (VEGF) at the gene level, RT-qPCR was performed to detect the expression of CD31 and VEGF mRNA on the 9th day after administration.

[0632] Fig.12 A showed that the expression of Cd 31 mRNA in the modeling group decreased significantly from 0.22±0.03 to 0.10±0.01 (P<0.01). After administration, the expression of CD31 mRNA increased to varying degrees. The expression of CD31 mRNA in the Dejie hydrocolloid group was 0.17±0.02, and the expression of CD31 mRNA in the 0.5%, 1%, and 2% sunflower total flavonoids cream groups was 0.10±0.01, 0.21±0.02, and 0.12±0.02, respectively. Among them, the 1% sunflower total flavonoids cream enhanced the expression of CD31 mRNA most significantly, with statistical differences (P<0.01), and there were no statistical differences in the other groups. Fig.12 B shows that the expression of Vegf mRNA decreased after modeling, from 0.25±0.07 to 0.14±0.04. After drug administration, the expression of VEGF mRNA increased to varying degrees. Compared with the model group, the expression of VEGF mRNA in the Dejie hydrocolloid group was 0.23±0.08, and the expression of VEGF mRNA in the 0.5%, 1%, and 2% sunflower total flavonoids cream groups were 0.10±0.02, 0.21±0.04, and 0.14±0.04, respectively. However, no significant difference was found between the drug administration group and the model group.

[0633] 3.5 Analysis of immunofluorescence staining results of skin tissue

[0634] CD31 is a typical marker of vascular endothelial cells and can be used to measure angiogenesis. Immunohistochemical staining of tissue sections using anti-CD31 antibodies can very intuitively and objectively obtain the distribution, density and content of CD31 in the new tissue, and then analyze whether its microcirculation is successfully established. Using the mean fluorescence intensity as an indicator, multiple fields of view of different sections were selected for photography to evaluate the angiogenesis of different groups.

[0635] like Fig.13 As shown in A, DAPI (blue) was used to locate the cell nucleus, and anti-CD31 antibody (red) was used to locate the vascular endothelial cells, and the clear distribution of CD31 in the tissue was obtained. The number of new blood vessels in the model group was small, and CD31 was weakly positive, with a relative fluorescence intensity of 41.63±7.46% of the control group (P<0.05). The CD31 expression in the Dejie hydrocolloid group was higher than that in the model group, with a relative fluorescence intensity of 73.75±18.13% of the control group, but there was no statistical difference. The CD31 expression in the different concentrations of the total flavonoids cream of Asparagus cochinchinensis was higher than that in the model group. The relative fluorescence intensities of the 0.5%, 1%, and 2% total flavonoids cream of Asparagus cochinchinensis were 49.49±13.50%, 70.92±9.53%, and 47.69±8.99% of the control group, respectively, but no statistical difference was shown.

[0636] 3.6 Changes in vascular endothelial growth factor (VEGF) protein levels

[0637] The main reason why diabetic wounds are difficult to heal is the insufficient microcirculatory perfusion caused by high blood sugar and persistent inflammatory response. Therefore, the most critical step in the healing process is the reconstruction of new blood vessels. The effective establishment of microcirculation makes the repair process more efficient, accelerates the exchange of nutrients between capillaries, and the migration of activated white blood cells. VEGF belongs to a subfamily of growth factors, namely the platelet-derived growth factor family. It is an important signaling protein involved in angiogenesis and vascularization. It can provide a matrix for the migration and angiogenesis of vascular endothelial cells, promote the proliferation of new capillaries in ulcer wounds, and stimulate the growth of granulation tissue, thereby promoting wound healing.

[0638] like Fig.14As shown, the VEGF protein level in the model group decreased compared with the blank group, and increased to varying degrees after administration. The VEGF protein level in the model group was 44.93±3.69pg / ml, the VEGF protein level in the Dejie hydrocolloid group was 114.30±13.11pg / ml, and the VEGF protein levels in the 0.5%, 1%, and 2% sunflower total flavonoids cream groups were 77.74±5.90pg / ml, 98.14±11.53pg / ml, and 99.29±17.35pg / ml, respectively. The data showed that among all the drug-treated groups, the Dejie hydrocolloid group had the most significant increase in VEGF protein level (P<0.01). The effects of the 1% and 2% sunflower flavonoids cream groups were weaker than those of Dejie hydrocolloid, but they were also able to significantly increase the VEGF protein level in skin tissue (P<0.01). The VEGF protein expression level in the 0.5% sunflower flavonoids cream group was increased compared with the model group, but there was no statistical difference.

[0639] 4. Experimental Conclusion

[0640] In this experiment, STZ-induced diabetes model was used, and a full-thickness skin excision model of rats was constructed using a sterile 8-mm Biopsy Punch. Dejie hydrocolloid was used as the positive control drug, and blank cream was used as the blank control drug of the model group to investigate the therapeutic effect of total flavonoids from Astragalus membranaceus on rats with diabetic ulcers.

[0641] The results showed that total flavonoids from Astragalus membranaceus can accelerate wound re-epithelialization, promote collagen fiber deposition, increase the expression of VEGF protein levels, and promote the healing of full-thickness skin wounds in diabetic rats. In addition, total flavonoids from Astragalus membranaceus can also promote the formation of new blood vessels by increasing the expression of CD31, thereby accelerating the healing process of diabetic ulcer wounds. In summary, total flavonoids from Astragalus membranaceus have a certain effect in treating diabetic ulcers.

[0642] The experimental samples of Example 2-A2, Example 4-2, Example 9-2, Example 19-1, and Example 19-2 also have the same functions or effects as the total flavonoids 1 of Astragalus membranaceus in the present example.

[0643] Example 24 Enteric-coated preparation of Hibiscus tiliaceus flower extract

[0644] Example 24-1 Preparation of an enteric-coated preparation of Hibiscus tiliaceus flower extract

[0645] 1. Preparation of Hibiscus tiliaceus Flower Extract

[0646] Take 1 kg of hibiscus flower, add 18 times the amount of ethanol, heat and reflux for 1 hour, filter, reduce the pressure of the filtrate to recover the ethanol, concentrate, adjust the pH to 6.0, let it stand, remove the upper oil layer, vacuum dry, and crush to obtain hibiscus flower extract. The total content of 7 components of total flavonoids in hibiscus flower is measured to be 9%.

[0647] 2. The prescription composition is shown in the following table

[0648] Table 24-1

[0649] Element Single dose (mg) Hibiscus tiliaceus Flower Extract 280 lactose 376.6 Low substituted hydroxypropyl cellulose 35 Polyethylene glycol 4.2 Magnesium Lauryl Sulfate 4.2 total 700

[0650] 3. Preparation of enteric-coated tablets or capsules

[0651] 1) Sieving: Crush the Hibiscus hibiscus flower extract through an 80-mesh sieve, and crush lactose, low-substituted hydroxypropyl cellulose, polyethylene glycol, and lauryl magnesium sulfate through a 60-mesh sieve for later use; prepare 85% ethanol solution for later use;

[0652] 2) Dry mixing, granulation, and whole granulation: taking the prescribed amount of hibiscus flower extract, and the prescribed amount of lactose, low-substituted hydroxypropyl cellulose, and polyethylene glycol, and putting them into a wet mixing granulator for dry mixing for 5-10 minutes, and then adding an appropriate amount of 85% ethanol solution to make wet granules; the wet granules are passed through a 20-mesh sieve for wet finishing, and then dried in an electric constant temperature blast drying oven to make the moisture content of the intermediate granules less than or equal to 3%; the dry granules are passed through a 20-mesh sieve for whole granulation;

[0653] 3) Total mixing and tableting: adding the prescribed amount of magnesium lauryl sulfate, mixing in a total mixer for 10-15 minutes; determining the particle content, calculating the tablet weight, tableting, and obtaining plain tablets;

[0654] 4) Prepare enteric coating solution: Take 200 mg of the prescribed enteric film coating presuspension enteric Opadry and slowly add it into 800 mL of purified water under stirring. Stir for 15-30 minutes and then pass through an 80-mesh sieve for later use;

[0655] 5) Coating: plain tablets are coated with enteric coating to increase weight by 4% to obtain enteric-coated tablets; or 2) the hibiscus flower granules are sized and polished, and loaded into enteric-coated capsule shells to obtain enteric-coated capsules.

[0656] Example 24-2 Preparation of an enteric-coated preparation of Hibiscus tiliaceus flower extract

[0657] 1. Preparation of Hibiscus tiliaceus Flower Extract

[0658] 1 kg of hibiscus flower was crushed into coarse powder, and 15 times of 60% ethanol was used for percolation extraction to obtain hibiscus flower extract; ethanol was removed from the hibiscus flower extract, diluted with water, adsorbed on activated carbon, and continuously countercurrently extracted with n-butanol, the material-liquid ratio of the extraction (i.e., extractant: extracting solution) was 1.5:1, the injection speed of the extraction was 40 mL / min, the speed of the extraction machine was 40 Hz, the extraction level of the extraction was 2, the extract was decompressed at 40° C. and the solvent was recovered, and then treated with D101 macroporous resin, the treatment process of the macroporous resin was as follows: the macroporous resin diameter-to-height ratio was 1:6, the concentration of the loading solution (aqueous solution) was 0.15 g crude drug / mL, the loading solution volume was 7 BV, the sample was loaded at a flow rate of 2 BV / h, 6 BV of pure water and 3 BV of 5% ethanol was used for impurity removal at a flow rate of 2BV / h, and 4BV60% ethanol was used for elution at a flow rate of 2BV / h to obtain an eluate, and then the eluate was decompressed at 50°C to recover ethanol to obtain a hibiscus flower flavonoid extract. The content was tested by adjusting the contents of 7 components through the addition method according to the content determination results to obtain a hibiscus flower extract, in which the proportion of the 7 components in the total solids was 83%.

[0659] 2. The prescription composition is shown in the following table

[0660] Table 24-2

[0661] Element Single dose (mg) Hibiscus tiliaceus Flower Extract 52.5 lactose 70.5 Low substituted hydroxypropyl cellulose 6.6 Polyethylene glycol 0.7 Magnesium Lauryl Sulfate 0.7 total 131

[0662] 3. Preparation method of enteric-coated tablets and enteric-coated capsules

[0663] 1) Sieving: Crush the Hibiscus hibiscus flower extract through an 80-mesh sieve, and crush lactose, low-substituted hydroxypropyl cellulose, polyethylene glycol, and lauryl magnesium sulfate through a 60-mesh sieve for later use; prepare 85% ethanol solution for later use;

[0664] 2) Dry mixing, granulation, and whole granulation: taking the prescribed amount of hibiscus flower extract, and the prescribed amount of lactose, low-substituted hydroxypropyl cellulose, and polyethylene glycol, and putting them into a wet mixing granulator for dry mixing for 5-10 minutes, and then adding an appropriate amount of 85% ethanol solution to make wet granules; the wet granules are passed through a 20-mesh sieve for wet finishing, and then dried in an electric constant temperature blast drying oven to make the moisture content of the intermediate granules less than or equal to 3%; the dry granules are passed through a 20-mesh sieve for whole granulation;

[0665] 3) Total mixing and tableting: adding the prescribed amount of magnesium lauryl sulfate, mixing in a total mixer for 10-15 minutes; determining the particle content, calculating the tablet weight, tableting, and obtaining plain tablets;

[0666] 4) Prepare enteric coating solution: Take 200 mg of the prescribed enteric film coating presuspension enteric Opadry and slowly add it into 800 mL of purified water under stirring. Stir for 15-30 minutes and then pass through an 80-mesh sieve for later use;

[0667] 5) Coating: plain tablets are coated with enteric coating to increase weight by 4% to obtain enteric-coated tablets; or 2) the hibiscus flower granules are sized and polished, and loaded into enteric-coated capsule shells to obtain enteric-coated capsules.

[0668] Example 24-3 Preparation of an enteric-coated preparation of Hibiscus tiliaceus flower extract

[0669] 1. Hibiscus tiliaceus flower extract

[0670] Add 80% ethanol to 1 kg of hibiscus flower, extract once, extract for 2 hours, combine the extracts, filter, concentrate the filtrate into a concentrate with a relative density of 1.13-1.16 at 60°C, add appropriate amount of water to settle for 24 hours, filter, concentrate to the corresponding volume, pass through a macroporous adsorption resin column, use alcohol-water gradient elution, water elution for 3 column volumes, 10% and 30% ethanol elution for 3 column volumes each, 70% ethanol elution for 1 column volume. After the eluate is concentrated, dried and crushed, the hibiscus flower total flavonoid extract is obtained, and the total flavonoid content is 65%.

[0671] 2. The prescription composition is shown in the following table

[0672] Table 24-3

[0673] Element Single dose (mg) Hibiscus tiliaceus Flower Extract 280 lactose 376.6 Low substituted hydroxypropyl cellulose 35 Polyethylene glycol 4.2 Magnesium Lauryl Sulfate 4.2 total 700

[0674] 3. Preparation method of enteric-coated tablets and enteric-coated capsules

[0675] 1) Sieving: Crush the Hibiscus hibiscus flower extract through an 80-mesh sieve, and crush lactose, low-substituted hydroxypropyl cellulose, polyethylene glycol, and lauryl magnesium sulfate through a 60-mesh sieve for later use; prepare 85% ethanol solution for later use;

[0676] 2) Dry mixing, granulation, and whole granulation: taking the prescribed amount of hibiscus flower extract, and the prescribed amount of lactose, low-substituted hydroxypropyl cellulose, and polyethylene glycol, and putting them into a wet mixing granulator for dry mixing for 5-10 minutes, and then adding an appropriate amount of 85% ethanol solution to make wet granules; the wet granules are passed through a 20-mesh sieve for wet finishing, and then dried in an electric constant temperature blast drying oven to make the moisture content of the intermediate granules less than or equal to 3%; the dry granules are passed through a 20-mesh sieve for whole granulation;

[0677] 3) Total mixing and tableting: adding the prescribed amount of magnesium lauryl sulfate, mixing in a total mixer for 10-15 minutes; determining the particle content, calculating the tablet weight, tableting, and obtaining plain tablets;

[0678] 4) Prepare enteric coating solution: Take 200 mg of the prescribed enteric film coating presuspension enteric Opadry and slowly add it into 800 mL of purified water under stirring. Stir for 15-30 minutes and then pass through an 80-mesh sieve for later use;

[0679] 5) Coating: plain tablets are coated with enteric coating to increase weight by 4% to obtain enteric-coated tablets; or 2) the hibiscus flower granules are sized and polished, and loaded into enteric-coated capsule shells to obtain enteric-coated capsules.

[0680] Example 24-4 Preparation of an enteric-coated preparation of Hibiscus tiliaceus flower extract

[0681] 1. Preparation of Hibiscus tiliaceus Flower Extract

[0682] The Hibiscus sibiricum flower extract was prepared as in Example 24-1.

[0683] 2. The prescription composition is shown in the following table

[0684] Table 24-4

[0685]

[0686]

[0687] 3. Preparation method of enteric-coated tablets and enteric-coated capsules

[0688] 1) Sieving: Crush the Hibiscus hibiscus flower extract through an 80-mesh sieve, and crush lactose, low-substituted hydroxypropyl cellulose, polyethylene glycol, and lauryl magnesium sulfate through a 60-mesh sieve for later use; prepare 85% ethanol solution for later use;

[0689] 2) Dry mixing, granulation, and whole granulation: taking the prescribed amount of hibiscus flower extract, and the prescribed amount of lactose, low-substituted hydroxypropyl cellulose, and polyethylene glycol, and putting them into a wet mixing granulator for dry mixing for 5-10 minutes, and then adding an appropriate amount of 85% ethanol solution to make wet granules; the wet granules are passed through a 20-mesh sieve for wet finishing, and then dried in an electric constant temperature blast drying oven to make the moisture content of the intermediate granules less than or equal to 3%; the dry granules are passed through a 20-mesh sieve for whole granulation;

[0690] 3) Total mixing and tableting: adding the prescribed amount of magnesium lauryl sulfate, mixing in a total mixer for 10-15 minutes; determining the particle content, calculating the tablet weight, tableting, and obtaining plain tablets;

[0691] 4) Prepare enteric coating solution: Take 180 mg of the prescribed enteric film coating presuspension enteric Opadry and slowly add it into 800 mL of purified water under stirring. Stir for 15-30 minutes and then pass through an 80-mesh sieve for later use;

[0692] 5) Coating: plain tablets are coated with enteric coating to increase weight by 5% to obtain enteric-coated tablets; or 2) the hibiscus flower granules are sized and polished, and loaded into enteric-coated capsule shells to obtain enteric-coated capsules.

[0693] Example 24-5 Preparation of an enteric-coated preparation of Hibiscus tiliaceus flower extract

[0694] 1. Preparation of Hibiscus tiliaceus Flower Extract

[0695] The Hibiscus sibiricum flower extract was prepared as in Example 24-1.

[0696] 2. The prescription composition is shown in the following table

[0697] Table 24-5

[0698] Element Single dose (mg) Hibiscus tiliaceus Flower Extract 280 lactose 420 Low substituted hydroxypropyl cellulose 39.2 Polyethylene glycol 5.9 Magnesium Lauryl Sulfate 5.9 total 751

[0699] 3. Preparation method of enteric-coated tablets and enteric-coated capsules

[0700] 1) Sieving: Crush the Hibiscus hibiscus flower extract through an 80-mesh sieve, and crush lactose, low-substituted hydroxypropyl cellulose, polyethylene glycol, and lauryl magnesium sulfate through a 60-mesh sieve for later use; prepare 85% ethanol solution for later use;

[0701] 2) Dry mixing, granulation, and whole granulation: taking the prescribed amount of hibiscus flower extract, and the prescribed amount of lactose, low-substituted hydroxypropyl cellulose, and polyethylene glycol, and putting them into a wet mixing granulator for dry mixing for 5-10 minutes, and then adding an appropriate amount of 85% ethanol solution to make wet granules; the wet granules are passed through a 20-mesh sieve for wet finishing, and then dried in an electric constant temperature blast drying oven to make the moisture content of the intermediate granules less than or equal to 3%; the dry granules are passed through a 20-mesh sieve for whole granulation;

[0702] 3) Total mixing and tableting: adding the prescribed amount of magnesium lauryl sulfate, mixing in a total mixer for 10-15 minutes; determining the particle content, calculating the tablet weight, tableting, and obtaining plain tablets;

[0703] 4) Prepare enteric coating solution: slowly add 210 mg of the prescribed enteric film coating presuspension enteric Opadry into 800 mL of purified water under stirring, stir for 15-30 minutes, then pass through an 80-mesh sieve and set aside;

[0704] 5) Coating: plain tablets are coated with enteric coating to increase weight by 3% to obtain enteric-coated tablets; or 2) the hibiscus flower granules are sized and polished, and loaded into enteric-coated capsule shells to obtain enteric-coated capsules.

[0705] Comparative Example 24-1 Preparation of an enteric-coated preparation of Hibiscus tiliaceus flower extract

[0706] 1. Preparation of Hibiscus tiliaceus Flower Extract

[0707] The Hibiscus sibiricum flower extract was prepared as in Example 24-1.

[0708] 2. The prescription composition is shown in the following table

[0709] Table 24-6

[0710] Element Single dose (mg) Hibiscus tiliaceus Flower Extract 280 Microcrystalline Cellulose 504 Cross-linked polyvinyl pyrrolidone 14 Sodium Carboxymethyl Cellulose 1 Magnesium Stearate 1 total 800

[0711] 3. Preparation method of enteric-coated tablets and enteric-coated capsules

[0712] 1) Sieving: the hibiscus flower extract is crushed and passed through an 80-mesh sieve, and the microcrystalline cellulose, cross-linked polyvinyl pyrrolidone, sodium carboxymethyl cellulose, and magnesium stearate are crushed and passed through a 60-mesh sieve for later use; 85% ethanol solution is prepared and set aside;

[0713] 2) Dry mixing, granulation, and whole granulation: taking the prescribed amount of hibiscus flower extract, and the prescribed amount of microcrystalline cellulose, cross-linked polyvinyl pyrrolidone, and sodium carboxymethyl cellulose, and putting them into a wet mixing granulator for dry mixing for 5-10 minutes, and then adding an appropriate amount of 85% ethanol solution to make wet granules; the wet granules are passed through a 20-mesh sieve for wet finishing, and then dried in an electric constant temperature blast drying oven to make the moisture content of the intermediate granules less than or equal to 3%; the dry granules are passed through a 20-mesh sieve for whole granulation;

[0714] 3) Total mixing and tableting: adding the prescribed amount of magnesium stearate, mixing in a total mixer for 10-15 minutes; determining the particle content, calculating the tablet weight, tableting, and obtaining plain tablets;

[0715] 4) Prepare enteric coating solution: take 320 mg of enteric film coating presuspension enteric hydroxypropyl methylcellulose in the prescribed amount and slowly add it into 800 mL of purified water under stirring, stir for 15-30 minutes, then pass through an 80-mesh sieve and set aside;

[0716] 5) Coating: plain tablets are coated with enteric coating to increase weight by 4% to obtain enteric-coated tablets; or 2) the hibiscus flower granules are sized and polished, and loaded into enteric-coated capsule shells to obtain enteric-coated capsules.

[0717] Comparative Example 24-2 Preparation of an enteric-coated preparation of Hibiscus tiliaceus flower extract

[0718] 1. Preparation of Hibiscus tiliaceus Flower Extract

[0719] Prepared as described in Example 24-1.

[0720] 2. The prescription composition is shown in the following table

[0721] Table 24-7

[0722]

[0723]

[0724] 3. Preparation method of enteric-coated tablets and enteric-coated capsules

[0725] 1) Sieving: the hibiscus flower extract is crushed and passed through an 80-mesh sieve, and the microcrystalline cellulose, cross-linked polyvinyl pyrrolidone, sodium carboxymethyl cellulose, and magnesium stearate are crushed and passed through a 60-mesh sieve for later use; 85% ethanol solution is prepared and set aside;

[0726] 2) Dry mixing, granulation, and whole granulation: taking the prescribed amount of hibiscus flower extract, and the prescribed amount of microcrystalline cellulose, cross-linked polyvinyl pyrrolidone, and sodium carboxymethyl cellulose, and putting them into a wet mixing granulator for dry mixing for 5-10 minutes, and then adding an appropriate amount of 85% ethanol solution to make wet granules; the wet granules are passed through a 20-mesh sieve for wet finishing, and then dried in an electric constant temperature blast drying oven to make the moisture content of the intermediate granules less than or equal to 3%; the dry granules are passed through a 20-mesh sieve for whole granulation;

[0727] 3) Total mixing and tableting: adding the prescribed amount of magnesium stearate, mixing in a total mixer for 10-15 minutes; determining the particle content, calculating the tablet weight, tableting, and obtaining plain tablets;

[0728] 4) Prepare enteric coating solution: take 240 mg of enteric film coating presuspension enteric hydroxypropyl methylcellulose in the prescribed amount and slowly add it into 800 mL of purified water under stirring, stir for 15-30 minutes, then pass through an 80-mesh sieve and set aside;

[0729] 5) Coating: plain tablets are coated with enteric coating to increase weight by 5% to obtain enteric-coated tablets; or 2) the hibiscus flower granules are sized and polished, and loaded into enteric-coated capsule shells to obtain enteric-coated capsules.

[0730] Example 24-6 Product dissolution curve test (pH1.2-pH7.8)

[0731] The enteric-coated tablets prepared in Examples 24-1 to 24-5 and Comparative Examples 24-1 to 24-2 were dissolved in artificial gastric juice (pH 1.2 hydrochloric acid solution) for 2 hours; artificial intestinal juice (pH 6.8 phosphate buffer) for 1 hour; and artificial colonic juice (pH 7.8 phosphate buffer) for 3 hours, and the solubility was investigated under the following conditions.

[0732] Specific test method: first, add 900mL of hydrochloric acid solution (pH1.2) into the dissolution cup to examine the release amount of the enteric-coated preparation within 2 hours; then discard the acid solution, immediately add phosphate buffer (pH6.8) at a temperature of 37℃±0.5℃, and measure the release amount of the enteric-coated preparation in the buffer solution; then discard the buffer solution, immediately add phosphate buffer (pH7.8) at a temperature of 37℃±0.5℃, and measure the release amount of the enteric-coated preparation in the buffer solution.

[0733] The release rate test is to detect the total amount of 7 components of total flavonoids of Asparagus corylifolia in each tablet, including hyperoside, rutin, isoquercetin, gossypol-8-O-β-D-glucuronide, myricetin, quercetin-3′-O-glucoside, and quercetin.

[0734] Table 24-8

[0735]

[0736] In the above experiment, the acidic medium of pH 1.2 simulates the gastric acid environment, the medium of pH 6.8 simulates the intestinal environment, and the medium of pH 7.8 simulates the colon environment.

[0737] It can be seen from the data in Table 24-8 that in an acidic medium with a pH of 1.2, the solubility of Examples 24-1 to 24.5 is less than 1% at 120 min, and the solubility of Comparative Examples 1 and 2 reaches 4% at 120 min, respectively.

[0738] In a medium of pH 6.8, the dissolution rate of the example does not exceed 10%, while the dissolution rate of the comparative example reaches more than 20%.

[0739] In the medium of pH 7.8, Examples 24-1 to 24.5 dissolve quickly without time lag effect, and the dissolution rate reaches more than 90% at 210 min (4th hour), which is excellent in performance. And the dissolution rate of Examples 24-1 to 24.3 reaches more than 95% at 210 min.

[0740] Example 24-7 Stability Test

[0741] The enteric-coated tablets prepared in Examples 24-1 to 24-3 of the present invention were subjected to stability tests under conditions of high temperature (40°C), high humidity (RH75%±5%), and illumination test (4500lx±500lx). The tablets were placed under the above test conditions for 10 days, and samples were taken at 0, 5, and 10 days to determine their release, and the determination method was ultraviolet spectrophotometry. Release 1 refers to the release in simulated artificial intestinal fluid (pH6.8 phosphate buffer solution); release 2 refers to the release in simulated artificial colon fluid (pH7.2-7.8 phosphate buffer solution).

[0742] The release test is to detect the total flavonoids of Huang Kui in each tablet, including hyperoside, rutin, isoquercetin, and cottonseed 8-O-

[0743] The total amount of 7 ingredients including β-D-glucuronide, myricetin, quercetin-3′-O-glucoside and quercetin was calculated.

[0744] Table 24-9

[0745]

[0746] The result data show that the content of the embodiment is relatively stable after being placed in high temperature (40°C), high humidity (RH75%±5%), and light experiment (4500lx±500lx) for 10 days. In addition, it is almost not released in the simulated artificial intestinal fluid environment, and the release rate is relatively stable in the artificial colon fluid environment.

[0747] Example 24-8 Animal Experiment on Ulcerative Colitis

[0748] The ulcerative colitis model rats were selected to carry out the pharmacodynamic evaluation of the drug of the present invention.

[0749] 1.1 Experimental animals

[0750] Healthy male SD rats, SPF grade, weighing 180-200 g.

[0751] 1.2 Reagents and drugs

[0752] Table 24-10

[0753]

[0754] 2. Experimental Methods

[0755] 2.1 Animal husbandry and management

[0756] The experimental rats were kept in an SPF-grade animal room throughout the experiment. The light-to-dark time ratio was 1:1, the room temperature was controlled at 23±2℃, the humidity was controlled at 55%, and the rats were able to eat and drink freely. The bedding was changed every three days to ensure that the rats were in a dry and clean environment.

[0757] 2.2 Preparation of DSS-induced ulcerative colitis (UC) model in rats

[0758] Preparation of 3% DSS solution: Weigh 3 g of DSS powder and fully dissolve it in 100 mL of pure water to obtain a 3% DSS solution.

[0759] After 5 days of adaptive feeding, the rats were randomly divided into 5 groups, each with two cages and 4 rats in each cage. They were blank control group (Control), model group (DSS), model + 5-aminosalicylic acid group (DSS + 140mg / kg / day 5-ASA), model + HK1 group (DSS + 280mg / kg / day HK1), and model + HK2 group (DSS + 52.5mg / kg / day HK2). The dosage was calculated based on the active ingredient.

[0760] As shown in the following method, the rat ulcerative colitis model was induced by free drinking of 3% DSS for 7 consecutive days. The 3% DSS solution (80 mL) was replaced every 2 days for each cage of 4 rats to ensure the effectiveness of the DSS solution; the rats in the blank control group were free to drink pure water, which was replaced every 2 days for each cage of 4 rats.

[0761] HK1, HK2 and the positive therapeutic drug 5-ASA were administered orally in a customized rat enteric-coated capsule at the corresponding doses from 9:00 to 10:00 am every day, and the blank group and the model group were given the same dose of blank vehicle solution (containing 2% DMSO, 2% Tween 80 and 0.5% CMC-Na) for 7 consecutive days. Before administration every day, the disease activity index (DAI) was scored; on the 8th day, the rats were euthanized and blood and colon tissue were collected.

[0762] 2.3 Stool consistency / fecal occult blood test and DAI score

[0763] The weight of the rats was recorded before daily administration, and feces were collected for fecal occult blood test. The severity of the disease was scored by DAI based on three indicators: weight loss, fecal viscosity, and fecal occult blood. Each indicator corresponds to 0-4 points. The scoring criteria are shown in Table 24-5. Fecal occult blood test: Take a small amount of feces and smear it on the middle of the glass slide (the glass slide was pre-burned to reduce color error), add 3 drops of 10 / L aminophenol sulfate acetic acid solution and 3 drops of 3% hydrogen peroxide solution, mix well, observe the results immediately, and score according to Table 24-11.

[0764] Table 24-11 DAI scoring details

[0765]

[0766] Table 24-12 Fecal occult blood test scoring table

[0767]

[0768] 2.4 Specimen Collection

[0769] After the last administration, rats in each group were fasted for 24 hours and killed by cervical dislocation. The rat's abdominal cavity was cut open to expose the rat's colon. All the colon tissues of the rat were measured and their lengths were recorded. They were placed in freshly prepared pre-cooled saline for intestinal content flushing. The 1 cm proximal rectal colon was cut and fixed in 4% paraformaldehyde overnight for paraffin section preparation and subsequent pathological examination. The remaining tissue was quickly frozen in liquid nitrogen in the middle section and stored at -80 ° C for subsequent experiments. The blood sample was left at room temperature for 2-3 hours, then centrifuged at 3500 rpm for 15 minutes, and the serum was taken and quickly stored at -80 ° C for subsequent testing.

[0770] 2.5 H&E staining

[0771] The colon was fixed with 4% paraformaldehyde for 24 hours and then routinely embedded in paraffin. The embedded colon tissue was serially sectioned (10 μm) and then stained with H&E. The steps of H&E staining were as follows:

[0772] 1) Dewaxing: dewaxing in xylene I for 10 min, dewaxing in xylene II for 5 min;

[0773] 2) Ethanol soaking: soak in anhydrous ethanol twice, then soak in 95%, 90%, and 85% ethanol once, each time for 1 min, and finally wash with water for 2 min;

[0774] 3) Staining: Stain with hematoxylin for 5 min, then wash with tap water for 1 min;

[0775] 4) Differentiation: Differentiate with 1% hydrochloric acid alcohol for 20 seconds, then wash with tap water for 1 minute;

[0776] 5) Anti-blueing: Anti-blueing with 1% dilute ammonia for 30 seconds, then washing with tap water for 1 minute;

[0777] 6) Eosin staining: stain for 5 minutes, then wash with tap water for 30 seconds;

[0778] 7) Ethanol dehydration: Dehydration was performed with different contents of ethanol in the following order: 85% ethanol dehydration for 20 s, 90% ethanol dehydration for 30 s, 95% ethanol I dehydration for 1 min, 95% ethanol II dehydration for 1 min, anhydrous ethanol I dehydration for 2 min, and anhydrous ethanol II dehydration for 2 min;

[0779] 8) Transparency: xylene I treatment for 2 min, xylene II treatment for 2 min, xylene III treatment for 2 min;

[0780] 9) Finally, the slides were sealed with neutral gum and scanned with a digital pathology slide scanner (NanoZoomer 2.0 RS);

[0781] 10) Pathological examination: The degree of colon damage was scored based on pathological indicators such as the degree of colon tissue lesions, inflammatory cell infiltration, and crypt cell damage. The specific scoring criteria are shown in Table 24-13.

[0782] Table 24-13 Inflammation Score Table

[0783]

[0784]

[0785] 2.6 Statistical analysis

[0786] GraphPad Prism (Ver 6.0) was used for statistical analysis. All data were expressed as mean ± standard error (Mean ± SEM). Two-way ANOVA was used to analyze weight changes and DAI score changes, and One-way ANOVA was used to analyze other data. Dunnett's multiple test was used to analyze the significance of the differences between the groups. When P < 0.05, the differences between the groups were statistically significant.

[0787] 3. Experimental results

[0788] 3.1 Effect of enteric-coated capsules of hibiscus flower extract on DAI scores in rats

[0789] The DAI score was calculated by adding the three index values ​​in Table 24-13 and taking the average value. As shown in Table 24-14, the DAI score of rats in the DSS model group increased significantly from the 3rd day, and the difference was statistically significant compared with the Control group (P<0.01). Three rats had diarrhea on the 6th day of the experiment, and 7 rats had diarrhea on the 7th day. The DAI score of the DSS+HK1 (280mg / kg / day) and DSS+HK2 (52.5mg / kg / day) groups showed a relatively slow growth trend. On the 4th, 5th, 6th, and 7th days, the DAI scores of the rats in the DSS model group showed a statistically significant difference. The difference between the DSS model group and the DSS group was statistically significant (P<0.01). During the experiment, one rat in the DSS+HK1 (280 mg / kg / day) group had diarrhea on the 6th day, and two rats in the DSS+HK2 (52.5 mg / kg / day) group had diarrhea. No rat in the DSS+HK2 (52.5 mg / kg / day) group had diarrhea. The positive therapeutic drug 5-ASA (140 mg / kg / day) alleviated the symptoms of DSS-induced colitis and reduced the DAI score. Starting from the 4th day, there was a significant difference compared with the DSS model group (P<0.01). No rat had diarrhea during the experiment.

[0790] Table 24-14 DAI scores of rats in each group

[0791]

[0792] Note: Data are expressed as mean ± standard error. N = 8. *, P < 0.05, **, P < 0.01, vs. Control; # , P<0.05, ## , P < 0.01, vs. DSS, analyzed using two-way ANOVA and Dunnett's multiple comparison test.

[0793] 3.2 Effect of Hibiscus tiliaceus Flower Extract on Colon Length in Rats

[0794] As shown in Table 24-15, the colon length of the Control group was 17.05±0.04 cm, and the colon of rats in the DSS model group shrank to 14.32±0.15 cm, which was significantly different from the Control group (P<0.01); 280 mg / kg / day HK1 and 52.5 mg / kg / day HK2 significantly improved DSS-induced colon atrophy, and the difference between the DSS+HK2 (52.5 mg / kg / day) group and the DSS model group was statistically significant (P<0.05); the positive drug 5-ASA (140 mg / kg / day) also improved DSS-induced colon atrophy, and the difference was statistically significant compared with the Control group (P<0.05).

[0795] Table 24-15 Statistics of colon length of rats in each group

[0796]

[0797] Note: Data are expressed as mean ± standard error. N = 8. **, P < 0.01, vs. Control; #, P < 0.05, vs. DSS, analyzed using one-way ANOVA and Dunnett's multiple comparison test.

[0798] 4. Experimental conclusions and discussion

[0799] This example uses a DSS-induced rat ulcerative colitis model, and uses 5-aminosalicylic acid as a positive control drug to investigate the therapeutic effect of enteric-coated capsules containing Hibiscus tiliaceus flower extract on colitis. The results show that the HK1 (280 mg / kg / day) and HK2 (52.5 mg / kg / day) groups significantly protect DSS-induced rats from weight loss, diarrhea, bloody stools and other colitis symptoms; HK2 (52.5 mg / kg / day) has a better effect than the others. It significantly improves DSS-induced colon atrophy, crypt structure damage, and tissue inflammatory infiltration and other histopathological changes.

[0800] In summary, enteric-coated capsules containing hibiscus flower extract have a certain therapeutic effect on colitis. At 52.5 mg / kg / day, the effect is comparable to that of the positive drug 5-ASA and has good safety.

[0801] Example 25 Experimental study on pharmaceutical composition and its effect on idiopathic pulmonary fibrosis

[0802] Example 25-1 Preparation of pharmaceutical composition

[0803] Take raw materials of hyperoside, isoquercetin, hibifolin, myricetin, quercetin-3′-O-glucoside, quercetin, and quercetin 3-O-sophoracoside, weigh each active ingredient according to the proportion in the table below, mix, and prepare a pharmaceutical composition.

[0804]

[0805] Example 25-2 Preparation of pharmaceutical composition

[0806] According to the feeding ratio in the following table, each active ingredient is weighed and mixed to prepare a pharmaceutical composition.

[0807]

[0808] Take the raw materials of hyperoside, isoquercetin, hibifolin, myricetin, quercetin-3′-O-glucoside, quercetin, and quercetin 3-O-sophoracoside, weigh each active ingredient according to the proportion in the table below, mix them, and prepare a pharmaceutical composition.

[0809] Example 25-3 Diabetic nephropathy experiment

[0810] Animal models: db / db mice, 16 weeks old, C57BL / 6 mice, 16 weeks old.

[0811] Administration: intragastric administration

[0812] Experimental modeling: After 17 weeks of breeding, urine protein was detected in db / db mice. If urine protein and renal function abnormalities were found, the model was successful and used for subsequent experiments.

[0813] Experimental grouping: C57BL / 6 mice were divided into a normal group, and db / db mice were divided into a model group, a positive drug group (dapagliflozin tablets, 45.5 mg / kg), and an Example 25-1 drug composition group (62.4 mg / kg), 15 mice in each group, and urine protein and urine creatinine and daily food intake were detected after 4 weeks of administration, and the status of the mice was observed. The test results are shown in the following table.

[0814] Table 25-1

[0815] Group Urine protein / mg Urine protein / creatinine Normal group 17.21±10.07 0.29±0.16 Model Group 61.97±32.17* <![CDATA[2.68±1.03 * ]]> Positive drug group <![CDATA[15.09±10.27 # ]]> <![CDATA[1.17±1.26 # ]]> Example 25-1 Group <![CDATA[19.38±14.67 # ]]> <![CDATA[1.31±1.28 # ]]>

[0816] Note: *Compared with the normal control group, P<0.05; #Compared with the model control group, P<0.05;

[0817] The results showed that the pharmaceutical composition group of Example 25-1 can reduce urine protein and urine protein / urine creatinine (ACR). Only one animal had diarrhea / abdominal distension, with low side effects. In the study of hibiscus flower extracts with different flavonoid components studied at the same time, it was found that the hibiscus flower extracts composed of flavonoid components in different proportions from Example 25-1 showed different side effects in animals. The hibiscus flower extracts containing flavonoid components in the proportion of the present invention had lower side effects and showed lower side effects than the hibiscus capsules with a larger dose.

[0818] Example 25-4 Idiopathic Pulmonary Fibrosis Effect Experiment

[0819] Experimental animals: 60 Kunming mice, half male and half female, weighing 18-22 grams, clean grade.

[0820] Animal grouping: Randomly divided into 5 groups, namely, normal group, model group, control drug group (rosiglitazone 5 mg / kg), Example 25-1 drug composition group (70 mg / kg), Example 25-2 drug composition group (70 mg / kg), Huangkui capsule sample group (180 mg / kg as extract), Example 25-2 drug composition group (70 mg / kg), with 10 mice in each group.

[0821] Experimental modeling: After the experimental mice were adaptively fed for 3 days, they were anesthetized by intraperitoneal injection of 4% chloral hydrate (0.01 ml / g). They were placed in a supine fixed position, routinely disinfected, and a midline cervical incision was performed. The trachea was exposed by blunt separation. The model group, control drug group, and treatment group were slowly injected with bleomycin (5 mg / kg) through puncture in the gap between the tracheal cartilage rings. The normal control group was injected with an equal volume of saline. Immediately after the injection, the mice were rotated upright for 3-5 minutes to evenly distribute the drug solution in both lungs. Then the skin was sutured and the suture was disinfected. After awakening, the mice were sent to a clean observation room for feeding.

[0822] Dosage method: Dosage began on the second day of modeling. The drug-treated group was given the above dose once a day. The normal group and the model group were given the same volume of distilled water 10 ml / kg in the same way for 28 consecutive days.

[0823] Pathological section staining of lung tissue: After the administration, the right lung was taken and fixed, embedded, sectioned, and HE stained according to conventional pathological methods. The degree of alveolitis and pulmonary fibrosis was divided into four grades.

[0824] Experimental results:

[0825] Group Alveolitis degree Degree of fibrosis Normal group 0.43±0.58 0.29±0.38 Model Group <![CDATA[1.69±0.66 * ]]> <![CDATA[1.87±0.69 * ]]> Control group <![CDATA[1.03±0.49 # ]]> <![CDATA[1.15±0.81 # ]]> Example 25-1 Sample Group <![CDATA[1.23±0.55 # ]]> <![CDATA[1.20±0.67 # ]]> Huangkui Capsule Group <![CDATA[1.48±0.62 # ]]> <![CDATA[1.69±0.63 # ]]> Example 25-2 Sample Group <![CDATA[1.33±0.74 # ]]> <![CDATA[1.48±0.54 # ]]>

[0826] Note: *Compared with the normal group, P<0.01; #Compared with the model group, P<0.05

[0827] The experimental results showed that the degree of alveolitis and pulmonary fibrosis in the lung tissue of the model group mice was significantly aggravated, showing typical pulmonary fibrosis parenchymal lesions. After 28 days of administration, the lung coefficient of mice in each dose group was significantly reduced, and the degree of alveolitis and pulmonary fibrosis in the lung tissue was significantly alleviated. The effective fraction of total flavonoids can significantly reduce the degree of alveolitis and pulmonary fibrosis in mice with pulmonary fibrosis, has a protective effect on the lungs of mice with pulmonary fibrosis, and can slow down the damage caused by fibrosis to the lung tissue of the other party.

[0828] Example 26 Preparation of formulation

[0829] The hibiscus flower extract of Example 2-A4 was crushed and taken out 400 g, and the following weight portions of hydroxypropyl cellulose 20 g, talcum powder 15 g, microcrystalline cellulose 20 g, and calcium sulfate 20 g were added and mixed, and passed through an 80-mesh sieve, and an appropriate amount of anhydrous ethanol was added to make a soft material, and then granulated with a 20-mesh sieve, dried, sized, and filled into capsules.

[0830] Example 27 Effect of Hibiscus tiliaceus Flower Extract on Liver Injury and Liver Fibrosis in Bile Duct Ligated (BDL) Mice

[0831] This example is used to illustrate the use of the Hibiscus tiliaceus flower flavonoids extract (HKC) provided by the present invention in improving hepatocyte injury induced by bile duct ligation (BDL) in the preparation of a drug for improving or treating liver injury and liver fibrosis.

[0832] 1. Experimental Animals

[0833] Twenty-four SPF-grade C57BL / 6J male mice, 8 weeks old and weighing 20-22 g, were purchased from Jinan Pengyue Experimental Animal Breeding Co., Ltd. The mice were placed in a quiet environment away from strong light for one week to adapt to the environment. The ratio of light to dark time was 1:1, the room temperature was controlled at 22-25°C, the humidity was 55%, and the mice were able to eat and drink freely.

[0834] 2. Experimental drugs and consumables

[0835]

[0836]

[0837] 3. Experimental equipment and devices

[0838]

[0839] Sterile cotton balls, towels, cotton swabs, and 1mL syringes.

[0840] 4. Experimental Methods

[0841] 4.1 Preparation of experimental solutions and reagents

[0842] (1) Composition of protein lysis buffer

[0843]

[0844] The above reagents were dissolved in pure water, and after being completely dissolved, they were divided into two bottles in equal amounts. One bottle needed to be added with 0.5% SDS, and the lysate was stored at 4°C. When used, the two lysate mother solutions were mixed at a ratio of 1:1, and before use, 1 μg / mL of Pepstatin, Aprotinin, Leupetin (1000× mother solution); 1 mg / mL of protease inhibitor type I, protease inhibitor type II, phosphatase inhibitor, and phenylmethylsulfonyl fluoride (PMSF) (100× mother solution) were added.

[0845] (2) Preparation of running buffer

[0846] Weigh 30.3 g Tris-base, 10 g SDS (sodium dodecyl sulfate) and 144 g glycine, add pure water and stir, dilute to 1 L after dissolving to make 10× working solution, store at room temperature, and dilute with pure water before use.

[0847] (3) Preparation of transfer buffer

[0848] Weigh 30.3 g Tris-base and 144 g glycine, add pure water and stir, dilute to 1 L after dissolving to make 10× working solution, store at room temperature, and dilute with pure water before use.

[0849] (4) Preparation of SDS (10%)

[0850] Weigh 5 g of SDS and dissolve it in 50 mL of pure water. Heat it in a 55°C oven to dissolve. After it is completely dissolved, store it at room temperature.

[0851] (5) Preparation of ammonium persulphate (AP)

[0852] Weigh 0.05 g AP and dissolve it in 0.5 mL pure water. Store at 4 °C and prepare before use.

[0853] (6) Preparation of Tris-HCl (pH = 8.8)

[0854] Weigh 27.23 g of Tris-base and dissolve it in pure water, adjust the pH to 8.8, make up to 150 mL with pure water, and store at room temperature.

[0855] (7) Preparation of Tris-HCl (pH = 6.8)

[0856] Weigh 6 g of Tris-base and dissolve it in pure water, adjust the pH to 6.8, make up to 100 mL with pure water, and store at room temperature.

[0857] (8) Preparation of acrylamide (30%)

[0858] Weigh 2.4 g of methylenebisacrylamide and 87.6 g of acrylamide and dissolve them in 300 mL of pure water. Stir and dissolve at room temperature in the dark, then filter and store in the dark at 4°C.

[0859] (9) Preparation of separation gel and concentration gel

[0860]

[0861] When preparing, first mix pure water, acrylamide (30%), Tris-HCl and SDS (10%), filter and degas, then add AP and TEMED. After adding, immediately pour them between the glass plates, press the glue with 75% ethanol, and solidify after about 30 minutes. After pouring out the 75% ethanol, pour in the concentrated glue, insert a 15-hole comb with a thickness of 1.5 mm, and solidify after about 30 minutes.

[0862] (10) Preparation of TBS and TBST

[0863] Weigh 24.22g Tris HCl and 87.75g NaCl and add them to pure water and stir. After dissolving, adjust the pH to 7.5, dilute to 1L with pure water to make a 10× working solution, and store at room temperature. Dilute with pure water to 1× TBS buffer solution before use, and add 0.1% Tween 20 to make 1× TBST buffer solution.

[0864] (11) Preparation of blocking solution (containing skimmed milk powder)

[0865] Weigh 0.5 g skim milk powder and dissolve it in 10 mL 1× TBS buffer solution and store at 4°C.

[0866] 4.2 Experimental animal grouping, BDL modeling, drug administration, and sampling

[0867] (1) Grouping

[0868] After one week of adaptive feeding, 8-week-old C57BL / 6J male mice were randomly divided into 4 groups. The feeding and treatment of experimental animals strictly followed the animal ethics standards and were approved by the Ethics Committee of China Pharmaceutical University (#SYXK 2016-0011). The flavonoid extract of Hibiscus hibiscus flower was the marketed drug Hibiscus hibiscus capsule (HKC), with a dose of 1.2g / kg / d. The specific experimental groups were: sham operation group (Sham + solvent), blank administration group (Sham + 1.2g / kg / d HKC), BDL group (BDL modeling + solvent), and HKC administration group (BDL + 1.2g / kg / d HKC).

[0869] (2) BDL modeling

[0870] Fasting was done the night before surgery. All non-sterile consumables were sterilized at 121℃ for 20min and then dried. Before the experiment, a small electric blanket was turned on to keep the temperature above 37℃. One dissecting dish was poured with saline and two dissecting dishes were poured with iodine. The sutures were soaked in the dissecting dish filled with iodine. The ligatures were cut into several sections of about 5cm and soaked in another dissecting dish with iodine. The medical tape was also cut into several sections of about 5cm for standby use. The mice were anesthetized by intraperitoneal injection of 0.2mL / 10g tribromoethanol solution. The hair on the chest and abdomen of the mice was shaved with a razor blade. The limbs were fixed on the cardboard with tape and placed on the electric blanket. Coated the chest and abdomen with iodine with a cotton swab, and the outer skin and endothelium were cut in turn, from the abdomen to the vicinity of the xiphoid process. The smaller the opening, the better. Two cotton swabs soaked with saline were used to gently push the liver and gastrointestinal tract upward and downward. A transparent thin tube parallel to the portal vein was seen, which was the common bile duct. Carefully separate the parallel blood vessels, pass two ligatures under the common bile duct and tie two knots, and cut the common bile duct from the middle of the two knots. Restore the liver and gastrointestinal tract to their original positions, suture the inner and outer skins in turn, apply iodine to the sutures, and place the mice with their abdomens facing up in a mouse cage covered with clean bedding, near a heater and wait for the mice to wake up, which should usually wake up within 30 minutes. The modeling time is one week, when liver fibrosis is severe enough, and iodine is applied to the wounds of the mice once a day for three days before modeling.

[0871] (3) Administration

[0872] Drug administration began on the second day after surgery. Each group was given the corresponding drug solution or solvent control, 0.2 mL per oral administration, twice a day.

[0873] (4)Acquisition of materials

[0874] After the modeling, the eyeballs were removed to collect blood, placed at room temperature for 30 minutes, centrifuged at 3000 rpm for 15 minutes, and then stored in a -20°C refrigerator. Cardiac perfusion was performed to flush out the blood in the liver as much as possible (the liver turned white), the liver was removed, the larger left lateral lobe or middle lobe was selected, and the edge of the liver lobe was cut off. The middle part was fixed in 4% paraformaldehyde solution, and another mung bean-sized tissue block was placed in a grinding tube and quickly frozen with liquid nitrogen overnight, and then transferred to a -80°C refrigerator for storage.

[0875] 4.3 Serum ALT and AST levels

[0876] The test kit used the Reitman method and the microplate method. The experiment was carried out according to the instructions of the kit. After the reaction was completed, the absorbance value at 510 urn was detected with an enzyme reader, and the enzyme activity level was obtained by conversion according to the standard curve given in the instructions.

[0877] 4.4 Masson staining of liver tissue pathology sections

[0878] The tissue block was placed in a pre-prepared 4% paraformaldehyde fixative and placed at room temperature for 2 days. After trimming, the tissue block was placed in alcohols from low to high concentrations for dehydration, and then placed in a transparent agent xylene for transparency. The transparent tissue block was embedded in paraffin. The embedded wax block was fixed on a slicer and cut into 5-8μm slices, ironed in heated water, and then attached to a slide and dried in a 45°C constant temperature box. Masson staining: The paraffin sections were first dewaxed to water, washed with tap water and distilled water in turn, stained with Regaud's hematoxylin stain for 5-10 minutes, washed thoroughly with water, and then used Masson Ponceau acid red solution for 5-10 minutes, rinsed with 2% glacial acetic acid aqueous solution for a while and differentiated with 1% phosphomolybdic acid aqueous solution for 3-5 minutes, and directly stained with aniline blue or light green solution for 5 minutes, rinsed with 0.2% glacial acetic acid aqueous solution for a while, and finally dehydrated, transparent, and sealed.

[0879] 4.5 Real time-qPCR detection of expression of fibrosis markers in liver tissue

[0880] (1) Total RNA extraction from liver tissue

[0881] Place a grinding bead in the grinding tube containing liver tissue, add 300 μL of total RNA extraction reagent (Trizol method), grind twice with a grinder at 60 Hz for 60 seconds, precool the centrifuge at 4°C in advance, centrifuge at 12000 rpm for 10 minutes, and transfer 250 μL of supernatant to a 1.5 mL enzyme-free EP tube. The RNA extraction was carried out on ice throughout the process, and mRNA was extracted according to the Trizol method. Add 50 μL of chloroform, shake vigorously and mix thoroughly, let stand for 10 minutes, centrifuge at 12000 rpm for 15 minutes, and transfer 100 μL of the upper colorless aqueous phase to a new enzyme-free EP tube. Add an equal volume of isopropanol to the aqueous phase solution, mix it upside down, let stand for 10 minutes, and centrifuge at 12000 rpm for 10 minutes. At this time, the RNA precipitates at the bottom of the tube and the supernatant is discarded. Add 1 mL of 75% ethanol (prepared with anhydrous ethanol and DEPC water), flick the bottom of the tube to suspend the RNA precipitate, centrifuge at 12000 rpm for 5 min, discard the supernatant, open the lid and stand on ice for 8 min to evaporate the ethanol, and add 100 μL of DEPC water to dissolve the RNA.

[0882] (2) RNA quantification and reverse transcription

[0883] Take 1 μL and use Nano-100 to quantify RNA. The OD260 / 280 value reflects the purity of RNA in the sample. When the OD260 / 280 is in the range of 1.8 to 2.0, the RNA purity is considered to be suitable for reverse transcription. Take out 1 μg of mRNA and use the HiScript II Q RTSuperMix for qPCR (+gDNA wiper) kit to construct a 20 μL reverse transcription system. Set the reverse transcription program to 42°C, 2min-55°C, 15min-95°C, 5s. Finally, each sample obtains 20 μL of cDNA stock solution and stores it in a -80°C refrigerator.

[0884] (3) Primer sequence

[0885] Table 1-1 Upstream and downstream primers used for qPT PCR experimental reactions

[0886]

[0887] (4) Amplification

[0888] According to the instructions of ChamQ SYBR qPCR Master Mix (Low ROX Premixed), a 20 μL q-RT PCR system was constructed in a 96-well PCR plate, sealed with a sealing film, and amplified according to the program set in the instructions on the Real-Time qPCR instrument: 94-95℃3min full pre-denaturation, 94-95℃15s denaturation 60℃30s annealing extension cycle 40 times. The Ct value of each group was taken to calculate the difference between the target primer and the internal reference Ct, and then the difference between the gene and its control group was calculated to obtain ΔΔCT. The experimental results were calculated using 2 -ΔΔCT Value representation.

[0889] 4.6 Western blotting to detect the expression of a-SMA in liver tissue

[0890] (1) Extraction of whole protein from liver tissue

[0891] Take the grinding tube containing the liver tissue block and put a grinding bead in it, add 300 μL of freshly prepared RIPA (lysate: PMSF = 100: 1) lysate, grind and centrifuge, and take the supernatant. The operation is the same as in Section 2.2. According to the instructions of the BCA protein concentration determination kit, the protein content is determined. After the protein sample is diluted 20 times, 20 μL per well is added to a 96-well flat-bottom white plate, and 80 μL of BCA working solution is added to each well. After incubation at 37°C for 30 minutes, the absorbance value at 562 nm is measured using an ELISA reader. The sample protein concentration is converted by standard curves. All samples are diluted to the lowest concentration with lysate, and protein loading buffer (5×) containing β-mercaptoethanol is added at 1 / 5 of the final volume. After vortex mixing, heat in a 95°C metal bath for 15 minutes and store at -20°C.

[0892] (2) Gel preparation and electrophoresis

[0893] Prepare separation gel and concentration gel. After the concentration gel solidifies, fix the glass plate in the electrophoresis tank. Pour the newly prepared running buffer into the electrophoresis tank. Calculate the loading volume according to the electrophoresis loading amount of 40 μg. Pull out the comb and add protein samples to the loading wells. Add 1 μL of protein marker to the holes at the appropriate positions.

[0894] (3) Transfer

[0895] Use wet transfer, put the transfer clip into the pre-cooled transfer solution, with the black side close to the gel and the white side close to the nitrocellulose filter membrane (NC membrane), clamp the sponge-transfer filter paper-gel-NC membrane-transfer filter paper-sponge with the transfer clip, pay attention to discharge the bubbles in the middle, insert the transfer clip into the transfer tank containing the pre-cooled transfer solution, put the transfer tank into a foam box filled with ice and turn on the power. Transfer at a constant current of 320mA for 90min.

[0896] (4) Incubation of primary and secondary antibodies

[0897] Place the NC membrane in a black box of appropriate size, wash it three times with TBS at room temperature for 5 minutes, then add blocking solution to cover the NC membrane and shake at room temperature for 1 hour. After that, wash the NC membrane three times with TBS, add diluted primary antibody solution, and incubate it on a shaker in a chromatography cabinet at 4°C overnight.

[0898] On the second day, recover the primary antibody solution and wash the NC membrane 3 times with TBST. Add fluorescent secondary antibody labeled with IRDye (680RD or 800CW), incubate at room temperature in the dark for 1 hour, then wash the NC membrane 3 times with TBST and once with TBS. The NC membrane can be stored at 4°C in TBS.

[0899] (5) Development

[0900] Place the NC membrane on the glass plate of the Odyssey developer under light-proof conditions, with the front side (i.e., the side with the protein) facing down, and set appropriate parameters to detect protein expression. Use NewBlot NC membrane-specific washing buffer to wash the scanned membrane, start from blocking, and re-incubate the protein to detect other molecular weight proteins with the same internal reference.

[0901] 5. Statistics

[0902] Real time-qPCR experiment statistics for each sample 2 -ΔΔCT The fluorescence values ​​of the bands were counted by Western blotting, and GAPDH was used as the internal reference to detect the changes in the expression of the corresponding proteins. All data were statistically analyzed using Graphpad Prism 6 software, and the data were expressed in the form of mean ± SEM. The significant differences between groups were analyzed using Student's t test; the significant differences between multiple groups were analyzed using one-way analysis of variance and Boferroni post-test. P < 0.05 was considered to be significantly different.

[0903] 6. Experimental Results

[0904] Seven days after the BDL modeling in mice, the levels of serum AST and ALT enzyme activity increased, which was significantly different from that in the sham group. In order to determine whether the total flavonoids extract of hibiscus flowers can improve the hepatocellular injury induced by bile duct ligation, the total flavonoids extract of hibiscus flowers was gavaged to each group of mice at a dose of 1.2 g / kg every day for seven days after the modeling, and the levels of serum AST and ALT enzyme activity were detected. Fig.15 As shown, the ALT and AST enzyme activities in the sham operation group were 78.45±0.6415U / L and 189.6±7.722U / L, which increased to 240.9±19.42U / L and 355.4±26.03U / L after BDL modeling, which were significantly different from those in the sham operation group (P<0.01); after BDL modeling + administration of HKC (1.2g / kg / d), they were 252.5±33.05U / L and 389.9±60.92U / L.

[0905] like Fig.16As shown in the figure, a large area of ​​collagen (the area stained blue in Masson staining) can be seen in the Masson-stained pathological sections of the BDL group, indicating that the BDL surgery successfully induced liver fibrosis in mice, and the above conditions were significantly improved after drug administration. The Masson-stained collagen area in the sham operation group was 0.2386% ± 0.04743%, which increased to 15.56% ± 0.8728% after BDL modeling, which was significantly different from the sham operation group (P < 0.01); after BDL modeling + HKC (1.2g / kg / d) administration, it decreased to 7.121% ± 0.7486%, which was significantly different from the BDL modeling group (P < 0.05). Compared with the BDL group, the collagen area of ​​the Masson-stained pathological sections of the drug administration group decreased significantly, indicating that the total flavonoids extract of Hibiscus tiliaceus significantly reduced the degree of liver fibrosis.

[0906] like Fig.17 As shown, the mRNA levels of liver fibrosis indicators α-Sma and Collal were detected. Compared with the sham operation group, the BDL modeling group increased by 52.22±15.53 times and 124.4±49.10 times, and the HKC administration group decreased by 3.809±0.7635 times and 16.39±3.653 times.

[0907] like Fig.18 As shown in the data, the fluorescence brightness of the α-SMA protein band in the BDL group was 11.37±2.450 times higher than that in the sham operation group, with a significant difference (P<0.01); while after administration of HKC, the protein level of α-SMA in the liver decreased to 2.738±0.6745 times, with a significant difference compared with the BDL group (P<0.01).

[0908] In summary, HKC has a certain improvement effect on BDL-induced cholestatic liver fibrosis in mice. At the same time, the same experiment was carried out on the sample of Example 9-2 at 75 mg / kg / d, and it also had a therapeutic effect comparable to that of HKC, indicating that Hibiscus tiliaceus flower extract has a certain anti-liver fibrosis potential.

[0909] Example 28 Total flavonoids extract from hibiscus flowers inhibits the in vitro self-activation process of mouse primary hepatic stellate cells

[0910] This example is used to illustrate the application of the hibiscus flower flavonoids extract provided by the present invention in inhibiting the activation of hepatic stellate cells in the preparation of a drug for improving or treating liver fibrosis.

[0911] 1. Experimental drugs and consumables

[0912]

[0913]

[0914] The remaining reagents are as in Example 1, and hkc is the sample of Example 9-2.

[0915] 2. Experimental equipment and devices

[0916]

[0917] The remaining instruments are shown in Example 1.

[0918] 3. Experimental Methods

[0919] 3.1 Preparation of culture medium

[0920]

[0921] Inactivation: 57℃ water bath for 30min

[0922] 3.2 Isolation of primary mouse hepatic stellate cells

[0923] All operations were performed in a clean bench. The 1mg / mL collagenase Tyβe 4 solution prepared with PBS and DMEM Low glucose for perfusion was preheated to 42°C, the mice were anesthetized with 4% chloral hydrate, the fur was disinfected with 75% alcohol and the limbs were fixed, the abdominal cavity of the mice was opened by cutting from the abdomen to the xiphoid process, a thicker blood vessel in the mesentery directly connected to the liver as the portal vein, the portal vein was gently separated with forceps, the indwelling needle was inserted into the blood vessel and the inferior vena cava in the abdomen was cut, the PBS was perfused to flush out the dirty blood, and then 20mL of 1mg / mL collagenase type 4 solution was perfused and the perfusion was stopped. Remove the liver and place it in 15mL 1mg / mL type 4 collagenase solution. Use forceps to tear the liver into pieces, try to pick out the fascia, transfer the liquid to a 50mL centrifuge tube with a sterile dropper, add 300-400μL of 1mg / mL DNase (Deoxyribonuclease 1) solution prepared with DMEM Low glucose, and shake and digest at 90 times / min in a 37℃ water bath for 20min. Filter the liquid into a new 50mL centrifuge tube with a 70μm cell strainer, centrifuge at 600×g for 10min, and discard the supernatant. Then fill it up to 15mL with DMEM Low glucose, add 150μL 1mg / mL DNase solution, pipette and mix evenly, centrifuge at 600g for 10min, and discard the supernatant, then repeat the above operation once. Add 2mL DMEM Low glucose to the supernatant discarded precipitate and pipette to mix evenly. Slowly add 40% Percoll separation solution (2.4mL of 100% Percoll + 1.6mL of saline) to a 15mL centrifuge tube containing 60% Percoll separation solution (1.6mL of 100% Percoll + 2.4mL of saline) along the wall, slowly add 2mL of cell solution to the tube along the wall, adjust the centrifuge speed to 1 and 0 to prevent the cells from stopping and resuspending, set 1,500g centrifugation for 20min, aspirate the cell layer at 7.8-8.8mL of the centrifuge tube scale, add DMEM Low glucose to 5mL, adjust the centrifuge speed back to 9 and 7, centrifuge at 600g for 10min, and discard the supernatant. If the digestion is complete, an 8-week-old C57BL / 6J male mouse can isolate about 6×10 HSCs. 6 Add the adhesion medium and blow it evenly, then spread it into a 96-well black-walled transparent bottom microplate. Culture in an incubator to allow HSC to adhere to the wall. After 2 hours, blow the bottom of the dish twice with PBS with a relatively light force to wash off the cells that cannot adhere to the wall, and add long-term culture medium for culture.

[0924] 3.3 Cell culture and drug administration

[0925] After HSCs were plated into 96-well black-bottom transparent plates for 2 or 4 days, the original culture medium was replaced with starvation medium, 300 mg / mL HKC stock solution to prepare 300 μg / mL HKC, 30 mg / mL hkc stock solution to prepare 30 μg / mL hkc, and dosing medium containing 1 / 1000 DMSO, and the plates were returned to the cell culture incubator for continued culture for 24 h.

[0926] 3.4 Immunofluorescence

[0927] (1) Fixation, permeabilization, and blocking

[0928] After administration, the cells were washed three times with warm PBS buffer, and then 60 μL / well of PBS buffer containing 4% paraformaldehyde was added to fix the cells, and the fixation was carried out for 30 minutes at room temperature. After fixation, the paraformaldehyde solution was discarded, and 60 μL / well of PBS buffer containing 0.15% Triton X-100 was added to the extracellular fluid, and permeabilization was carried out for 10 minutes at room temperature. After permeabilization, the Triton X-100 solution was discarded, and 60 μL / well of PBS buffer containing 5% BSA was added to the extracellular fluid, and the cells were blocked for 1 hour at room temperature.

[0929] (2) Incubation with antibodies

[0930] After blocking, discard the BSA solution and prepare α-Smooth Muscle Actin (D4K9N) with the above BSA solution according to the ratio (1:300) in the instruction manual. Rabbit mAb solution, add 50 μL to each well, incubate overnight at 4°C. After incubation, recover the antibody, wash the cells 3 times with BSA solution, prepare Anti-rabbit IgG (H+L), F(ab′)2Fragment (Alexa Fluor 488Conjugate) solution with the above BSA solution according to the ratio (1:1,000) in the instruction manual, add 50 μL to each well, and incubate at room temperature in the dark for 1 hour.

[0931] (3) Incubation with Hoechst 33342

[0932] After the antibody incubation, the antibody was discarded, the cells were washed three times with PBS buffer, Hoechst 33342 dye was added to stain the cell nucleus, and the cells were incubated in the dark for 20 minutes at room temperature. After the incubation, the cells were washed three times with PBS buffer.

[0933] (4) Photography and statistics

[0934] Fluorescence photography was performed using a Leica Microsystems CMS GmbH Emst-Leitz-Str microscope and the accompanying Application Suite X (LAS X) software. FITC filters were used to capture green fluorescence, and DAPI filters were used to capture blue fluorescence. ImageJ software was used to manually count the number of α-SMA-positive cells covered by green fluorescence, and the activation ratio of hepatic stellate cells was obtained by dividing the number of a-SMA-positive cells by the total number of cell nuclei in the field of view.

[0935] 3.5 Real time-qPCR detection of fibrosis markers in primary HSCs

[0936] Primer sequences are shown in Table 2-1.

[0937] Table 2-1 Upstream and downstream primers used in qPT PCR experimental reactions

[0938]

[0939] The experimental method and other primer sequences are the same as in Example 1.

[0940] 4. Statistics

[0941] GraphPad (Version 6.01) software was used for processing and analysis of real time-qPCR and immunofluorescence data. All data were expressed as mean ± SEM. The significant differences between groups were analyzed using Student's t test. The significant differences between multiple groups were analyzed using one-way analysis of variance and Boferroni post-test. P < 0.05 was considered to be significantly different.

[0942] Experimental Results

[0943] Mouse HSCs were almost not activated when cultured in vitro for 3 days, but they could be significantly activated after 5 days.

[0944] The mouse HSC cultured in vitro for 3 and 5 days were administered with 300 μg / mL HKC. The percentage of α-SMA protein positive cells in mouse HSC cells cultured for 3d and 5d was 0.5896%±0.1660% and 8.509%±1.716%, and changed to 1.909%±0.5745% and 2.046%±1.269% after administration of HKC. The percentage of cells treated with 30 μg / mL hkc was 1.859%±1.485%. The results showed that mouse HSC cultured in vitro for 5d was significantly activated (P<0.01), and the activation ratio was significantly decreased after administration of total flavonoids extract of hibiscus flower (P<0.05). It can be seen that total flavonoids extract of hibiscus flower has a significant inhibitory effect on the activation of hepatic stellate cells.

[0945] The experimental results showed that mouse HSCs were significantly activated after 5 days of primary culture, and the flavonoids extract of Hibiscus hibiscus had a significant inhibitory effect on the self-activation of mouse HSCs. After 12 hours, the mRNA levels of Colla1, α-Sma, Pdgfr, Tgfβr1, and Tgfβr2 decreased by 0.3224±0.03695, 0.5635±0.05035, 0.5134±0.06016, 0.5235±0.04298, and 0.5784±0.09011 times, respectively, after HKC administration compared with the solvent control group. After HKC administration, the above indicators decreased by 0.3913±0.04512, 0.6194±0.07326, 0.5699±0.08732, 0.6721±0.0952, and 0.4982±0.09759 times, respectively. The results showed that the expression of multiple liver fibrosis-related factors in activated HSCs was significantly decreased after administration of total flavonoids extract from hibiscus flowers.

[0946] The above-mentioned embodiments only express several implementation methods of the present invention, and the description thereof is relatively specific and detailed, but it cannot be understood as limiting the scope of the patent of the present invention. It should be pointed out that, for ordinary technicians in this field, several variations and improvements can be made without departing from the concept of the present invention, which all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be subject to the attached claims.

Claims

1. Application of hibiscus flower extract in the preparation of medicines for treating diseases related to liver fibrosis.

2. The use according to claim 1, characterized in that: The anti-liver fibrosis is anti-TGF-β-induced liver fibrosis.

3. The use according to claim 1, characterized in that: The medicament is used to alleviate one or more of the following symptoms: cirrhosis, liver damage and intrahepatic lipid deposition.

4. Application of Hibiscus tiliaceus flower extract in the preparation of a drug having the effect of inhibiting the proliferation of hepatic stellate cells.

5. Application of Hibiscus tiliaceus flower extract in the preparation of drugs for preventing or treating anti-tumor.

6. Application of Hibiscus tiliaceus flower extract in the preparation of medicines for treating fatty liver.

7. The use according to claim 6, characterized in that: The fatty liver is selected from alcoholic fatty liver.

8. The use according to any one of claims 1 to 7, characterized in that: The hibiscus flower extract, The flavonoid components contain the following mass ratio: the mass ratio of gossypol-8-O-β-D-glucuronide: hyperoside: isoquercetin: myricetin: quercetin-3′-O-glucoside: quercetin is 10: 2.0-25: 3.0-20: 1.0-7.0: 4.0-23: 0.6-12.0; Alternatively, the flavonoid component contains the following mass ratio: isoquercetin:quercetin:quercetin-3′-O-glucoside:myricetin:gossypol-8-O-β-D-glucuronide:hyperoside is 0.8-1.2:0.05-1.6:0.2-4.6:0.05-1.2:0.2-3.5:0.25-3.6; Alternatively, the flavonoid components contain the following mass contents: 8-26% hyperoside, 12.0-19.8% isoquercetin, 5-30% gossypol-8-O-β-D-glucuronide, 1.6-11% myricetin, 12.1-25% quercetin-3′-O-glucoside, and 1.4-10% quercetin; further, 8-26% hyperoside, 12.0-19.8% isoquercetin, 8.5-30% gossypol-8-O-β-D-glucuronide, 3.0-4.9% or 5.1-6.0% myricetin, 14-25% quercetin-3′-O-glucoside, and 1.6-4.9% quercetin; The preparation is a non-aqueous liquid preparation; The mass content of the pharmaceutically acceptable excipients in the preparation is 0.5%-99.5%.

9. The use according to any one of claims 1 to 7, characterized in that: The Hibiscus tiliaceus flower extract contains the following flavonoid components in mass ratio: The mass ratio of quercetin-8-O-β-D-glucuronide: hyperoside: isoquercetin: myricetin: quercetin-3′-O-glucoside: quercetin is 10: 3.0-20: 4.0-18: 1.9-6.0: 6.0-20: 1.0-10.0, or 10: 6-15: 5-13: 1.0-2.9: 4.0-9.5: 0.6-6.0, or 10: 6-15: 5-13: 1.0-1.8: 4.0-5.9: 0.6-0.99; Further, the mass ratio of gossypol-8-O-β-D-glucuronide: hyperoside: isoquercetin: myricetin: quercetin-3′-O-glucoside is 10: 4.0-17: 4.50-16: 1.9-5.5: 7.0-16; Further, the mass ratio of gossypol-8-O-β-D-glucuronide: hyperoside: isoquercetin: myricetin: quercetin-3′-O-glucoside is 10: 6.0-15: 5.0-13: 2.0-5.0: 8.0-14; Further, the mass ratio of quercetin-8-O-β-D-glucuronide to quercetin is 10:1.0-6.0, preferably 10:1.2-6, and more preferably 10:1.5-5.0; Furthermore, it contains rutin, and the mass ratio of the cotton lin-8-O-β-D-glucuronide to rutin is 10:0.05-0.6, preferably 10:0.1-0.4, and more preferably 10:0.1-0.3; Furthermore, it contains quercetin-3-O-acacia glycoside, wherein the ratio of quercetin-8-O-β-D-glucuronide to quercetin-3-O-acacia glycoside is 10:0.1-2.5, preferably 10:0.1-0.9, and more preferably 10:0.15-0.5; Further, the mass ratio of gossypol-8-O-β-D-glucuronide: hyperoside: isoquercetin: myricetin: quercetin-3′-O-glucoside: quercetin is 10: 6-16: 5-13: 1.0-4.5: 4.0-12: 0.6-6.0, or 10: 15.1-16: 5-13: 3.0-4.5: 9.6-12: 0.6-6.0; Furthermore, it contains rutin, and the mass ratio of the cotton lin-8-O-β-D-glucuronide to rutin is 10:0.05-0.6, preferably 10:0.1-0.4, and more preferably 10:0.1-0.3; Furthermore, it contains quercetin-3-O-acacia glycoside, and the mass ratio of quercetin-8-O-β-D-glucuronide to quercetin-3-O-acacia glycoside is 10:0.1-2.5, preferably 10:0.1-0.9, and more preferably 10:0.15-0.

5.

10. The use according to any one of claims 1 to 7, characterized in that: The Hibiscus tiliaceus flower extract contains the following flavonoid components in mass ratio: Isoquercetin: quercetin: quercetin-3′-O-glucoside: myricetin: cottonwood-8-O-β-D-glucuronide: hyperoside is 0.8-1.2: 0.05-1.6: 0.2-4.6: 0.05-1.2: 0.2-3.5: 0.25-3.6; further 0.8-1.2: 0.1-1.2: 0.4-3.1: 0.10-0.9: 0.4-3.1: 0.5-3.0; further 0.8-1.2: 0.16-1.0: 0.6-2.4: 0.14-0.75: 0.6-2.5: 0.6-2.4; further 0.8-1.2: 0.2-0.8: 0.8-2.1 ∶0.18-0.6∶0.8-2.0∶0.7-2.0; further 0.8-1.2∶0.2-0.7∶0.8-1.6∶0.2-0.5∶0.8-1.8∶0.8-1.4; further 0.8-1.2∶0.2-0.6∶1.0-1.2∶0.2-0.4∶0.9-1.7∶1.0-1.3; or 0.8-1.2∶0.09-1.6∶0.2-2.0∶0.05-1.2∶0.5-3.0∶0.25-3.6; or 0.8-1.2∶0.12-0.7∶0.8-1.6∶0.2-0.5∶0.85-1.7∶1.0-1.4; Furthermore, the mass ratio of the isoquercetin is 1.2 or 1.0; Further, the ratio of isoquercetin:quercetin:quercetin-3′-O-glucoside:myricetin:cotton-8-O-β-D-glucuronide:hyperoside is 1:0.05-1.6:0.2-4.6:0.05-1.2:0.2-3.5:0.25-3.6; further 1:0.1-1.2:0.4-3.1:0.10-0.9:0.4-3.1:0.5-3.0; further 1:0.1 6-1.0: 0.6-2.4: 0.14-0.75: 0.6-2.5: 0.6-2.4; further: 1: 0.2-0.8: 0.8-2.1: 0.18-0.6: 0.8-2.0: 0.7-2.0; further: 1: 0.2-0.7: 0.8-1.6: 0.2-0.5: 0.8-1.8: 0.8-1.4; further: 1: 0.2-0.6: 1.0-1.2: 0.2 -0.4∶0.9-1.7∶1.0-1.3; or 1.2∶0.05-1.6∶0.2-4.6∶0.05-1.2∶0.2-3.5∶0.25-3.6; further 1.2∶0.1-1.2∶0.4-3.1∶0.10-0.9∶0.4-3.1∶0.5-3.0; further 1.2∶0.16-1.0∶0.6-2.4∶0.14-0.75∶0.6 -2.5∶0.6-2.4; further 1.2∶0.2-0.8∶0.8-2.1∶0.18-0.6∶0.8-2.0∶0.7-2.0; further 1.2∶0.2-0.7∶0.8-1.6∶0.2-0.5∶0.8-1.8∶0.8-1.4; further 1.2∶0.2-0.6∶1.0-1.2∶0.2-0.4∶0.9-1.7∶1.0-1.3; Furthermore, it contains rutin, and the mass ratio of isoquercetin to rutin is 1:0.001-0.08, preferably 1:0.005-0.06, more preferably 1:0.006-0.05, more preferably 1:0.007-0.04, still more preferably 1:0.008-0.03, and most preferably 1:0.009-0.03; Furthermore, it contains quercetin-3-O-acacia glycoside, and the mass ratio of isoquercetin to quercetin-3-O-acacia glycoside is 10:0.1-2.5, preferably 10:0.1-0.9, and more preferably 10:0.15-0.

5.

11. The use according to any one of claims 7 to 10, characterized in that: The hibiscus flower extract contains the following flavonoid components by mass: 10-25% of hyperoside, 8-19% of isoquercetin, 5-30% of gossypol-8-O-β-D-glucuronide, and 12.1-25% of quercetin-3′-O-glucoside; Further, the quercetin-3′-O-glucoside content is 12.6-23% or 13-20%; Further, hyperoside 12-23%, isoquercetin 10-17%, gossypol-8-O-β-D-glucuronide 8.5-25%, quercetin-3′-O-glucoside 12.6-23%; Further, hyperoside 13-22%, isoquercetin 11-17%, gossypol-8-O-β-D-glucuronide 12-21%, quercetin-3′-O-glucoside 13-20%; Furthermore, it also contains 2-10% quercetin, preferably 2.5-9% quercetin, further preferably 3-8.5% quercetin, and further preferably 1.5%-5% quercetin; Furthermore, it contains 2-11% myricetin, preferably 3-7% myricetin, and further preferably 3-5% myricetin. Further, it contains 0.08-2.5% of quercetin-3-O-acacia glycoside, preferably 0.1-1.5% of quercetin-3-O-acacia glycoside, further preferably 0.1-0.9% of quercetin-3-O-acacia glycoside, and further preferably 0.1-0.5% of quercetin-3-O-acacia glycoside; Further, hyperoside 11-22%, isoquercetin 12.0-17%, gossypol-8-O-β-D-glucuronide 12-23%, myricetin 1.6-4.9% or 5.1-9.0%, quercetin-3′-O-glucoside 13-22%, quercetin 1.4-8% or 1.4-7.8%; Furthermore, it contains 0.01-1.0% rutin, preferably 0.05-0.8% rutin, further preferably 0.09-0.8% rutin, and further preferably 0.1-0.6% rutin.

12. The use according to any one of claims 7 to 10, characterized in that: The mass content of flavonoids in the hibiscus flower extract is 55% or more, preferably 60% or more, more preferably 65-85% or 66-84%, and even more preferably 69-82% or 69-90%; Furthermore, the total content of quercetin, quercetin-3'-O-glucoside, myricetin, gossypol-8-O-β-D-glucuronide, isoquercetin and hyperoside is 55% or more, preferably 60% or more, more preferably 65-85%, and even more preferably 69-82%; Further, the quercetin-3′-O-glucoside content is 12.1-25%, preferably the quercetin-3′-O-glucoside content is 12.6-23%, 13-20%, 13-20%, or 14-25%; Or further, the content of quercetin is higher than 0.7%, preferably higher than 1.0%, further preferably 1.0%-10%, further preferably 1.5%-5%; Or further, the content of cotton lin-8-O-β-D-glucuronide is 8.5-30%, preferably 12%-23%.

13. The use according to any one of claims 7 to 10, characterized in that: The hibiscus flower extract is prepared by the following steps: (1) extracting hibiscus flower or the medicinal part of hibiscus with ethanol to obtain an extract; (2) concentrating the extract and then extracting it to obtain an extract; (3) removing the solvent from the extract and eluting it with a macroporous resin to obtain the hibiscus flower extract; the preferred extraction method is percolation; Alternatively, the method can be prepared by the following method: (1) extracting hibiscus flower or its medicinal part with ethanol to obtain an extract; (22) adding a clarifying agent to the extract, treating it in a water bath, and filtering out the supernatant; (33) eluting the supernatant with a polyamide resin to obtain a hibiscus flower extract; the preferred extraction method is percolation.

14. The use according to claim 13, characterized in that In step (1), the amount of ethanol is 10-25 times that of hibiscus flower or medicinal part of hibiscus, and the ethanol is a 60-95% ethanol solution; in step (2), the extractant used for extraction is n-butanol, petroleum ether or ethyl acetate, the extraction method is continuous countercurrent extraction, the material-liquid ratio of the extraction is 0.8-4:1, and the extraction level of the extraction is 1-5 levels; in step (3), the macroporous resin model is D101, HPD100 or AB-8; in step (22), the water bath temperature is 50-70°C, and the water bath time is 30-90min; in step (33), the resin diameter-to-height ratio is 1:4-9, the sample solution concentration is 0.10-0.60g crude drug / mL, the sample solution volume is 4-12BV, and elution is carried out with 4-8BV pure water and 4-8BV 60-95% ethanol.

15. The use according to any one of claims 13-14, characterized in that: Step (2) includes subjecting the extract to activated carbon adsorption, alcohol precipitation or acid precipitation treatment before extraction.

16. The use according to any one of claims 13-14, characterized in that: The elution process of the macroporous resin is as follows: the diameter-to-height ratio of the macroporous resin is 1:4-9, the concentration of the loading solution is 0.10-0.30 g crude drug / mL, the volume of the loading solution is 4-12 BV, the sample is loaded at a flow rate of 1-4 BV / h, 4-8 BV of pure water and 1-5 BV of 3-15% ethanol are used for impurity removal at a flow rate of 0.5-4 BV / h, and 2-8 BV of 50-80% ethanol are used for elution at a flow rate of 1-5 BV / h.

17. The use according to any one of claims 7 to 10, characterized in that: The preparation method of the hibiscus flower extract comprises the following steps: (101) extracting hibiscus flowers or medicinal parts of hibiscus with ethanol to obtain an extract; (102) adjusting the pH value of the extract to 2.0-3.0, refrigerating, filtering out the precipitate, and adding water to dissolve it; (103) extracting the dissolved solution to obtain an extract; (104) removing the solvent from the extract and eluting with a polyamide resin to obtain the effective part or extract of flavonoids from hibiscus flowers; the preferred extraction method is reflux.

18. The use according to claim 17, characterized in that The amount of ethanol used in step (101) is 10-25 times that of hibiscus flower or medicinal part of hibiscus, and the ethanol is a 60-95% ethanol solution; the pH regulator in step (102) is hydrochloric acid, sulfuric acid, acetic acid, phosphoric acid, citric acid, tartaric acid or maleic acid; the extractant used for extraction in step (103) is n-butanol, petroleum ether or ethyl acetate, the extraction method is continuous countercurrent extraction, the material-liquid ratio of the extraction is 0.8-4:1, and the extraction level of the extraction is 1-5; the resin diameter-to-height ratio in step (104) is 1:4-9, the sample solution concentration is 0.10-0.60g crude drug / mL, the sample solution volume is 4-12BV, and elution is performed with 4-8BV pure water and 4-8BV 60-95% ethanol.

19. The use according to any one of claims 1 to 7, characterized in that: The hibiscus flower extract is prepared by the following method: adding ethanol to hibiscus flowers, heating and refluxing, filtering, reducing the pressure of the filtrate to recover the ethanol, concentrating, adjusting the pH to 5-7, standing, removing the upper oil layer, vacuum drying, and crushing to obtain the extract; further, the amount of ethanol used is 10-20 times that of the hibiscus flowers, refluxing for 0.5-2 hours, and the pH is 6.

0.

20. The use according to any one of claims 1 to 7, characterized in that: The total mass content of quercetin, quercetin-3'-O-glucoside, myricetin, gossypol-8-O-β-D-glucuronide, isoquercetin and hyperoside contained in the hibiscus flower extract is more than 6% of the hibiscus flower extract; preferably 8-15%, and more preferably 8-12%; further, the total mass content of quercetin, quercetin-3'-O-glucoside, myricetin, gossypol-8-O-β-D-glucuronide, rutin, isoquercetin and hyperoside contained in the hibiscus flower extract is more than 55% of the hibiscus flower extract, preferably more than 60%, and preferably 65-85%.

21. The use according to any one of claims 1 to 7, characterized in that: The preparation of the hibiscus flower extract comprises the following steps: (1) extracting hibiscus flowers with ethanol to obtain an extract; (2) removing ethanol from the hibiscus flower extract, diluting with water, adsorbing with activated carbon, and continuously countercurrent extracting with n-butanol to obtain an extract; (3) removing the solvent from the extract, eluting with D101 macroporous resin, removing impurities with pure water and ethanol in turn after loading, and eluting to obtain an eluate, and removing the solvent from the eluate under reduced pressure to obtain the hibiscus flower extract.

22. The use according to any one of claim 21, characterized in that The ethanol is a 50-70% ethanol solution, and its dosage is 5-25 times that of hibiscus flower, preferably 10-20 times, and more preferably 15 times; the material-liquid ratio of the extraction is 0.5-2.5:1, preferably 1.0-2.0:1, and more preferably 1.5:1; the number of extraction levels is 1-3, and more preferably 2; the diameter-to-height ratio of the macroporous resin is 1:5-7, and more preferably 1:5.5-6.5, and more preferably 1:6; the concentration of the loading solution is 0.05-0.25g crude drug / mL, and more preferably 0.1-0.2g crude drug / mL, and more preferably 0.15g crude drug / mL.

23. The use according to any one of claim 21, characterized in that The preparation of Hibiscus tiliaceus flower extract comprises the following steps: 1) Grinding hibiscus flowers into coarse powder, and extracting by percolation with 15 times 60% ethanol to obtain hibiscus flower extract; 2) removing ethanol from the hibiscus flower extract, diluting with water, adsorbing with activated carbon, and continuously countercurrent extracting with n-butanol, the solid-liquid ratio (i.e., extractant: extracting solution) of the extraction is 1.5:1, the extraction speed of the extraction is 40 mL / min, the speed of the extraction machine of the extraction is 40 Hz, the extraction level of the extraction is 2, and the extract is decompressed at 40° C. to recover the solvent; 3) treated with D101 macroporous resin, the treatment process of the macroporous resin is as follows: the diameter-to-height ratio of the macroporous resin is 1:6, the concentration of the loading solution (aqueous solution) is 0.15 g crude drug / mL, the loading volume is 7BV, the sample is loaded at a flow rate of 2BV / h, 6BV of pure water and 3BV of 5% ethanol are used at a flow rate of 2BV / h to remove impurities, 4BV of 60% ethanol is used at a flow rate of 2BV / h to elute to obtain an eluent, and then the eluent is decompressed at 50°C to recover ethanol to obtain the flavonoid extract of hibiscus flower.

24. The use according to claim 23, characterized in that The mass content of total flavonoid components in the hibiscus flower extract is 40-90%, preferably 50-80%, and more preferably 60-70%.

25. The use according to claim 24, characterized in that The hibiscus flower extract is prepared by the following method: 80% ethanol is added to hibiscus flowers for extraction, the extract is filtered and concentrated, and the filtrate is concentrated into a concentrated solution with a relative density of 1.13 to 1.16 at 60° C. to obtain a concentrated solution; water is added to the concentrated solution for precipitation, and the concentrated solution is concentrated by suction filtration to a corresponding volume, and the elution is carried out by a macroporous adsorption resin column with an alcohol-water gradient, and the eluate is concentrated, dried, and crushed to obtain the hibiscus flower extract.

26. The use according to claim 21, characterized in that The hibiscus flower extract is prepared by the following method: adding an appropriate amount of 80% ethanol to the hibiscus flower, extracting once for 2 hours, combining the extracts, filtering, concentrating the filtrate into a concentrate with a relative density of 1.13 to 1.16 at 60°C, adding an appropriate amount of water to precipitate for 24 hours, filtering, concentrating to a corresponding volume, passing through a macroporous adsorption resin column, using an alcohol-water gradient elution, eluting with water for 3 column volumes, eluting with 10% and 30% ethanol for 3 column volumes each, and eluting with 70% ethanol for 1 column volume. After the eluate is concentrated, dried, and crushed, the hibiscus flower extract is obtained.

27. The use according to any one of claims 1 to 7, characterized in that: The preparation of the Hibiscus tiliaceus flower extract comprises the following steps: Add 70-80% ethanol to the flower of Hibiscus hibiscus, extract 1-2 times, each time for 1-4 hours, combine the extracts, filter, concentrate the filtrate into a concentrate with a relative density of 1.13-1.16 at 60°C, add appropriate amount of water to precipitate for 24 hours, filter, concentrate to the corresponding volume, pass through a macroporous adsorption resin column, use alcohol-water gradient elution, water elution for 3 column volumes, 10% and 30% ethanol elution for 3 column volumes, 70% ethanol elution for 1 column volume. After the eluate is concentrated, dried and crushed, a total flavonoid extract is obtained, and its total flavonoid content is 5-95%.